Peptide rotaxanes as potential prodrugs by Potok, Stephanie
Peptide rotaxanes as potential prodrugs 
LM 
Stephanie Potok 
Degree of Doctor of Philosophy 
Department of Chemistry 
University of Edinburgh 
November 2004 
Table of Contents 
Abstract 	 iii 
Declaration 	 iv 
Attended Lectures and Meetings 	 v 
Acknowledgements 	 vi 
List of Abbreviations 	 vii 
General Remarks on the Experimental Data 	 viii 
Layout of Thesis 	 ix 
Chapter 1: 	Naturally occurring peptides: 
Muses for the synthesis of interlocked architectures 
Chapter 2. 	Elongation of readily-accessible building blocks: 	 39 
An efficient synthesis of a Leu-enkephalin rotaxane 
Chapter 3: 	A convenient synthesis of oligopeptide rotaxanes via classical 	71 
peptide coupling reactions 
Chapter 4: Synthesis of a two-side-extension rotaxane building block for 	114 
extensive oligopeptide rotaxane synthesis! 





Peptides are potential therapeutic agents involved in a wide range of biological 
processes. In principle, rotaxanes can be used as novel prodrug delivery systems to 
overcome the problems of peptide degradation in vivo and their poor membrane 
transport permeability. The presence of the macrocycle around the peptide thread 
acts as a protective shield against peptidases and modifies its cell membrane 
transport characteristics. However, the classical 'clipping' method of rotaxane 
formation is mainly limited to dipeptide sequences since the presence of 
intramolecular hydrogen bonds in longer peptide threads causes folding of the 
backbone, preventing good interactions with the precursor to the macrocycle. This 
thesis focused on the synthesis of short peptide rotaxane building blocks. Their 
elongation on both sides of the peptide backbone was then applied to the 
straightforward synthesis of oligopeptide [2] and [3]rotaxanes in very good yields. 
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TFA trifluoroacetic acid 
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General Remarks on Experimental Data 
All the melting points (m.p.) were determined using a Electrotermal 9100 melting 
point apparatus and are uncorrected. 'H (400 MHz) and '3C (100 MHz) NMR spectra 
were recorded on a Bruker DPX 400 MHz spectrometer using dilute solution in 
CDC13, 4-DMSO, C2D2C14, d4-MeOD) and the chemical shifts are reported in part 
per million (ppm) from low to high field. All the 'H and '3C NMR spectra were 
recorded at 298K unless otherwise stated. 'H NMR are reported as follows: br = 
broad, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, dt doublet of 
triplets, q = quartet, m = multiplet, J(H,H) = coupling constant. H-H COSY and 
HMQC were also recorded for most of the compounds to enable more detailed 
assignement of 'H and 13C signals. Column chromatography was carried out using 
Kiesegel C60 (Merck) as stationary phase. TLC detection was performed on silica 
gel plates (0.25 mm thick, 60 F254, Merck, Germany). The TLC plates were 
observed under UV light or spotted using 0.2% ninhydrin in EtOI-I and successively 
heated with an heatgun. Mass spectrometry and FIRMS analyses, using Masslynx 
software version 2.3, were performed by the University of Edinburgh mass 
spectrometry service using fast atom bombardment (FAB) from m-nitrobenzyl 
alcohol matrix unless otherwise stated. FIPLC grade MeOH was obtained from 
Fischer. Solution of 0.1% TFA in MeOH was prepared. Luna 5u C18(2) 100A 
column (250 mm x 2.00 mm, 5 gm) was purchased from Phenomenex. Reagents and 
anhydrous solvents used for the reactions were purchased from Aldrich and were in 
general used without further purification. Isophthaloyl dichloride was routinely 
recrystallized from hexane and para-xylylenediamine was distilled under reduced 
pressure. 
viii 
Layout of this Thesis 
The work presented in this thesis describes (i) the synthesis of rotaxane building 
blocks and their C- and N-elongation towards oligopeptide rotaxanes. A brief review 
of the literature is given in chapter one describing the background of hydrogen 
bondings as templates for rotaxane synthesis, from simple amides to elaborate 
peptides. 
The remainder of the thesis discusses my own experiments in this area and is 
presented in the form of three chapters that are actually articles that have either 
already been published, are in press or have been prepared for submission to a peer-
reviewed journal. No attempt has been made to rewrite the work out of context. 
Stephanie Potok, November 2004. 
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Chapter One 
Introduction 
Naturally occurring peptides: 
Muses for the synthesis of interlocked architectures 
1.1. Naturally occurring interlocked peptide architectures 
Nature is a rich source of topologically complex molecular architectures with more and 
more examples being reported every year. In 1967, Vinograd described the first 
mitochondrial DNA dimers and higher oligomers as stable and isolable DNA Molecules.  112 
They consist of independent, double stranded closed circles topologically interlocked as 
catenanes. Diverse enzymes have shown their ability to form knots and catenanes in DNA 
rings including Escherichia coli DNA topoisomerase 13  and a resolvase or recombination 
enzyme .4  The formation of such topological structures is of crucial importance as it 
occurs during the replication or recombination of the DNA. 
It has also been known for many years that proteins often contain "random" disulfide 
bonds between cysteine groups of different loops, origin of knot formation. The first 
cystine knot was discovered in 1982 by Rees and Lipscomb in the potato inhibitor 
complex of carboxypeptidase A.5 This amazing structure, now known to be common in 
proteins, consists of a macrocycle, formed by two disulfide bonds and their 
interconnecting backbone segments, threaded by a third disulfide bond. Following this 
1 
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cystine knot-containing bioactive peptides were discovered. Their compact structure, 
their remarkable high stability' in vivo due to high content in disuffide bridges and their 
"knotted" architecture make them very attractive scaffolds for drug design.7 Indeed they 
exhibit a broad range of biological properties including antiviral,'-'o antibiotic" and 




Growth f,ior cy~~finc knot 	 1nhihror cystine knot 	 Cyclic cystine knot 
Figure 1.1 The three classes of cystine knots. The beta-strands are represented as arrows, the cysteine 
residues are labelled I-VT from the N- to C-terminus and the disulfide bonds are drawn as red lines. 
(i) The growth factor cystine  knots are made of 60 to 4000 amino acids, with an 8 to 
14 amino acid ring. There are more than 600 members known, most being hormones. (ii) 
The inhibitor cystine knots are made of 25 to 100 amino acid residues, with an 8 to 15 
amino acid ring. There are more than 300 members known including cation-channel 
blockers, protease inhibitors, neurotoxins, antimicrobials, antitumour agents, insecticides. 
(iii) The cyclic cystine knots, or "cyclotides", include one more degree of topological 
complexity as they combine both a head-to-tail cycized backbone and the cystine knot. 
They are made of 28 to 38 amino acid residues, with an 8 amino acid ring. There are 
more than 40 members known including antivirals, neurotensin inhibitors, antimicrobials, 





Figure 1.2. The structure of kalata BI elucidated in 1995.12  The first cyclotide, kalata B  isolated 
from the leaves of the plant Oldenlandia affinis in the 1970's13 due to its uterotonic activity. 
In the early 1990's, knots in the backbone were unambiguously identified in proteins. 14 
18  The presence of a knot in the middle of the protein backbone of lyvel was recently 
confirmed by the use of a computer algorithm to "smooth" the folded structure. 
17 
Between 1994 and 1996, several "lasso" peptides were identified including RES-701-1,'9 
anantin,20 siamycin I and 11,21  RP 71955522  and MS-271 
23  Their common features are: (i) 
16 to 21 amino acid residues including a ring of 8 or 9 amino acids, (ii) a "tail" passing 
through the "ring" region, (iii) a compact structure along with high in vivo stability and 
high biological activity. 
In 1998, Duda identified the bacteriophage HK97 capsid as a 42 kDa protein containing 
420 monomers and a portal 
.24  This icosohedral-shaped viral capsid is made of 60 
hexameric and 12 pentameric rings assembled into a pseudo-catenated supramolecular 
architecture which, after closure, give a "protein chainmail": a network of topologically 
catenated protein macrocycles.25  
3 
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In 2003, three research groups2628  simultaneously reported a seventh 3D "lasso" 
structure in Microcin J25 (MccJ25), a 21-amino acid peptide (Figure 1.3.). At one end of 
the peptide is a ring formed by an amide linkage between the N-terminus and the side 
group on the eighth amino acid residue, the linear end of the peptide loops back and 
threads through the cyclic part. This rotaxane-like secondary structure is stabilized by the 






threaded segment (18-21) 
cycle (1-8) 
Phel 9 "lock 
'' connector (9-17) 
Figure 1.3. Microcin J25 (MccJ25), a 21 amino acid "lasso" peptide. 
Originally reported to be circular 
'29  MccJ25 has generated a widespread interest 
primarily because of its highly unusual mode of antibacterial action as well as its 
intriguing structural characteristics. MccJ25 was mainly shown to inhibit bacterial 
transcription by binding to RNA-polymerase and obstructing its secondary channel. 
30-33 
MccJ25 also exhibits interesting pharmacological features: extreme stability to peptidases, 
unique modes of antimicrobial and antiviral action, impressive membrane transport and 




Recently, chemists have taken up the challenge proposed by nature by endeavoring the 
synthesis such interlocked molecules. In 2001 Dawson reported the synthesis of the first 
protein [2catenane, via a folding-directed strategy.35 Taking advantage of the dimeric 
type structure of the tumor suppressor protein p53 and of its particular spatial 
conformation, a [2]catenane was obtained  by joining the N-terminal of a cysteine residue 







Figure 1.4. Synthesis of the p53 catenane.35 
The Leigh group has pioneered the derivatization of peptides as rotaxanes as means of 
providing enzymatic resistance against proteases and modulating physical properties of 
the peptide - such as its solubility and lipophilicity - via the wrapping of a macrocycle 
along the backbone (Scheme 1.1.).36 My thesis took place with the aim of building 
hybrids of natural peptides using rotaxanes (See clipping strategy as part of the hydrogen-
bonding interactions section). 
5 
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H2N 	N H2 
CHCI3, Et3N 
Scheme 1.1. Synthesis of peptide rotaxanes. 
In order to efficiently build such interlocked architectures, chemists have developed 
synthetic strategies using four different templating interactions for self-assembly. 
Hydrogen bonding will be examined more deeply in this short review as a key-feature for 
the synthesis of peptide rotaxanes. Previous work on their synthesis will be exposed along 
with their inherent limitations. Finally, an insight into rotaxanes and their future potential 
as drug delivery systems will be discussed. 
1.2. Towards template directed synthesis of interlocked architectures 
Interlocked architectures have generated a widespread interest because of their intrinsic 
properties: the individual components can move independently of each other, but cannot 
be separated without the cleavage of a covalent bond. 
1.2.1. Definitions and synthetic strategies 
The most studied and synthesized interlocked architectures are rotaxane, catenanes and 
knots (Figure 1.5.) 
Chapter One 
Rotaxa tie 
U  e" IN 4*.D 	~o 
Cat enane 	 Trefoil Knot 
Figure 1.5. Examples of interlocked architectures. 
A catenane, from the Latin calena, meaning chain, is a molecular species formed by 
two, or more, mechanically interlocked macrocycles which can only be separated by 
breaking one or more covalent bonds. A rotaxane, from the Latin rota and axis meaning 
respectively wheel and axle, consists of one or more macrocycles threaded onto a linear 
molecule ("thread") which is kinetically stable due to the bulky groups ("stoppers") at 
both ends preventing the "slippage" of the macrocycic unit. A rotaxane without stopper" 
is referred to as a "pseudo-rotaxane". In all these systems, a prefix number in square 
bracket indicates the number of the interlocked components. 
Three distinct strategies have been developed for the synthesis of rotaxanes (Figure 
1.6.): i) "threading",3739 where the equilibrium-dependent formation of a pseudo-
rotaxane is trapped by a "capping" reaction with two bulky stoppers preventing the 
macrocycle from dethreading, ii) "slippage 
40,41 where a macrocyclic unit passes over the 
stoppers of a thread, usually at elevated temperatures and iii) "clipping",42 where the 
7 
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rotaxane is obtained by the closure of an acyclic unit templated around a "stoppered" 
thread. 
threading 	




o—o 0  Uo+o 
Figure 1.6. Three different synthetic strategies to obtain rotaxanes. 
1.2.2. Early attempts of synthesis via statistical methods 
The first synthesis of a [2]rotaxane, 1.3, was reported by Harrison and Harrison in 
1967. The synthesis used a statistical approach based on the random threading of a 
linear dialcohol 1.1 through a 30-membered ring loaded on a Merrifield resin 1.2. The 
resulting pseudo-rotaxane was "stoppered" by reaction with an excess of a trityl chloride 









 Ph Ph 
H 	 2)28 	 Ph 
Ph 	 Ph 
1.3 (CHI)78 
HO OH  
1.1 
Scheme 1.2. Synthesis of the first rotaxane 1.3 in 6% yield by a statistical method repeated 70 times. a) 
(i) triphenylmethyichioride, pyridine, DMF, toluene, (ii) cleavage. 
Shortly after this, Schill and co-workers reported another synthetic methodology 
consisting of the directed synthesis of a rotaxane precursor 1.4. Selective cleavage of 
covalent bonds afforded the desired interlocked molecule 1.5 (Scheme 	
44  This 
methodology did not resolve the major and limiting problem of extremely poor yields in 
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Scheme 1.3. Synthesis of the first rotaxane 1.5 by "covalently" directed synthesis. 
The low yields in the above examples highlight the problem of using statistical 
methods: as there is no thermodynamic driving force to facilitate the formation of 
interlocked species. Research aimed at improving the yields of interlocked species 
focused on the use of templating interactions. 
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1. 2.3. Template directed synthesis 
The advent of templates marked a new era for interlocked architectures. The use of 
non-covalent intermolecular interactions made it possible to form stable interlocked 
complexes in high yields. 
1.2.3.1. Hydrophobic interactions 
The most extensively studied type of rotaxanes formed by the use of hydrophobic 
interactions are those with a cyclodextrin-based structure. Cyclodextrins (CDs) are cyclic 
oligosaccharides consisting of six or more a-1,4-linked D-glucopyranose units. The 
conformation of CDs is a rigid cavity with a truncated cone shape. They have an 
hydrophilic exterior, due to the hydroxyl groups on the outside surface, and a 
hydrophobic core due to the hydrocarbon units of the interior. Such physicochemical 
properties make them both water-soluble and convenient hosts for complexing molecular 
guests in water. 
Examples of cyclodextrin-based [2]rotaxanes, reflecting the diversity of possible 
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1.2. 3.2. 	Metal template 
Another strong type of interaction used in the synthesis of interlocked molecules is the 
metal coordination of organic ligands. The synthesis and study of rotaxanes and 
catenanes based on these interactions have been carried out by the group of Sauvage 
since 1983, after the successful preparation of a [2]catenane.47 Once an interlocked 
molecule has been synthesized via a metal template, it can generally be demetallated, 




1.8 	 1.9 
1.12 
Scheme 1.5. Synthesis of rotaxane 1.12 via transition metal coordination, with —CAr3 -C(p-t- 
BuC6114)2Ph.. a) [Cu(CH3CN)41BF4 1.10; b) (i) I(CH2)3CAr3, K2CO3,  (ii) Amberlite-CN.37 
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1.2.3.3. 	ir- 'r stacking interactions 
Stoddart's research group studied 41  the inclusion complexes of electron-deficient 
paraquat with electron-rich crown ethers 1.13, and the analogous it-deficient tetracationic 
receptor with it-rich guests such as 1,4-dimethoxybenzene 1.14 (Scheme 1.6.). 
(0 0O )  
0 	N 	0 	 N OMe 
OMe 
/ 	
N 	 N / .\ 	N 
MeJ 
0 0 0 
'I 
1.13 	 1.14 
Scheme 1.6. Inclusion complexes using aromatic it - it stacking interactions 
Stoddart used these it - it stacking interactions as a template for the synthesis of 
rotaxanes, such as rotaxane 1.15 (Scheme 
1.15 
Scheme 1.7. Example of rotaxane 1.15 using aromatic interactions. 
12 
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1.2.3.4. 	Hydrogen-bonding interactions 
1.2.3.4.1. Threading 
Vogtle et al. reported the first synthesis of an amide-based rotaxane5° by threading of 
an acid chloride through a preformed macrocycle that serves as hydrogen-bond donor 
(Scheme 1.8.). With the aim of studying the limits of the templating effect, a series of 
rotaxanes were synthesized using heterocyclic diamide threads5053 threads. The threading 
process was found to be very tolerant of the different structural and electronic 
characteristics of the selected threads. The key-step of this molecular recognition 
mechanism is the formation of an amide bond between one stopper and the dichloride 










Scheme 1.8. Synthesis of [2]rotaxanes 1.19. 
Expansion of the macrocycle by a sulfonamide54'55 and methylene groups56 enabled the 




It is noteworthy that Vogtle reported the first synthesis of rotaxane by trapping of an 
anion-macrocycle complex in 1999.64  The phenolate anion 1.20 was bound to the 
tetralactam macrocycle 1.17 by hydrogen-bond interactions. This nucleophile then 






Scheme 1.9. Anion-template synthesis of rotaxanes 1.22. 
1.2. 3.4.2. Slippage 
Vogtle synthesized rotaxanes by fast melting of the macrocycle and the thread .6' The 
Slippage strategy allows for the synthesis of the "unobtainable" rotaxane 1.24 where no 




Scheme 1.10. Nontemplate synthesis of rotaxane 1.24 by slippage. 
1. 2.3.4.3. Clipping and preambule to the thesis 
Leigh et al. reported the synthesis of the first benzylic amide rotaxane 1.28 in 28% by 
clipping around the isophthalamide thread 1.25 of an equimolar mixture of isophthaloyl 
dichloride 1.26 and para-xylylene dianiine 1.27 in presence of Et3N in CHC13 (Scheme 
1.11.).66 
	
Ph Ph 	 Ph Ph 
CI Ph 0 oXo :Xo CI A( 
0 1.26 
L H-N) 	H2N NH2 
1.27 





Scheme 1.11. Synthesis of rotaxane 1.28 via the clipping strategy. 
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The more rigid fumaric rotaxane 1.29 was synthesized in 97% yield.67 The success of 
the fumaramide template was explained by the spatial arrangement of the cooperative 
hydrogen bonding sites on the rigid thread, due to the E-isomery of its double bond, at an 
ideal distance apart to template the formation of the benzylic amide macrocycle through 
the intercomponent hydrogen bonding. Remarkably enough the substitution of one or 
both the amides of the highly preorganized thread by much weaker hydrogen bond 
acceptor groups as esters 68  still templated the formation of rotaxanes 1.30 and 1.31 
(Scheme 1.12.). 
1.29 X,YNH 	97% 
1.30 X=OY=NH 35% 
Ph 
1.31 X,Y=O 	3% 
Scheme 1.12. Fumaramide-containing rotaxanes 1.29-1.31. 
The mechanism of rotaxane formation is initiated by the directed assembly of the 
macrocycle around two transold amide bonds. It is noteworthy that peptide sequences 
carry this structural arrangement leading to the synthesis of the first dipeptide rotaxane, 
GlyGly 1.32, in 62% yield .36 The thread template induces a conformational change of the 
open-chain precursor from syn-anti to syn-syn via cooperative multipoint hydrogen 
bonding interactions, bringing the terminal amine and acid chloride in close proximity in 
complex I to lead to rapid cyclization. During the crucial phase of the "wrapping", the 
precursor to the macrocycle establishes a complicated pattern of weaker secondary 
interactions depending on the intermolecular binding  with the two amide groups of the 
17 
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thread (Scheme 1.13.). The better the fit between the thread and the macrocycle 
precursor, the higher the yield in rotaxanes as illustrated by the series of dipeptide 
rotaxanes synthesized via clipping strategy (Scheme 1. 13.).366971 
Et3N anti 	syn 
o,tciL.ro + H2NII 	
CHCI3 
NH2 




0 R R3 




Gly-Gly 1.32 R1  = H R2 = H R3 = H R4 = H 62% 
Gly-Sar 1.33 R1  = H R2 = H R3 = Me R4 = H 60% 
H20 
GIy-L-Trp 1.34 R1  = H R2 = H R3 = H R4 = 	I1J 56% 
GIy-L-Ala 1.35 R1  = H R2 = H R3 = H R4 = OH3  40% 
GIy-L-Leu 1.36 R1  = H R2 = H R3 = H R4 = CH2CH(CH3 )2  37% 
GIy-L-Met 1.37 R1  = H R2 = H R3 = H R4  = CH2CH2SMe 36% 
GIy-L-Phe 1.38 R1  = H R2 = H R3 = H R4 =  CH2Ph 32% 
GIy-L-Cys 1.39 R1  = H R2 = H R3 = H R4 = CH2SCH2Ph 25% 
Sar-Gly 1.40 R1  =Me R2 = H R3 = H R4 = H 22% 
GIy-L-Ser 1.41 R1  = H R2 = H R3 = H R4 = CH200H2Ph 19% 
GIy-L-Asp 1.42 R1  = H R2 = H R3 = H R4  = CH2002CH2Ph 16% 
GIy-L-Tyr 1.43 R1  = H R2 = H R3 = H R4 = CHCH300H2Ph 14% 
GIy-L-Thr 1.44 R1  = H R2 = H R3 = H R4 = H2C-(j-OCH2Ph 12% 
GIy-L-Pro 1.45 R1  = H R2 = H R3 	H R4  = ç-co 6% 
L-AIaGIy 1.46 R1  = H R2 = OH3  R3 = H R4 = H 0% 
Scheme 1.13. Rotaxane synthesis with flexible peptide-based hydrogen-bond templates.67 
18 
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These results showed that structural requirements for efficient dipeptide rotaxane 
synthesis via hydrogen bonding are: (i) an N-terminal glycine residue is necessary to 
avoid steric hindrance, (ii) the distance and the transoid arrangement of the two amide 
carbonyl moieties in the peptide backbone are suitable for the template effect between 
the peptide thread and the precursor of the macrocycle, (iii) the a-substituent on the 
second amino acid residue must not be too bulky to allow a correct hydrogen bonding 
site. The synthesis of the L-PheGIyGly and TyrGlyGlyPheLeu rotaxanes in 2.5 and 1% 
yield respectively highlighted that an internal template site in a longer peptide chain can 
satisfy the requirements for rotaxane formation. However the likely folding of the 
backbone by intramolecular hydrogen bonding is probably responsible for the 
dramatically low yields obtained, preventing from a good preorganisation of the 
precursor macrocycle around the thread 
.71 
Leigh et al. has shown 71  that the presence of a macrocycle around a peptide thread 
protects against enzymatic degradation and can completely modify the cell membrane 
transport characteristics of the peptide. Derivatization of peptides into rotaxanes could 
allow the design of novel prodrug delivery systems as, despite of their involvement in a 
wide range of biological processes, peptides generally fail as therapeutic agents72 because 
of their degradation in vivo and their poor membrane transport permeability and 
73 	 . absorption properties. However, there has been recently a renewed interest to their 
development into human therapies as selective drug-delivery systems in treatments of 
infections, inflammation, immune system disorders, obesity, diabetes, cardiovascular 
74 diseases and cancer. 
19 
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The main issue towards the use of peptide rotaxanes as prodrugs is their efficient 
synthesis in good yields. This thesis describes the synthesis of oligopeptide rotaxanes via 
extension of short rotaxane building blocks. In chapter two, the synthesis of a series of 
activated ester rotaxane building blocks is reported. Their elongation was carried out for 
the efficient synthesis of oligopeptide rotaxanes and especially of the rotaxane of a 
protected bioactive pentapeptide. Chapter three is dedicated to the synthesis of N-
protected tripeptide rotaxane building blocks functionalized on their lateral chain by a 
labile bulky stopper and elongated after N-deprotection, via classical peptide couplings, 
to reach oligopeptide [2] and [3]rotaxanes in solution. Fusion of both types of building 
blocks leads to the synthesis of an N-protected tripeptide activated ester rotaxane 
building block extended via both the C- and N-terminal sides (chapter 4). 
20 
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1.3. Properties modulation via encapsulation and potential applications towards 
drug delivery systems 
Such interlocked architectures are interesting candidates for the design of potential 
drug delivery systems. A rotaxane made of a physiologically active macrocycle or thread 
could indeed be carried to a specific receptor and then be decomposed into its 
constituting components via stopper cleavage and release the active form of the prodrug. 
Little research has been done so far on this topic and investigations still remain at the in 
vitro step. 
1.3.1. Rotaxane encapsulation: towards modulation of solubility, lipophilicily 
and enzymatic degradation 
Leigh et al. showed that encapsulation of the thread within the macrocycle results in 
changes in the physical, chemical and biological properties of both components.7' The 
effect of encapsulation on lipophilicity was studied by measurement of the 
Chromatography Hydrophobicity Index (CHI log D values,75 comparable to log P76) of a 





CHI log D=3.60 
Scheme 1.14. Svnthess of a Ihmilv of functionalized [21rotaxanes. 
21 
Chapter One 
The CIII log D values varied with the structure of the macrocycle. Pyridyl derivative 
1.51 showed a high value in the Clii log D series, due to its exceptionally lipophiic 
nature (Table 1.1.). 
peptide rotaxane 
derivatives 
Yield % CHI log D 
C I-I 1.32 62 3.67 
C 1.48 49 4.25 
C 1.49 55 
OH 
C O)OH J 	1.50 97 2.03 
N 1.51 45 4.53 
C NO2 1.52 50 3.10 
Table 1.1. Lipophilicity data for a family of functionalized [2]rotaxanes at pH 7.4. 
Reagents: (i) 2,2 N-methylmorpholine N-oxide, cat. 0s04, CH2C12, 97%. 
Conditions: reverse phase HPLC - 0DS2-1K5 Inertsil column - 150 x 4.6 x mm 
(Capital HPLC Ltd., Broxburn, Scotland), mobile phase: 50 MM ammonium acetate 
(7.0<pH<7.3)/acetonitrile, flow-rate: 1.00 inL/min. 
Leigh et al. synthesized the rotaxane of the Leu-enkephalm (TyrGlyGlyPheLeu) 1.53, a 
bioactive pentapeptide, in order to evaluate the protective potential of the macrocycle 
towards enzymatic degradation (Scheme 1.15.). 







Scheme 1.15. Synthesis of the Leu-enkephalin rotaxane 1.53. 
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a-chymotrypsin-catalyzed degradation showed the protective effect of the macrocycle on 
the peptide thread as no degradation of the debenzylated Leu-enkephalin rotaxane 1.55 
could be detected even after 24 hours compared to a 35 minute half-life for the 
corresponding debenzylated thread 1.54 (Scheme 1.16.). 
HO 
0\ 	 -chymotpsin 
u-OH 	
10% CH3CN/H20 








YO N 	N 
0.05M tris buffer pH 7.8 
H 0.01 M CaCl2 
1.55 
cleavage between 
Phe and Leu residues 
half-life= 35 mm 
no cleavage 
after 24 h 
Scheme 1.16. Biodegradation studies of the tBoc-protected Leu-enkephalin 1.54 and its corresponding 
rotaxane 1.55 by a-chymotrypsin. Conditions: 10% acetonitrile/water (0.05M tris buffer, pH 7.8) 
using a 0.01M solution of a-chymotrypsin. 
These results indicate that encapsulation of peptide threads within a tetraamide 
macrocycle can be used to modulate lipophilicity and enzyme degradation of the 
supramolecular architecture, two properties of fundamental importance to successful 
peptide based drug design. 
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1.3.2. Host-[2]rotaxanes as guest transporters 
Smithrud et al.'s research aims at using rotaxane architectures as mimetics for artificial 
receptors able to carry a guest through the many biological environments encountered 
during cell penetration. For this purpose, a series of host- [2]rotaxanes77 was synthesized. 
The convergent arrangement of the functional groups of the hydrophobic pocket and the 
macrocyclic amino acid residue was shown to be particularly efficient for binding amino 
acid type guests that have an aromatic ring and a negative charge (Scheme 1. 17. 
).71 
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Scheme 1.17. Host-[2jrotaxanes 1.56-1.58 79 
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1.3.3. Biodegradable polyrotaxanes as potential drug delivery systems 
Cyclodextrins (CDs) are of interest in medicinal chemistry due to their ability to form 
water-soluble and low-toxicity complexes with encapsulated guest molecules in their 
hydrophobic cavities. Yui and Ooya have proposed new types of drug carriers made of 
biodegradable cyclodextrin and PEG polyrotaxanes that can be dissociated via terminal 
hydrolysis of their bulky stoppers. 
1.3.3.1. Characterization of biodegradable cyclodextrin polyrotaxanes 
The drug-polyrotaxane conjugates are characterized by the supramolecular structure of 
the drug carrier and the drug-immobilized cyclodextrin (Figure 1.7.). 
Biodegradable moiety 
PEG 	Hydroxypropylated O.CD 	(e.g. extraceliWarty 







Figure 1.7. Design of a prodrug polyrotaxane conjugate. 
80,81 
Specific drug delivery can be achieved by building conjugates with two distinct 
degradable moieties: (i) the endgroup stoppers cleaved by an extracellular enzyme and (ii) 
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Drug.poyrotaxana conjugate 	Release of drug-immobilized a-CD 	 Release of active drugs 
Figure 1.8. Drug release from drug-polyrotaxane conjugates via enzymatic degradation. 80 
1.3.3.2. Synthesis of drug-polyrotaxane conjugates 
1.3.3.2.1. Example of the Theophylline-polyrotaxane conjugate 
The theophylline-polyrotaxane conjugate 1.59 was the first example of drug-
















Scheme 1.18. The theopylline-polyrotaxane conjugate 1.59.80 
Efficient release of Theo-a-CDs from theopylline-polyrotaxane conjugate 1.59 was 





of the conjugates does not bring any steric hindrance  but rather enhances the accessibility 
of the enzyme to the terminal peptide linkage. 
1.3.3.2.2. Multivalent-ligand-polyrotaxane conjugates 
Many ligand molecules have the ability to interact with surface binding proteins, 
especially in the intestine, which expose multivalent interactions on cell surfaces as 
multiple copies of recognition elements. 12 Multivalent-ligand-polyrotaxane conjugates, 
including biotin-83'84 and peptide-polyrotaxane conjugates,85 have been designed to 
temporally bind with transporters until dissociation via controlled terminal enzymatic 
hydrolysis leading to ligand-ct-CD conjugate release (Figure 1.9.). 
UuitivalenI binding with transporters 
lnhtbifing the absorption of nutrients 
Ailanng The orug tra17spcft perntenbilitt 
Dissociation from the Change to Monovalent binding transporters 
PIOcJeNJ4IJQM4 Biodegradable polyrolaxanes 
Specific lIqar8te for transporters 
ralisporTers 
Figure 1.9. Controlled-multivalent binding with the transporters using ligand-polyrotaxane conjugates 
for altering the transporter properties. 83 
1.3.3.3 Polyrotaxanes as drug penetration enhancers 
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Transdermal drug delivery is an ideal form of drug administration as it maintains quasi-
constant plasma level of drugs. However this requires the use of penetration enhancer 
formulations necessary to increase the skin permeability to the drug at rates sufficiently 
high for therapeutic efficacy. The use of polymeric enhancers may be a solution to 
increase drug penetration with no induction of physiological problems in subcutaneous 
tissues, such as acute and chronic inflammation. The mechanical aspects of their 
introduction into the cell membranes have been extensively discussed in relation to (i) 
changing the structure or dissolving skin lipids, (ii) altering the conformation or 
denaturing skin proteins, (iii) disrupting the water structure in skin and (iv) increasing 
membrane fluidity. Increased membrane fluidity can indeed accelerate two cellular 
functions: (i) the mobility of membrane proteins or enzymes, which are related to 





1- regulation of intracellular metabolism 
GP: glycoprotein 	 2- enhanced drug absorption 
Figure 1.10. Effect of enhanced membrane fluidity on cellular functions. 
86 
Ooya's and Yui's polyrotaxanes have been shown (i) to increase plasma fluidity of red 
blood cells,86 (ii) to decrease the bound water rate at the stratum corneum87 at 37°C, 
indicating effective extraction of polar lipids or proteins, or the exchange of water in the 
29 
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polar lipids and (iii) to maintain the structure of the lipid bilayers in the stratum corneum 
even after treatment. Enhanced permeation of indomethacin, a drug used in the treatment 
of arthritis, through the skin was observed by treatment with polyrotaxanes.88 
Ooya and Yin have shown that biodegradable polyrotaxanes are promising drug 
delivery systems due to (i) their supramolecular dissociation via terminal hydrolysis and 




1. 4. Conclusion and Outlook 
Nowadays interlocked architectures are not only curiosities as this was the case in the 
1960's: the creation of functional molecules has been proved to be feasible in the 
laboratory. 
This is due to a better understanding of self-assembly and especially to the use of 
chemical templates for the synthesis of a large range of incredibly elaborate interlocked 
architectures. 
Besides synthesizing these challenging molecules, their use as new therapeutic agents is 
getting more and more challenging.  Much attention is focused on their potential as drug 
delivery systems including mimetics for artificial receptors in a host-guest molecular 
recognition process, permeation enhancers, enzyme resistant structures. 
In vitro assays have shown their great potential and hopefully in vivo assays will be the 
next step towards their further development. 
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Elongation of readily-accessible building blocks: 
An efficient synthesis of a Leu-enkephalin rotaxane 
Prepared as aflulipaper to Journal ofAmerican Chemical Society. 
Abstract: The synthesis of new activated ester rotaxane budding blocks, in peptidic and 
fumaric series, as new tools for making hard to reach molecules is reported. Their further 
elongation was carried out to efficiently give oligopeptide rotaxanes in very good yields. 
To overcome solubility problems and folding of the backbone, the method was then 
extended to the synthesis of a Leu-enkephalin rotaxane and a bistable molecular shuttle, 
otherwise isolated in poor yields via the conventional "clipping" strategy. This strategy 
leads easily to very large libraries of interlocked architectures. 
Keywords: activated ester - peptides - building blocks —rotaxanes - hydrogen bonds 
solubility - library. 
Chapter Two 
2.1. 	Introduction 
In the last few years, knots, 
1-4  then catenanes5'6 and finally rotaxanes79 of naturally 
occurring peptides and protein backbones have been unambiguously identified. Amongst 
the latter, a few naturally occurring "lassoed" type small peptides (16-21 amino acids) 
have been reported: Microcin J25(MccJ25),79 anantin,10  RES-701-01," RP 71955,12 
syamicyn H,13 and MS-271.'4  Unlike conventional peptides, these have shown very 
exciting properties such as unique modes of antimicrobial and antiviral actions, 
15-17 
impressive membrane transport and solubility characteristics, unprecedented stability to 
thermal and chemical denaturing" and, of greater relevance, an extreme stability to 
peptidases. Inspired by the impressive interlocked architectures that nature can build, we 
recently described the derivatization of dipeptides into rotaxanes incorporating benzylic 
1,3-carbamide macrocycles, using a five-component hydrogen bond-directed 
assembly. 19,20  Solubility in organic solvents and enzymatic resistance properties of the 
threads can be greatly modulated by the presence of the macrocycle,2' thus tailoring their 
cell membrane transport characteristics towards successful peptide based prodrug 
systems. However, encapsulation via the clipping strategy has been limited so far to short 
peptide sequences. Intramolecular hydrogen bonding and insufficient  solubility of longer 
peptide threads in apolar solvents can induce the folding of the backbone, thus preventing 
a good preorganization between the peptide thread and the precursor of the macrocycle. 
As an example, the rotaxane formation of a Leu-enkephalin has previously been reported 
in a low yield of 1%.21 
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In order to remedy this problem we describe here an efficient and versatile synthesis of 
new activated ester rotaxane building blocks in peptidic and fumaric series. The choice of 
2,6-diphenyl-para-nitrophenyl as an activated ester was two-fold: (i) its bulkiness 
prevents the disassembly between the macrocycle and the thread, and (ii) its reactivity is 
controlled: despite the steric hindrance in the rotaxane building blocks, the ester was 
found to be sufficiently reactive to nucleophilic attack 
22  and of similar reactivity to para-
nitrophenyl ester but still less reactive than isophthaloyl dichloride towards a large 
excess of para-xylylene diamine during the rotaxane formation. Also these building 
blocks are stable enough to be purified by column chromatography and stored for many 
weeks at room temperature. Only two other examples of rotaxane building blocks used 
for elongation have been reported in the literature so far, however none has been applied 
to the preparation of oligopeptide rotaxanes.24'25  
2.2. Results and discussion 
Synthesis of rotaxane building blocks in peptidic andfumaric series 
Three activated ester threads were prepared with the aim of synthesising  rotaxane 
building blocks (Schemes 2.1. and 2.2.). They only differed in their templating moiety for 
rotaxane formation: (i) a glycylglycine subunit, the best template in dipeptide series,2' (ii) 
a fumaric amide ester and (iii) a fumaric diamide template, the latter having been reported 
as the most efficient hydrogen bonding motif in our interlocked systems.26 The dipeptide 
activated thread 2.4 was prepared in a three step sequence from the dipeptide 
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Ph) N 1JLoH 
2.3 
Scheme 2.1. Synthesis of the dipeptide activated ester thread 2.4. a) Diphenylacetyichioride, Et3N, 
CHC13, 99%; b) i) KOH, EtOHJH2O, ii) HC1 94%; 
c) 2,6-diphenyl para-nitrophenol, BOP, Et3N, CHC13, 60%. 
The fumaric threads 2.8 and 2.11 were both synthesised from the fumaric acid 
monoethylester 2.5 in 3 and 5 step standard coupling syntheses respectively (Scheme 
2.2.). 
H 0 	 Ph 	H 0 	 Ph 	H 0 
a 	 N 	OEt b Ph 
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OEt 	.-Ph 
0 H 	 0 H 	 0 H 
2 2.6 2.7 
Cd 
Ph - NO2 
Ph 	H 0 - H 
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2.11 	 2 	 2.10 
Scheme 2.2. Synthesis of the fumaramide ester and amide activated ester threads 2.8 and 2.11. a) 
Diphenylethyl amine, DMAIP, EDCI.HC1, CHC13, 97%; b) i) NaOH, EtOHIH2O, ii) HC1, 94%; c) 2,6- 
diphenyl para-nitrophenol, BOP, Et3N, CHC13, 65%; d) HC1.H-Gly-OEt, BOP, Et3N, CHC13, 81%; e) i) 
NaOH, EtOHJH20, ii) HC1, 90%; f) 2,6-diphenyl para-nitrophenol, BOP, Et3N, CHC13, 68%. 
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Unlike our previous studies,28  the formation of rotaxanes from the three threads was 
then carried out by adding equimolar quantities of isophthaloyl dichloride in chloroform 
and a mixture of para-xylylene diamine and triethylamine in chloroform (Scheme 2.3.). 
The presence of a large excess of base mixed with the thread can indeed be responsible 
for the formation of an oxazolone, then leading to the dissociation of the macrocycle 












Scheme 2.3. Synthesis of the rotaxane building blocks 2.12-2.14. 
It is noteworthy that the three rotaxane building blocks could be stored for many weeks 
at room temperature without observing  any degradation. The yields of the pure isolated 
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Table 2.1. Rotaxane formation from the activated 2,6-para-nitrophenyl esters: synthesis of the 
building blocks 2.12-2.14. 
As previously observed in the fumaric series,26 the fumaric ester rotaxane 2.13 was 
obtained in the lowest yield of 37%. Ester carbonyls being poor hydrogen bond 
acceptors ,29  their interaction with the amide NH of the precursors of the macrocycle are 
weaker than with the corresponding amide carbonyls. In the dipeptide series, the 
glycyiglycine rotaxane 2.12 was obtained in 48% yield, lower than for the corresponding 
diphenylethyl ester stoppered rotaxane (62%), ° probably due to a partial nucleophilic 
side-attack of the para-xylylene diamine on the activated ester. 
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Rotaxane building block solid slate structures 
Crystals of the building blocks were obtained from slow diffusion of methanol into 
solutions of rotaxanes 2.12 and 2.13 in chloroform (Figure 2.1.). 
2.12 	 2.13 
038-HN11 2.04, 166.5'-1 04 1 -HN20 2.52, 	N3914-028 2.17,173.1'; 040-HN2 2.19,160.5'; 040- 
161.2°; 041-HN29 2.51, 161.7°. 	 HNII 2.10, 166.9°; 043HN20 2.30, 142.9°. 
Figure 2.1. X-ray crystallographic structures of the building blocks 2.12 and 2.13. Intramolecular 
hydrogen-bond lengths (A) and angles as indicated. Carbon atoms of the macrocycle are shown in blue 
and those of the thread in yellow; oxygen atoms are red, nitrogen atoms dark blue and amide hydrogen 
atoms white. Non-amide hydrogen atoms are omitted for clarity. 
In both structures, a set of hydrogen bonds, from weak to strong, is observed between 
the macrocycle and the thread. The crystal structure of the glycyiglycine rotaxane 2.12 
contains one pair of bifurcated intramolecular hydrogen bonds (NHO 2.51-2.52 A, 
OHN 161.20-161.70) and one standard short intramolecular hydrogen bond (NHO 
2.04 A, OHN 166.5). Similarly, the fumaraniide ester 2.13 contains one set of 
bifurcated hydrogen bonds (NHO 2.10-2.19 A, OHN 160. 5°-166.9°) and one standard 
hydrogen bond (NH''O 2.30 A, OlIN 142.90). However, its hydrogen bonding pattern 
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differs to that of 2.12 since one amide NH of the thread interacts with one carbonyl of the 
macrocycle (NH-0 2.17 A, O ... IIN 174.80). 
Ready-accessibility to oligopeptide rotaxanes 
With the aim of making oligopeptide rotaxanes, the C-terminus elongation of the 
rotaxane 2.12 was investigated using various stoppered amino acids (Scheme 2.4.). 
Unlike the thread 2.4, the corresponding rotaxane did not react with the primary amine of 
stoppered amino acids at room temperature, due to the presence of the macrocycle which 
acts as a stenc protective shield along the thread. In a first attempt, rotaxane 2.12 was 
heated at reflux in chloroform in the presence of an excess of triethylaniine to free in situ 
the stoppered glycine derivative from its tnfluoroacetate salt. The resulting tripeptide 
GlyGlyGly rotaxane 2.15 was then isolated in an average yield of 61%. In a typical 
procedure then, and to prevent this side reaction, a mixture of rotaxane 2.12 and at least 
two equivalents of mono- or tri-peptides as a free amine moiety in chloroform was heated 
at reflux and the reaction monitored by TLC (Table 2.2.). The appearance of a yellow 
color in the reaction crude indicated the release of the 2,6-diphenyl-para-nitrophenolate. 
R 	0Ph 
N, 
	tE 	 f 	
'N "1i' 	"Ph Ph 	NO, H: 
	Ph 	 N :equivalent) 
Ph H C13, 
 or 
2.12 	 2.15-2.19 






nb t (hours) Yield % 
GlyGlyGly 2.15 2 24 91 
GIyGIy-L-Ala 2.16 2 24 88 
GlyGly-L-Leu 2.17 2 24 78 
GlyGly-L-Phe 2.18 5 52 74 
GlyGly-L-AlaGlyGly_2.19 2 72 55 
Table 2.2. Synthesis of ohgopeptide rotaxanes 2.15-2.19. 
The yields of isolated rotaxanes 2.15-2.19 varied from good to excellent depending on 
the bulkiness of the side-chain of the amino acid added. 
The 'H NMR comparisons in CDCI3 of the glycyiglycine activated ester thread 2.4, its 
corresponding rotaxane building block 2.12, and the tripeptide glycylglycylglycine 
rotaxane 2.15 are reported in Figure 2.2. In spectra b and c, the asymmetry of the thread 
stoppers leads to two different dd signals for the enantiotopic benzylic hydrogens HF of 
the macrocycle. A shielding effect occurs on the hydrogens of the thread located in the 
cavity of the macrocycle. In spectrum b, the signals for F-f., HF and H, of the rotaxane 
building block 2.12 are shifted upfleld compared to the corresponding signals in the 
thread 2.4 (spectrum a), indicative of the macrocycle being positioned over these protons. 
It can be assumed that the macrocycle interacts with the two amide carbonyls of the 
thread in CDC13, in accordance with the X-ray structure of 2.12 (Figure 2.1.). In the 
GlyGlyGly rotaxane 2.15 (spectrum c), H H:. and Ii are now shifted downfield whereas 




almost the same shielding effect of the macrocycle, thus indicating that the macrocycle in 
compound 2.15 is moving quickly in the NMR time scale. 
a) 







h - 	 A 




Figure 2.2. Comparison of the 1H NMR spectra (400 MHz, CDC13) of a) the GlyGly activated thread 
2.4, b) the activated GlyGly rotaxane building block 2.12 and 
c) the GlyGlyGly tripeptide elongated rotaxane 2.15. 
Rotaxane building blocks as new tools for overcoming solubility problems and folding 
of the backbone 
Previous work in our laboratory has evidenced that insufficient solubility and folding of 
long thread backbones lead to rotaxane formation in poor yield. This is mainly due to 
intramolecular hydrogen bonding in the thread preventing good preorganization with the 
precursor of the macrocycle. Rotaxane building blocks appear to be a very convenient 
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tool for making elaborate rotaxanes, not easily reachable by conventional encapsulation 
methods. 
The synthesis of the rotaxane of a biologically active pentapeptide, the protected Leu-
enkephalin, has been reported in a very low yield of 1% via a clipping strategy.2' In order 
to improve this result, the new methodology discussed in this chapter was successfully 
applied to the synthesis and elongation of a tyrosylglycylglycine rotaxane building block 
2.24 (Scheme 2.5.). The Boc and benzyl protecting groups on the tyrosine residue and 
the side-chains of successive phenylalanine and leucine residues were found to be bulky 
enough to act as stoppers for the size of the benzylic 1,3-carbamide macrocycle. Thus, 
the tripeptide thread 2.23 was prepared in a three-step sequence in an overall yield of 
59%. The rotaxane formation was carried out similarly to that for the building blocks 
2.12-2.14, but using 16 equivalents of para-xylylene diamine and isophthaloyl dichloride. 
Rotaxane building block 2.24 was very easily purified via silica gel chromatography and 
isolated in 19% yield, then further elongated with H-Phe-Leu-013n to give the protected 
Leu-enkephalin rotaxane 2.25 in 86% yield. This strategy allows the straightforward 
synthesis of a pentapeptide rotaxane in very good yield, purified via convenient silica gel 
chromatography and with no solubility problems. 
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2.25 	 2.24 
Scheme 2.5. Synthesis of the Leu-enkephalin 2.25. a) HC1.H-GlyGly-OEt, EDCI.HC1, CHC13, 98%; b) i) 
KOH, MeOH, ii) 2,6-diphenyl para-nitrophenol, BOP, Et3N, CHC13, 59%; c) isophthaloyl dichloride, 
para-xylylene diamine, Et3N, CHC13, 19%; d) H-PheLeu-OBzl, CHC13 reflux, 86%. 
The synthesis of a bistable molecular shuttle 2.28 has been previously reported' in an 
overall 32% yield via a clipping strategy around the Z-thread 2.26 followed by thermal 
isomerisation at 120°C in C211204  for 7 days. In fact, the E-thread could not be used for 
the rotaxane formation via a clipping strategy due to its very poor solubility in non 
hydrogen bonding disrupting solvent. With the aim of improving the feasibility and 
overcoming solubility problems, the new methodology was successfully applied to the 
straightforward elongation of the fumaric activated ester rotaxane building block 2.13 
with N-(12-aminododecyl)-N'(2, 2-diphenylethyl) succinaniide to give 2.28 in 71% yield 
(Scheme 2.6.). Although it is similar to the clipping strategy in terms of reaction steps 
and yield, our methodology ensured a real improvement of the physical properties of 
these interlocked architectures: (i) purification via silica gel chromatography was made 
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very easy due to the large difference in polarity of 2.13 and 2.28 and (ii) no solubility 
problem was experienced at any step of the formation of the latter rotaxane derivatives. 
Ph Ph 
	 Ph Ph 
0 	 Ph 
- 










10 	 H Ph 
Scheme 2.6. Synthesis of a bistable molecular shuttle 2.28. a) isophthaloyl dichloride, para-xylylene 
diamine, Et3N, CHC13, 40%; b) C2112C14 at 1200C for 7 days, 80%; c) 
NEI2(CH2)12C0(CH2)2CONT4CH2CHPh2 (5 equivalents), CHC13 reflux, 72 hours, 71%. 
Compared to the direct encapsulation strategy, the synthesis of rotaxane building 
blocks, followed by elongation with nucleophiles appears to give much better results both 
in terms of yields and convenience, since the problems of solubility and folding of threads 
can be avoided. Moreover, the synthesis of a few rotaxane building blocks allows for the 
preparation of a wide range of elaborate interlocked architectures and could then be an 




We have shown a versatile synthesis of activated ester rotaxane building blocks via 
standard coupling chemistry, in dipeptide and fumanc series, which can be isolated and 
stored for many weeks at room temperature with no degradation. They have then been 
efficiently used for the synthesis, in very good yield, of a wide range of oligopeptide 
rotaxanes, reached in very poor yield by the classical methods of encapsulation due to the 
folding of the peptide backbone. The syntheses of a bistable molecular shuttle and a 
protected Leuenkephalin rotaxane in very good yields illustrate the ability of the strategy 
to reach, in only a few steps, non readily-accessible molecules by overcoming solubility 
and folding problems. It is noteworthy that, when encapsulated within a tetraaniide 
macrocycle, oligopeptides present interesting changing properties: their solubility in 
organic solvents and their vulnerability against enzymes can indeed be incredibly 
modulated by the macrocycle acting as a protective sheath around the peptide backbone. 
These are very promising results for the design of successful peptide based drugs. 
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2.4. Experimental section 
Method for the preparation of the dipeptide thread 2.4 
N-diphenylacetylglycylglycine ethyl ester 2.2 
Triethylamine (7.700 g, 0.076 mmol) was added to a stirring suspension of glycyl 
glycine ethyl ester hydrochloride (2.1, 5.000 g, 0.025 mmol) in anhydrous chloroform 
(200 mL). When no more material remained in suspension, diphenylacetyl chloride (7.050 
g, 0.030 mmol) was added in small portions as a solid. After 2 hours of stirring, the 
reaction mixture was washed with water (3 *200 mL) and the organic layer dried over 
MgSO4. The solvent was then removed under reduced pressure and the crude material 
recristallised from toluene to give the desired product as a white powder. Yield (8.750 g, 
97%); mp 158°C; 1H NMR (400 MHz, CDC13): ö = 8.27 (t, 1H, J = 6.0 Hz, 
CONHCH2CO), 8.12 (t, 1H, J = 6.0 Hz, CONHCH2CO), 7.21-7.10 (m, 10 H, Ar-H), 
4.81 (s, 1 H, Ph2CHCONH), 3.82 (q, 2H, J = 7.0 Hz, CO2C112CH3), 3.59 (d, 2H, 
J_z 6.0 
Hz, NHCH2CO), 3.54 (d, 2H, J = 6.0 Hz, NHCHZCO), 0.94 (t, 311, J = 7.0 Hz, 
CO2CH2CH3); 13C NMR (100 MHz, CDC13): ö = 173.02, 169.67, 169.34, 139.20, 
129.36, 129.00, 128.86, 127.43, 61.55, 58.57, 43.35, 41.30, 14.25; FAB-MS m/z 355 
[M+H4], calcd. for C20H22N204: C, 67.8, H 6.3, N 7.9, found C, 67.8, H 6.4, N 7.9. 
N-diphenylacetylglycylglycine 2.3 
The (N-diphenylacetyl)glycyl glycine ethyl ester (2.2, 9.521 g, 26.900 mmol) was 
dissolved in 180 mL of absolute EtOH. A solution of KOH (3.130 g, 55.800 mmol) in 20 
mL of water was added. The reaction mixture was stirred at RT during 3 hours. The 
solvent was removed under reduced pressure. HC1 was added. The precipitate was 
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filtered and dried by evaporation under reduced pressure to afford a white powder that 
showed spectroscopic data according to literature.32 Yield (8.146 g, 94%). 
N-diphenylacetylglycylglycine 4-nitro-2,6-diphenylphenylester 2.4 
N-diphenylacetyl)glycylglycine (2.3, 1.046 g, 3.200 mmol), 4-nitro-2,6-diphenyl phenol 
(4.662 g, 16.000 mmol), NEt3 (4.877 g, 48.000 mmol) and BOP (2.119 g, 4.800 mmol) 
were dissolved in 70 mL of CHC13. The reaction mixture was stirred 4 hours at room 
temperature. The crude material was purified via silica gel chromatography 
(AcOEt/cyclohexane: 1/1) to afford a yellow powder. Yield (1.146g. 60%); mp 171.4°C; 
'H NMR (400 MHz, CDC13): ö = 8.20 (s, 2 H, NO2-Ph-H), 7.20-7.10 (in, 20 H, Ar-H), 
6.25-6.21 (br t, 2H, Gly CONI{CH2CO), 4.81 (s, 1 H, Ph2CHCONH), 3.70 (d, 2H, J5.3 
Hz, NHCH2CO), 3.65 (d, 2H, J=5.3 Hz, NHCH2CO); 13C NMR (100 MHz, CDC13): ö = 
172.72, 168.60, 166.86, 149.26, 146.06, 138.83, 137.44, 135.31, 128.86, 128.81, 
128.73, 127.62, 127.42, 124.99, 58.68, 43.19, 40.96; FAB-HRMS for C361130N306 m/z 
[M+l{1], calcd. 600.21346, found 600.21254. 
Methodfor the preparation of the fumaramide ester thread 2.8 
2,2-diphenylethylaminofumarylethylester 2.6 
Fumaric acid monoethyl ester (2.5, 3.320 g, 0.023 mol), 2,2-diphenylethylaniine (5.000 
g, 0.025 mol) and DMAP (2.810 g, 0.023 mol) were dissolved in 150 mL of CH202. The 
reaction mixture was cooled at 0°C. Then EDCI.HC1 (4.410 g, 0.023 mol) was added. 
The reaction mixture was stirred one hour at 0°C and brought to room temperature and 
stirred overnight. The crude material was concentrated under reduced pressure. The 
organic phase was washed with 2M HC1 and saturated NaHCO3. The organic phase was 
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dried over MgSO4. The solvent was removed under reduced pressure to afford a pink 
solid. Yield (7.480 g, 91%); mp 128°C; 'H NIMIR (400 MHz, CDC13): 6 = 7.36-7.20 (m, 
1011, Ar-H), 6.78 & 6.72 (2d, 2H, J = 15.6 Hz, COCH & CHCOO), 5.75 (br t, 1H, 
Ph2CHCH2NHCO), 4.25-4.17 (m, 3H, Ph2CHCH2 & COOCH2CH3), 3.99 (t, 2H, J— 8.0 
Hz, Ph2CHC), 1.29 (t, 3H, J = 7.2 Hz, COOCH2CH3); 13C NMIR (100 MHz, CDC13): 
6 = 165.52, 163.49, 141.40, 135.95, 130.63, 128.86, 127.98, 127.04, 61.20, 50.35, 
44.07, 14.11; FAB-HRMS for C20H22NO3 rn/z [M+H], calcd. 324.15997, found 
324.16098. 
2,2-diphenytethylaminofumaric acid 2.7 
Following the experimental procedure leading to derivative 2.3. 
Yield (0.958 g, 100%); mp 203°C; 'H NTMR (400 MHz, CDC13): 6 =8.50 (t, 111, J = 
6.6 Hz, Ph2CHCH2NHCO), 7.27-7.09 (m, 1OH, Ar-H),  6.77 & 6.41 (2d, 211, J = 15.4 
Hz, COCH & CHCOO), 4.17 (t, 1H, J = 6.6 Hz, Ph2CHCH2), 3.76 (t, 2H, J = 6.6 Hz, 
Ph2CHCH2); 13C NMR (100 MHz, CDC13): 6 = 167.17, 163.91, 143.3 0, 13 7.04, 130.81, 
129.09, 128.45, 127.05, 50.54, 43.99; FAB-HRMS for C,8H18NO3 m/z [M+1{], calcd. 
296.12867, found 296.12800. 
2,2-diphenylethylaminofumaryl 4-nitro-2,6-diphenylphenylester 2.8 
Following the experimental procedure leading to derivative 2.4. 
Yield (1.081 g, 65%); mp 191°C; 'H NI[VIIR (400 MHz, CDC13): 6 = 8.29 (s, 2 H, NO2-
Ph-H), 7.45-7.16 (in, 2011, Ar-H), 6.62 & 6.43 (2d, 2H, J = 15.2 Hz, COCH & 
CHCOO), 5.54 (br t, 1H, Ph2CHCH2NHCO), 4.15 (t, 111, J= 8.2 Hz, Ph2CHCH2), 3.94 
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(dd, 211, J = 5.6 & 8.2 Hz, Ph2CHCH2); 13C NMR (1100 MHz, CDC13): 6 = 162.59, 
158.38, 149.46, 145.94, 141.19, 137.45, 135.41, 135.41, 128.91, 128.76, 128.71, 
128.65, 128.16, 127.92, 124.99, 50.26, 44.06; FAB-HRMS for C36H29N205 m/z [M+}r], 
calcd. 569.20765, found 569.20870. 
Methodfor the preparation of the fumaramide glycine thread 2.11 
2,2-diphenylethylaminofumaryigLycytethylester 2.9 
Following the experimental procedure leading to derivative 2.4. 
Yield (0.600 g, 81%); mp 237°C; 'H NIIVIR (400 MHz, CDC13): 6 = 7.36-7.19 (m, IOH, 
Ar-H), 6.95 & 6.74 (2d, 2H, J = 14.8 Hz, COCH & CHCONH), 6,57 (br t, 1H, 
CONHCH2CO), 5.87 (br t, 1H, Ph2CHCH2NHCO), 4.25-4.18 (m, 3H, Ph2CHCH2 & 
COOCH2CH3), 4.10 (d, 211, J = 4.8 Hz, NHCHCO),  3.99 (dd, 2H, J = 6.0 & 8.0 Hz, 
Ph2CHCH2), 1.28 (t, 311, J = 6.8 Hz, COOCH2CH); 13C NMR (100 MHz, CDC13): 6 = 
164.84, 163.77, 132.97, 131.73, 128.32, 127.42, 126.50, 61.23, 49.79, 43.53, 41.09, 
13.57; FAB-HRMS for C22R25N204 m/z [M+H], calcd. 381.18143, found 381.18135. 
2,2-diphenylethylaminofuniarylglycine 2.10 
Following the experimental procedure leading to derivative 2.3. 
Yield (0.250 g, 90%); mp 214°C; 'H NMR (400 MHz, CDC13): 6 = 8.76 (t, 111, J= 6.0 
Hz, CONH),  8.52 (t, 111, J = 5.2 Hz, CONH),  7.35-7.16 (m, 1011, Ar-H),  6.86 & 6.78 
(2d, 211, J = 15.2 Hz, COCH & CHCONH), 4.23 (t, 1H, J = 8.0 Hz, Ph2CHCH2), 3.87-
3.78 (in, 4H, Ph2CHCH2 & NHCH2CO); 13C NMR (100 MHz, CDC13):  6 = 168.75, 
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161.90, 161.42, 140.52, 130.93, 129.75, 126.26, 125.64, 124.21, 47.76, 41.14, 38.59; 
FAB-HRMS for C201121N204 m/z [M+H4], calcd. 353.15013, found 353.15093. 
2,2-diphenylethylaminofumarylglycyl-4-nitro-2,6-dipheflylpheflYleSter 2.11 
Following the experimental procedure leading to derivative 2.4. 
Yield (0.190 g, 68%); 'H NMR (400 TVII-Iz, CDC13):  ö = 8.28 (s, 2H, NO2-Ph-11), 7.47-
7.15 (m, 20H, Ar-H), 6.73 & 6.63 (2d, 211, J= 14.8 Hz, COCH & CHCONH), 6.06 (brt, 
1H, CONHCH2CO), 5.83 (br t, 1H, Ph2CHCH2NHCO), 4.17 (t, 1H, J = 8.0 Hz, 
Ph2CHCH2), 3.94 (t, 211, J= 6.4 Hz, Ph2CHC), 3.84 (d, 2H, J= 7.4 Hz, NHCFjCO); 
13C NMR (100 IVII-Iz, CDC13): 8 =166.82, 164.58, 158.22, 141.36, 138.91, 137.39, 
135.24, 133.78, 131.78, 128.89, 128.86, 128.82, 128.72, 127.94, 127.47, 127.06, 
125.02, 50.32, 44.05, 41.33; FAB-HRMS for C38H32N306 rn/z [M+H], calcd. 
626.22911, found 626, 23 05 1. 
Method for the preparation of the tripeptide activated ester thread 2.24, precursor of 
the Leu-enkephalin 
N-terbutoxycarbonyl—O-benzyl-t,-tyrosylglycylglycine ethyl ester 2.21 
Following the experimental procedure leading to derivative 2.6. 
Yield (2.905 g, 98%), 111  NMR (400 MHz, CDC13): 5 = 7.45-7.23 (m, 611, Ar-H & Gly 
CONHCH2CO), 7.11 (d, 211, J = 7.8 Hz, CH2ArHH'OBn), 6.91 (d, 211, J 7.8 Hz, 
CH2ArHH'OBn), 6.74 (br t, 111, Gly CONHCH2CO), 5.10 (d, 1H, J = 6.6 Hz, 
(CH3)3COCONH), 5.03 (s, 1H, OCH2Ph), 4.28 (q, 1H, J= 6.6 Hz, Tyr NHCHCO), 4.17 
(q, 211, J= 7.6 Hz, COOCH2CH3),  4.04-3.86 (mn, 411, Gly NIHCFJ2CO), 3.06 (dd, 1H, J= 
6.8 Hz & 14.0 Hz, Tyr PhCH20ArCHH'), 2.96 (dd, 1H, J = 6.8 Hz & 14.0 Hz, Tyr 
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PhCH2OArCHH'), 1.39 (s, 9H, (Cj)3COCO), 1.25 (t, 3H, COOCH2Cj); 13C NMR 
(100 MHz, CDC13): 6 - 169.74, 167.24, 166.70, 155.57, 134.55, 127.95, 126.27, 
126.21, 125.69, 125.14, 112.77, 78.26, 67.68, 59.16, 54.12, 40.62, 38.86, 34.84, 25.93; 
FAB-HRMS for C27H36N307 m/z [M+W], calcd. 514.25533, found 514.25639. 
N-terbutoxycarbonyl—O-benzyl-L-tyrosylglycylglycinate 2.22 
N-terbutoxycarbonyl—O-ben.zyl-L-tyrosylglycylglycine ethyl ester (2.21, 1.720 g, 3.350 
mmol) was dissolved in 30 mL of a solution of 1M KOH in MeOH. The reaction 
temperature was stirred 3 hours at RT and monitored by TLC. The solvent was removed 
under reduced pressure to afford a solid. Yield (1.400 g, 80%); 1 H NMR (400 MHz, 
DMSO): 6 = 8.54-8.43 (2 br s, 2T-T, Gly CON114CH2), 7.54-7.43 (m, 5H, Ar-H),  7.26 (d, 
2H, J = 8.4 Hz, CH2ArHH'OBn), 7.06 (d, IH, J = 8.0 Hz, (CH3)3COCONH),6.96 (d, 
2H, J= 8.4 Hz, CH2ArHH'OBn), 5.12 (s, 111, PhCO), 4.22-4.14 (m, 1H, J= 6.6 Hz, 
Tyr NHCHCO), 3.92-3.65 (m, 4H, Gly NHCIjZCO), 3.09-2.99 (br t, 1H, 
PhCH20ArCHH'), 2.78-2.69 (m, 1H, PhCH20ArCHH'), 1.35 (s, 911, (CH3)3COCO) 
(CH)3COCO, 13C NMR (100 MHz, DMSO): 6 = 172.16, 169.71, 167.41, 156.77, 
155.26, 137.21, 130.52, 130.19, 128.35, 127.69, 127.59, 77.89, 69.05, 56.04, 44.03, 
42.25, 40.06, 36.62, 28.10; FAB-HRMS for C25H31KN307 rn/z [M+H], calcd. 
524.17991, found 524.17971. 
N-terbutoxycarbonyl--O-benzyl-L-tyrosylglycylglycine 4-nitro-2, 6-diphenyiphenyl 
ester 2.23 
Following the experimental procedure leading to derivative 2.4. 
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Yield (0.825 g, 59%) 111  NMR (400 MHz, CDC13): 5 = 8.30 (s, 211, NO2Ph-H), 7.52-
7.27 (m, 16H, Ar-H & CONH), 7.09-7.06 (m, 2H, CH2ArHH'OBn), 6.91-6.88 (m, 2H, 
CH2ArHH'OBn), 6.71 (br s, 1H, CONH), 6.57 (br s, 1H, CONH), 5.04 (s, 211, 
OCPh), 4.26-4.10 (m, IH, Tyr NHCHCO), 3.90-3.69 (m, 4H, Gly NI{CCO), 3.05-
2.97 (in, 1H, Tyr NIHCH(CHH')CO), 3.05-2.97 (in, 111, Tyr NIHCH(CHH')CO), 1.35 (s, 
9H, (Cfl)3COCO),  13C NMIR (100 MHz, CDCI3): 8 = 172.16, 169.02, 166.80, 157.96, 
149.28, 145.99, 137.44, 136.82, 135.32, 130.23, 130.17, 128.89, 128.81, 128.75, 
128.62, 128.25, 128.06, 127.49, 124.99, 115.14, 80.79, 70.01, 56.43, 42.67, 40.98, 
36.99, 28.21, FAB-HRMS for C43H43N409 m/z [M+H], calcd. 759.30300, found 
759.30444. 
General procedure for the preparation of /2]rotaxane building blocks 2.12-2.14 and 
2.24 
Thread 2.4, 2.8, 2.11 or 2.23 (1.910 mmol) was dissolved in 100 mL of CHC13 under 
nitrogen and stirred vigorously whilst solutions of the mixture ofpara-xylylene (2.121 g, 
15.600 mmol) and NEt3 (3.965 g, 39.300 mmol) in 50 mL of CHC13 and the isophthaloyl 
dichloride (3.151 g, 15.500 mmol) in 50 mL of CHC13 were simultaneously added to the 
reaction mixture over a period of 3 hours using motor-driven syringe pumps. The 
reaction mixture was stirred 2 hours under nitrogen, then filtered on celite and the filtrate 
was evaporated under reduced pressure to afford a syrup which was purified via silica gel 
chromatography to yield, in order of elution, the unconsumed activated ester thread 
(AcOEt/cyclohexane: 1/1) and the rotaxane (CHC13/MeOH: 98/2). 
Glycyiglycine activated rotaiane 2.12 
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Yield (1.047 g, 48%); m.p. 171°C; 'H NMR (400 MHz, CDC13): ö = 8.27 (s, 2 H, 
NO2-Ph-H), 8.11 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-11), 7.88 (s, 211, isophthaloyl 
2-H), 7.59 (t, 211, J = 7.6 Hz, isophthaloyl 5-11), 7.48-6.90 (m, 21 H, thread Ar-Il & 
CON}{), 7.22 (br t, 4H, macrocyclic CONB), 6.76 (s, 8H, macrocyclic para-xylylene, 
Ar-H), 5.18 (br t, 1 H, Ph2CHCONH), 4.41 (dd, 411, J = 4.8 Hz, J = 13.8 Hz, 
macrocyclic NHCHH'), 4.18 (dd, 411, J = 4.4 Hz, J = 13.8 Hz, macrocyclic NHCHH'), 
3.95 (s, 111, Ph2CHCONIIT), 3.67 (d, 2H, J = 5.2 Hz, Gly NllCCO), 2.58 (br d, 211, 
Ph2CHCONHCH2CO); 13C NMR (100 MHz, CDC13): ö = 172.15, 169.82, 166.66, 
165.85, 148.94, 146.17, 138.17, 137.31, 135.17, 133.84, 131.57, 129.48, 128.76, 
128.61, 128.17, 127.58, 125.01, 123.74, 58.07, 43.60, 41.70, 40.30; FAB-FIRMS for 
C68H58N7010 rn/z [M+H], calcd. 1132.42452, found 1132.42500; [aID = 0 in CHC13. 
Fumatyl activated rotaxane 2.13 
Yield (0.428 g, 37%); m.p. 135°C; 'H NMR (400 MHz, CDC13): ö = 8.16 (d, 4H, J= 
8.0 Hz, isophthaloyl 4-H & 6-11), 8.13 (br s, 411, isophthaloyl 2-H & NO2-Ph-H), 7.59 (t, 
211, J = 8.0 Hz, isophthaloyl 5-H), 7.50-6.92 (m, 24H, macrocyclic CONH & thread Ar-
H & thread CONIH), 6.51 (s, 811, macrocyclic para-xylylene ArH), 5.88 & 5.30 (2d, 211, 
J = 15.2 Hz, COCH & CHCOO), 4.42 (dd, 411, J = 4.8 Hz, J = 14.8 Hz, macrocyclic 
NHCHH'), 4.34 (dd, 411, J= 4.4 Hz, J= 14.8 Hz, macrocyclic NHCHH'), 3.79 (t, 111, J 
= 8.0 Hz, Ph2CHCH2), 3.16 (m, 21-1, Ph2CHCj); 13C NMR (100 MHz, CDC13): ö = 
166.78, 163.72, 162.44, 145.97, 141.63, 137.65, 137.44, 136.87, 135.40, 134.18, 
134.11, 130.90, 129.33, 129.06, 128.90, 128.83, 128.76, 128.66, 128.21, 127.81, 
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126.93, 125.12, 125.08, 52.44, 44.86, 44.11; FAB-HRMS for C68H57N609 rn/z [M+W], 
calcd. 1101.41870, found ll0l.41928. 
Fumaryiglycine activated rotaxane 2.14 
Yield (0.176 g, 80%); m.p. 183°C; 'H NIVIR (400 MHz, C2D204): 6 = 8.47 (s, 2H, 
NO2-Ph-H), 8.19 (s, 2H, isophthaloyl 2-H), 8.16 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 
6-H), 7.66 (t, 211, J= 7.6 Hz, isophthaloyl 5-H), 7.54-6.99 (m, 26H, macrocyclic CONH 
& thread Ar-H & thread CONH), 6.66 (s, 8H, macrocyclic para-xylylene Ar-H), 5.37 & 
5.32 (2d, 2H, J= 14.8 Hz, COCH & CHCO), 4.30-4.26 (m, 4H, macrocyclic NHCHH'), 
4.15-4.12 (m, 4H, macrocyclic NHCHH'), 4.04 (t, 1H, J = 8.0 Hz, Ph2CHCH2), 3.68-
3.67 (m, 4H, Ph2CHCH2 & Gly NHCH2CO); 6 = 13C NMIR (100 MHz, C2D2C14): 167.06, 
166.50, 166.28, 165.73, 165.30, 149.66, 147.47, 146.44, 142.08, 137.76, 137.28, 
135.61, 134.04, 132.02, 130.01, 129.37, 129.17, 129.12, 129.09, 128.18, 127.66, 
125.49, 124.68, 45.19, 43.96, 43.95, 39.09, 38.88; FAB-HRMS for C70H 0N7010  m/z 
[M+H], calcd. 1158.44017, found 1158.43976. 
EBoc-L-tyrosylglycyl glycine activated iotaxane 2.24 
Yield (0.107 g, 19%); 'H NMR (400 MHz, CDC13): 6 = 8.26 (s, 211, NO2-Ar-H), 8.04 
(d, 411, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 7.97 (s, 2H, isophthaloyl 2-H), 7.54 (br s, 
1H, macrocyclic CONH), 7.52 (t, 2H, J = 7.6 Hz, isophthaloyl 5-H), 7.48-7.20 (m, 2611, 
isophthaloyl 5-H & thread Ar-H & thread CONH & macrocyclic CONH), 7.04 (s, 811, 
macrocyclic para-xylylene, Ar-H), 6.83 (m, 4H, CH2ArHH'OBn & CH2ArHH'OBn), 
5.81 (br s, 1H, BocTyr(OBn)NHCH2CO), 5.01 (s, 211, OCH2Ph), 4.49-4.29 (m, 911, 
macrocyclic NHCHH' & macrocyclic NHCHH' & Tyr (CH3)3COCON}1), 3.89-3.61 (m, 
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3H, Tyr NHCHCO & Gly NHCHH'COO & Gly NHCHB'COO), 2.80-2.63 (m, 3H, Gly 
NHCHCO & Tyr NHCH(CHIH')CO), 2.36-2.24 (m, 1H, Tyr NHCH(CHH')CO), 1.12 
(s, 9H, (CH3)3COCO); 13C NMR (100 MHz, CDC13): 8 = 171.69, 169.33, 166.94, 
166.83, 166.23, 157.80, 149.05, 146.14, 137.44, 137.35, 137.29, 136.86, 135.27, 
134.27, 131.39, 131.12, 130.02, 129.08, 128.95, 128.89128.76, 128.70, 128.60, 128.32, 
128.00, 127.39, 127.05, 124.28, 114.99, 80.95, 69.97, 55.06, 44.27, 44.05, 41.89, 40.78, 
36.75, 27.90; FAB-IIRMS for C75H70N8013Na m/z [M+Na+], calcd. 13 13.49604, found 
1313.49817. 
General procedure for the elongation of /2Jrotaxane building blocks 2.12, 2.13 and 
2.24 
The [2]rotaxane building block 2.12, 2.13 or 2.24 (0.079 mmol) and a stoppered 
nucleophile (0.390 mmol but 0.980 mmol for 2.18) were dissolved in 20 mL of CHCI3. 
The reaction mixture was then heated at reflux and monitored by TLC (CHC13/MeOH: 
90/10). The solvent was removed under reduced pressure. The crude material was 
directly purified via silica gel chromatography (CHC13/1\4eOH: from 98/2 to 95/5) to 
afford in order of elution the 2,6-diphenyl-para-nitrophenol, and the elongated rotaxane 
as a white powder. 
Glycyiglycyiglycine rotaxane 2.15 
Yield (0.078 g, 91%); m.p. 123°C; 1H NIN'IIR (400 MHz, CDC13): 8 = 8.21 (s, 2H, 
isophthaloyl 2-H), 8.06 (d, 411, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 7.75 (br t, 4H, 
macrocycic CONH), 7.51 (t, 2H, J = 7.6 Hz, isophthaloyl 5-H), 7.23-7.06 (m, 22 H, 
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thread Ar-H & thread Gly CONHCH2CO), 6.95 (s, 8H, macrocyclic para-xylylene, Ar-
H), 6.28 (br s, 1H, Gly CONHCH2CO), 4.59 (s, 1H, Ph2CHCO), 4.45-4.14 (m, 11H, 
macrocyclic NHCHH' & NHCHH' & COOCHH'CHPh2 & COOCHJ'CHPh2 & 
COOCHH'CHPh2), 3.41 (s, 2H, Gly NHCHCO), 3.07 (s, 2H, Gly NHCH2CO), 3.02 (s, 
21-1, Gly N}{CH2CO); 13C NMR (100 MHz, CDC13): ö = 172.8 8, 169.27, 168.79, 167.16, 
167.09, 140.49, 138.71, 137.25, 134.03, 131.27, 129.17, 128.96, 128.69, 128.62, 
128.53, 127.97, 127.49, 126.96, 124.62, 67.50, 58.17, 44.05, 43.92, 41.83, 40.65; FAB-
FIRMS for C66H62N709 m/z [M+H], calcd. 1096.46090, found 1096.45996; [aID = 0 in 
CHC13. 
Glycylglycyl-L-alanine rotaxane 2.16 
Yield (0.078 g, 88%); m.p. 134°C; H NMR (400 MIHz, CDC13): ö = 8.10 (s, 211, 
isophthaloyl 2-H), 8.03 (d, 2H, J = 7.6 Hz, isophthaloyl 4-H), 8.02 (d, 2H, J = 7.6 Hz, 
isophthaloyl 6-H), 7.51-7.43 (m, 4H, macrocyclic CON}j), 7.47 (t, 2H, J = 7.6 Hz, 
isophthaloyl 5-H), 7.27-7.02 (m, 22 H, thread Ar-H & CONII), 6.95 (d, 4H, J = 8.0 Hz, 
macrocyclic para-xylylene, Ar-H),  6.92 (d, 4H, J = 8.0 Hz, macrocyclic para-xylylene, 
Ar-H), 5.87 (br t, 1H, CONH), 4.62 (dd, 1H,J = 10.7 Hz, J= 8.3 Hz, COOCH2CHPh2), 
4.50 (s, 1H, Ph2CHCO), 4.41-4.17 (m, 1OH, macrocyclic NHCHH' & NHCHH' & 
COOCHH'CHPh2 & COOCHH'CHPh2), 4.09 (quint., 111, J = 6.8 Hz, Ala 
NHCH(CH3)CO), 3.16 (dd, 111, J= 4.8 Hz, J = 16.8 Hz, Gly NHCfH'CO), 3.09 (dd, 
1H, J = 4.0 Hz, J = 16.8 Hz, Gly NFICHH'CO), 2.99 (br s, 2H, Gly NHCHCO), 0.98 
(d, 31-1, J = 6.8 Hz, Ala NHCH(Cth)CO);  13C NMR (100 MHz, CDC13): 8 = 172.61, 
172.14, 169.26, 167.62, 166.89, 166.83, 138.62, 137.27, 137.21, 134.07, 134.01, 
131.39, 131.31, 129.20, 129.09, 128.88, 128.80, 128.67, 128.62, 128.53, 128.15, 
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128.07, 127.61, 127.04, 126.98, 124.34, 76.73, 67.43, 58.43, 49.68, 48.32, 44.17, 42.43, 
42.13, 29.72, 17.44; FAB-HRMS for C64164N709 m/z [M+W], calcd. 1110.47655, found 
1110.47762; [a}D= -9.6 in CHC13  
GlycylglycyL-L-Ieucine rotaxane 2.17 
Yield (0.087 g, 78%); m.p. 143°C; 'H NMR (400 M1E-Iz, CDC13): 6 = 8.10 (s, 2H, 
isophthaloyl 2-H), 8.07-7.99 (m, 4H, isophthaloyl 4-H & 6-H), 7.51-7.43 (m, 6H, 
macrocyclic CONH, isophthaloyl 5-H), 7.20-7.06 (m, 22H, thread Ar-fl & CONH), 6.95 
(d, 4H, J = 8.4 Hz, macrocyclic para-xylylene, Ar-H), 6.94 (d, 4H, J = 8.4 Hz, 
macrocyclic para-xylylene, Ar-H), 5.90 (br t, 1H, CONH), 4.63 (dd, 1H, J = 8.8 Hz J 
10.8 Hz, COOCH2CHPh2), 4.52 (s, 1H, Ph2CHCO), 4.44-4.22 (m, 1OH, macrocyclic 
NBC}IH' & NHCHH' & COOCHII'CHPh2 & COOCHH'CHPh2), 4.19-4.10 (m, 1H, 
Leu NHCH(CH2CH(CH3)2)CO), 3.17 (br s, 2H, J = 2.8 Hz, Gly NHCH2CO), 3.04 (br s, 
2H, Gly N}ICH2CO), 1.25-1.04 (in, 3H, Leu NHCH(CH2CH(CH3)2)CO & 
NIHCH(CH2CH(CH3)2)CO), 0.58 (d, 3H, J = 6.4 Hz, Leu 
NHCH(CH2CH(C113)(CH'3))CO), 0.56 (d, 3H, J 	6.0 Hz, Leu 
N}TCH(CH2CH(CH3)(CH'3))CO); 13C NIMR (100 MHz, CDC13): 6 = 172.68, 172.33, 
169.31, 167.95, 166.84, 166.79, 140.54, 140.25, 138.62, 137.24, 137.22, 133.96, 
131.35, 129.16, 129.08, 128.88, 128.79, 128.66, 128.61, 128.52, 128.11, 128.04, 
127.58, 127.01, 126.97, 124.31, 67.45, 58.44, 52.41, 51.12, 49.69, 44.17, 42.49, 42.04, 
40.79, 29.71, 24.67, 22.40, 21.69; FAB-HRMS for C70H70N709 m/z [M+H], calcd. 
1152.52350, found 1152.52267; [a]D =  -5.1 in CHC13. 
Glycylglycyl-L-phenylalanine rotaxane 2.18 
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Yield (0.063 g, 74%); m.p. 144°C; 'H NAM (400 MHz, CDC13): ö = 8.05 (s, 2H, 
isophthaloyl 2-14), 8.01 (d, 4H, J= 8.0 Hz, isophthaloyl 4-H & 6-H), 7.46 (t, 411, J= 7.6 
Hz, macrocyclic CONH), (7.36 (t, 2H, J= 5.2 Hz, isophthaloyl 5-H), 7.21-7.02 (m, 3111, 
thread Ar-H & CONH & macrocyclic para-xylylene Ar-H), 6.87 (d, 4H, J = 3.8 Hz, Phe 
Ar-H), 6.81 (d, 4H, J = 3.8 Hz, Phe Ar-H), 5.87 (br d, IH, Phe CONH), 4.50 (s, 1H, 
Ph2CHCO), 4.58 (dd, 1H, J= 10.8 Hz, J— 8.4 Hz, COOCH2CHPh2), 4.43-4.21 (m, 1011, 
macrocyclic NHCHH' & NIHCHH' & COOCHH'CHPh2 & COOCHET'CHPh2), 4.14 (t, J 
= 8.0 Hz, 1H, Phe NI{CH(CH2Ph)CO), 3.06 (d, 2H, J = 5.4 Hz, Gly NHCH2CO), 3.00 
(d, 2H, J = 5.4 Hz, Gly NHCH2CO), 2.69 (dd, 1H, J = 6.6 Hz, J = 14.4 Hz, Phe 
NHCH(CHH'Ph)CO), 2.57 (dd, 1H, J= 6.6 Hz, J= 14.4 Hz, Phe NHCH(CHH'Ph)CO); 
13C NMR (100 MZHz, CDC13): 8 = 172.61, 170.98, 169.23, 168.05, 166.79, 166.70, 
140.59, 140.34, 138.62, 137.25, 137.02, 135.97, 134.03, 133.87, 131.48, 131.25, 
129.18, 129.12, 129.08, 129.02, 128.80, 128.66, 128.51, 128.13, 128.03, 127.61, 
127.58, 127.32, 127.07, 124.31, 67.64, 58.49, 54.12, 49.53, 44.164, 42.40, 41.99, 37.24; 
FAB-IIIRMS for C731- 68N709 rn/z [M+H], calcd. 1186.50785, found 1186.50971; [ct]D = 
-1.8 in CHC13. 
Glycylglycyl-L-alanylglycylglycine rotaxane 2.19 
Yield (0.074 g, 55%); m.p. 133°C; 1H NMIR (400 MHz, C2D204): ö = 8.17 (s, 211, 
isophthaloyl 2-H), 8.01 (d, 211, J = 7.6 Hz, isophthaloyl 4-H), 7.99 (d, 2H, J = 7.6 Hz, 
isophthaloyl 6-H), 7.58 (br s, 1H, macrocyclic CONH), 7.49 (t, 2H, J = 7.6 Hz, 
isophthaloyl 5-H), 7.30-7.03 (m, 23H, thread Ar-H & macrocyclic CONE-I), 7.01 (s, 811, 
macrocyclic para-xylylene Ar-H), 6.92 (br s, 111, CONH), 6.81 (br s, 1H, CONH), 6.64 
(br s, 111, CONH), 6.56 (br s, 1H, CONH), 6.51 (br s, 1H, CONH), 4.79 (s, 1H, 
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Ph2CHCO), 4.47-3.24 (m, 18 1:1, Ala NHCH(CH3)CO & Gly NHCH2CO & macrocyclic 
NHCH2 & COOCFIIHI'CHPh2 & COOCHH'CHPh2 & COOCHH'CijPh2), 3.05-2.95 (m, 
2H, Gly NHCCO), 1.01 (d, 3H, J = 6.4 Hz, Ala NHCH(CH3)CO); 13C NMR (100 
MHz, C2D204): ö = 169.88, 169.66, 169.30, 167.62, 167.43, 164.14, 162.75, 162.39, 
141.05, 141.04, 139.30, 137.75, 129.71, 129.59, 129.47, 129.38, 129.36, 129.33, 
129.29, 129.55, 128.05, 127.61, 62.56, 50.06, 47.74, 47.44, 46.47, 46.21, 45.17, 45.00, 
44.77, 44.61; FAB-HRMS for C71H70N9011 rn/z [M+Ir], calcd. 1224.51948, found 
1224.51808; [aID not measurable in CHCI3 . 
tBoc Le Enkephalin OBn  rotaxane 2.25 
Yield (0.040 g, 86%); 'H NMR (400 MHz, CDCI3): 6 = 8.11 (s, 2H, isophthaloyl 2-H), 
7.96 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 7.76 (br t, 111, CONH), 7.67 (br s, 
IH, CONH), 7.40 (t, 211, J = 7.6 Hz, isophthaloyl 5-H), 7.34-6.97 (m, 26H, thread Ar-H 
& CONH & macrocyclic CONH& macrocyclic para-xylylene Ar-H), 6.91 (br t, 1H, Gly 
CONHCH2CO), 6.83 (d, 2H, J = 8.4 Hz, CH2ArHH'OBn), 6.75 (d, 2H, J = 8.4 Hz, 
CH2ArHH'OBn), 6.42 (br d, 1H, CONH), 6.34 (br s, 1H, Leu 
CONHCH(CH2CH(CH3)2)CO), 5.00 (s, 2H, PhCH2COO), 4.95-4.86 (m, 3H, Tyr 
(CH3)3COCON}j & OCH2Ph), 4.48-4.31 (m, 1OH, macrocyclic NIHCIIH' & macrocyclic 
NHCHH' & Phe NHCHCO & Leu NHCHCO), 3.99-3.94 (m, 1H, Tyr NHCHCO), 3.06-
2.70 (mn, 711, Tyr N}TCH(CHH'ArOBn)CO & Phe NHCH(CHH'Ph)CO & Phe 
NHCH(CHII'Ph)CO & Gly NHCH2CO & Gly NHCH2CO), 2.52-2.38 (m, 111, Tyr 
NHCH(CHH'ArOBn)CO), 1.45-1.29 (m, 3H, Leu NHCH(CHCH2CH(CH3)2)CO & 
NHCH(CHCH2CH(CH3)2)CO), 1.15 (s, 9H, (C)3COCO), 0.71-0.69 (m, 611, 
N-HCH(CHCH2CH(CH3)2)CO); 13C NMR (100 MHz, CDC13): 8 = 172.55, 172.38, 
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171.44, 169.07, 168.18, 167.31, 167.24, 157.62, 155.82, 137.18, 136.83, 136.43, 
135.19, 134.05, 133.94, 131.28, 131.22, 130.20, 129.92, 129.24, 129.03, 128.68, 
128.60, 128.54, 128.42, 128.16, 127.95, 127.42, 127.10, 125.01, 114.78, 80.48, 69.96, 
67.03, 55.29, 54.68, 51.05, 44.15, 42.33, 41.73, 40.47, 38.19, 37.08, 27.99, 24.70, 
22.47, 21.65; FAB-FIRMS for C79H86N9013 m/z [M+1{1, calcd. 1368.63451, found 
1368.63346. 
Bistable molecular shuttle rotaxane 2.28 
Yield (0.082 g, 71%); m.p. 194.7°C; 'H NMR (400 M1-1z, CDC13): ö = 8.40 (s, 2H, 
isophthaloyl 2-H), 8.11 (d, 4H, J = 7.8 Hz, isophthaloyl 4-H & 6-H), 7.64 (br t, 4H, 
macrocyclic CONH), 7.55 (t, 2H, J = 7.8 Hz, isophthaloyl 5-H), 7.32-7.14 (m, 21 H, 
thread Ar-H & thread CONH), 6.94 (s, 8H, macrocyclicpara-xylylene, Ar-H), 6.87 (br s, 
1H, CONH), 6.27 (br s, 1H, CONH), 6.13 (br s, 111, CONH), 5.88 & 5.73 (2d, 2H, J 
15.0 Hz, NHCOCH & CHCONH), 4.42 (br d, 8H, J = 4.4 Hz, macrocydic NHCH2), 
4.20 & 4.15 (2t, 2H, J =7.8 Hz & 7.6 Hz, Ph2CHCH2NHCOCH2 & 
CHCONHCH2CHPh2), 3.89-3.79 (m, 4H, Ph2CHCH2NETCOCH2 & 
CHCONHCH2CHPh2), 3.15-3.07 (m, 4H, CH2NHCOCH & CH2CON}TCH2), 2.13-2.02 
(m, 4H, succinic COCH2 & CH2CO), 1.48-1.39 (m, 4H, CH2CONIEICH2CH2 & 
CCH2NUCOCH), 1.31-1.22 (m, 16H, alkyl CONHCH2CH2(CH2)8CH2CH2NHCO); 
NMIR (100 MHz, CDC13): ö = 172.37, 172.22, 166.70, 165.63, 165.29, 141.86, 
141.59, 136.91, 131.32, 129.10, 129.01, 128.86, 128.70, 128.00, 127.99, 127.88, 
127.14, 126.84, 126.81, 124.55, 50.55, 50.41, 44.76, 43.93, 40.06, 39.56, 31.83, 31.74, 
29.69, 29.47, 29.38, 29.31, 29.26, 29.25, 29.16, 29.07, 26.96, 26.76; FAB-FIRMS for 
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A convenient synthesis of oligopeptide rotaxanes 
via classical peptide coupling reactions 
Prepared, together with Chapter Four, as a paper to Angewandle (]hemie 
International Edition in English. 
Abstract: The synthesis of three tnpeptide rotaxane building blocks, N-Fmoc and —tBoc 
protected L-SerGlyGly and L-AspGlyGly functionalized on the lateral chain by ether and 
ester labile bulky stoppers respectively, is described. After N-deprotection, further 
elongation of the building blocks via classical peptide coupling synthesis was carried out 
to conveniently give oligopeptide rotaxanes. The N-Fmoc-L-SerGlyGly rotaxane building 
block gave the best results in terms of (i) feasibility and (ii) fast shuttling of the 
macrocycle along the peptide backbone. By reacting this N-deprotected building block, 
with our previously reported 2,6-diphenyl para-nitrophenyl activated ester dipeptide 
rotaxane building block,' the method was successfully applied to the synthesis in solution 
of oligopeptide [3]rotaxanes which could be purified via reverse phase HPLC. Such 
peptide rotaxane building blocks are very versatile and convenient tools for overcoming 
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usual foldings of long peptide backbones and making libraries of oligopeptide rotaxanes 
in good yields, with no purification and solubility problems. 
Keywords: amino acid lateral chain - protection - peptide coupling - building blocks - [2] 
and [3]rotaxanes - hydrogen bonds - library. 
3.1. Introduction 
DNA is well-known to exhibit a large range of topologies: linear, circular and 
catenated2'3 and knotted 
.4  Until very recently, the case for naturally occurring interlocked 
peptides and secondary protein structures was not so clear. Dogma long held that 
proteins, even of complicated structures, contained mechanical links or knots only 
through disulfide bonds and cofactors. 
1,6 In the last few years, however, knots,
710 
 
catenanes11'12  and most recently rotaxanes'35  have been clearly characterized in peptide 
and protein skeletons. A few naturally occurring small peptides (16-21 amino acids) 
including a rotaxane-like substructure has indeed been reported: Microcin 
J25(MccJ25),1315 anantin,'6 RES-701-01,17  RP 71955,18 syamicyn 11,19 and MS-271.2°  
These unconventional peptides, with a "lasso"-like structure, exhibit intriguing properties 
ranging from unique modes of antimicrobial and antiviral action 
21-23  to remarkable 
membrane transport and solubility characteristics, impressive stability to thermal and 
chemical denaturing24  and, of higher significance, an extraordinary stability to peptidases. 
Efficient syntheses of such interlocked architectures rely upon non-covalent interactions 
between the components to direct the kinetically stable entanglement. We recently 
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reported the synthesis of dipeptide rotaxanes incorporating benzylic 1,3-carbamide 
macrocycles, using a five-component hydrogen bond-directed assembly.2527  However this 
approach is restricted to short peptide sequences only. In fact, in longer sequences the 
components will be largely self-satisfied in terms of hydrogen bonding through folding of 
the backbone, thus preventing a good preorganization between the peptide thread and the 
precursor of the macrocycle.28 
A method to overcome this problem is the recently reported synthesis of versatile 
activated ester rotaxane building blocks which can be elongated via their C-terminal side 
to promote the synthesis of oligopeptide rotaxanes in very good yields.' A new strategy 
we describe herein is the synthesis of new tripeptide rotaxane building blocks which can 
be N-extended via classical peptide coupling reactions. The choice of N-Fmoc or -(Boc 
protected L-Ser- or L-Asp-GlyGly sequences as a tripeptide was three-fold: (i) they 
contain the most efficient GlyGly dipeptide 
template, 28  (ii) the lateral chain of the first 
amino acid residue, L-Ser or L-Asp, respectively, functionalized as an ether or an ester, 
acts as a labile bulky stopper for the macrocycle and (iii) N-terminal Fmoc or tBoc 
deprotection of L-Ser or L-Asp residues promotes peptide coupling reactions towards the 
synthesis of oligopeptide rotaxanes, followed by further deprotection of the labile bulky 
stopper, allowing shuttling of the macrocycle along the peptide backbone at a rate that is 
within the NMR time scale. 
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3.2. 	Results and discussion 
Synthesis of tripeptide rotaxane building blocks 
Three tripeptide threads were prepared as templates for rotaxane formation. The 
threads only differed in their first amino acid residue and their N-terminal and lateral 
protecting groups: (i) an N-Fmoc protected L-Ser residue made bulky on its lateral chain 
by a tert-butyldiphenylsilyl ether (TBDPS) and (ii) N-Fmoc- and N-tBoc-protected L-Asp 
residues with, respectively, a tert-butyl and a diphenylethyl ester on the lateral chain. 
The N-Fmoc protected L-SerGlyGly tripeptide thread 3.3 was prepared in a two step 
sequence starting from the commercially available N-Fmoc-L-Ser-OH 3.1, using standard 
EDCI coupling peptide chemistry followed by TBDPS protection of the lateral alcohol 
(Scheme 3.1.). 
a 
HO 	 1 
3.1 	 PhPh 	3.3 
Scheme 3.1. Synthesis of the N-Fmoe-L-serylglyeylglycifle thread 3.3. a) (i)H-GlyGly-NHCH2CHPh2, 
DMAP, EDCI.HC1, CHC13, 45%, (ii) TBDPSC1, imidazole, DMF, 700C, 67%. 
The N-Fmoc protected L-AspGlyGly tripeptide thread 3.5 was prepared in one step 














(C H 3)3C0 
3.5 
Scheme 3.2. Synthesis of the N-Fmoc-L-asparticglycylglycfflC thread 3.5. a) TFA.H-GlyGly-
NHCH2CHPh2, DMAP, EDCI.HC1, CHCI3, 91%. 
The N-iBoc protected L-AspGlyGly tripeptide thread 3.9, protected on the lateral chain 
as a diphenyl ethyl ester, was prepared in a three step synthesis (Scheme 3.3.). 
O OCHph 	 OCH2Ph b 
HO 	 Ph2HCH2CO 	 Ph2HCH2CO 
3.6 	 3.7 	 3.9 
Scheme 3.3. Synthesis of the N-tBoc-L-asparticglycylglycine thread 3.9. a) HOCH2CIWh2, DMAP, 
EDCI.HC1, CHC13, 95%; b) (i) H2, Pd/C, P atm, EtOAc, 98%, 
(ii) H-GlyGly-NHCH2CHPh2, DMAP, EDCI.HC1, CHC13, 49%. 
In a typical procedure for rotaxane formation, equimolar quantities of isophthaloyl 
dichloride in chloroform and a mixture of para-xylylene diamine and triethylamine in 
chloroform were added to a solution of the thread 3.3, 3.5 or 3.9 in chloroform (Scheme 
3.4.).' 
H ° 	H 
N 	 Ph 
N-PG N( 
H 	 H Ph 
PG 
3.3, 3.5, 3.9 
oo 
C1 	C1 
H2N 	 NH2 	N-PG 
Et3N 
CHCI3 
Scheme 3.4. Synthesis of the rotaxane building blocks 3.10-3.12. 
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The yields of pure isolated rotaxane building blocks ranged from 11 to 19% (Table 1), 
similar to a previous result obtained in the tnpeptide series.28 The yields 	were improved 
by using multiple rotaxanation (see overal yields). 
N-PG 	X PG Peptide rotaxane 
derivative 
Yield % 	Overall 
yield % 
Fmoc 	0 TBDPS L-SerGlyGly 3.10 14 	
73a 
Fmoc 	CO2 tBu L-AspGlyGly 3.11 19 	
62b 
tBoc 	CO2 CH2CH2Ph2 L-ASpGIyGIy3.12 11 	
49C 
Table 3.1. Synthesis of the building blocks 3.10-3.12. * Overall yield respectively obtained after a) 4, 
b) 6 and c) 5 cycles of rotaxane formation. A cycle includes the synthesis of the rotaxane followed by its 
purification. The thread collected back from the column is then put on rotaxanation again. 
The 1H NMR comparison in CDC13  of the N-Fmoc-L-SerGlyGly thread 3.3 and its 
corresponding N-Fmoc protected and deprotected rotaxane building blocks 3.10 and 
3.13, respectively, are reported in figure 3.1. In spectra b and c, two different dd signals 
are observed for the enantiotopic benzylic hydrogens 1-l i of the macrocycle due to the 
asymmetry of the thread stoppers. A shielding effect on the protons of the thread located 
in the cavity of the macrocycle is observed. Thus in spectrum b, the signals for }-.., H and 
the first Gly residue are shifted upfield compared with those spectrum a, indicating the 
average position of the macrocycle around these protons. The R and H. protons are 
shielded in the deprotected rotaxane 3.13, compared with those in the building block 
3.10, by ö = 0.54 and 0.20 ppm respectively. This shielding effect indicates the 
localization of the macrocycle mainly around the L-Ser residue, which hinders the lone 






Figure 3.1. Comparison of the 1H NMR spectra (400 MHz, CDC1) of a) the N-Fmoc protected 
tripeptide L-SerGlyGly thread 3, b) the N-Fmoc protected tripeptide L-SerGlyGly rotaxane 3.10 and c) 
the deprotected tripeptide L-SerGlyGly rotaxane 3.13. See scheme 3.5 for the proton assignement. 
Straightforward synthesis of oligopeptide rotaxanes via classical peptide coupling 
reactions 
In order to make oligopeptide rotaxanes, the N-terminal elongation of rotaxanes 3.10 
and 3.12 was investigated using various stoppered amino acids (Scheme 3.5.) and 
classical peptide chemistry. In a typical procedure, rotaxane building block 3.10 was N-
Fmoc deprotected using piperidine in chloroform. The resulting free amine rotaxane 3.13 
was then reacted overnight at room temperature with 2 equivalents of stoppered mono-
and di-peptides using BOP coupling peptide chemistry. The TFA salt obtained after N-
tBoc deprotection of the rotaxane building block 3.12 was directly converted into the free 
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amine in situ by using an excess of base, for further coupling with a stoppered amino 
acid. The resulting oligopeptide rotaxanes 3.14-3.17 and 3.18 were further deprotected 
on their lateral chain with a 1M TBAF solution in TUF and potassium hydroxide in 
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Scheme 3.5. Synthesis of oligopeptide rotaxanes promoted by coupling of rotaxane 3.10 with various 
stoppered amino acids (n1, 2). a) piperidine/CHC13: 1/3, 99%; 
b) stoppered amino acid, BOP, Et3N, CHC13; c) IM TBAF in THE 
The yields of isolated rotaxanes 3.14-3.18 varied from good to excellent depending on 
the steric hindrance of the stoppered amino acids added (Table 3.2.). 
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Fmoc 0 TBDPS 1 GIy-L-SerGlyGly 3.14/ 3.19 90 
Fmoc 0 TBDPS 2 GlyGly-L-SerGIyGlY 3.15/ 3.20 
77 
Fmoc 0 TBDPS I L-Ala-L-SerGIyGly 3.16/ 3.21 
69 
Fmoc 0 TBDPS I L-Leu-L-SerGlyGIy 3.17! 3.22 47 
tBoc CO2 CH2CHPh2 1 GIy-L-ASpGIyGIY 3.18/ 3.23 70 
Table 3.2. Synthesis of oligopeptide rotaxanes 3.14-3.18. 
The 1  NMR comparisons in CDCI3  of the TBDPS-protected and deprotected Gly-L-
SerGlyGly rotaxanes 3.14 and 3.19, respectively, and the deprotected rotaxane GlyGly-L-
SerGlyGly 3.20 are shown in figure 3.2. After deprotection of 3.14, a shielding effect on 
one set of Gly protons is observed, this indicates that the macrocycle is shuttling along 
the whole peptide backbone at a rate that is fast on the NIVIR timescale. The same 
behaviour is observed in the longer deprotected GlyGly-L-SerGlyGly rotaxane 3.20. It 
has been shown that such a shuttling of the macrocycle along the peptide thread allows 
for peptide resistance against enzyme biodegradation.28 
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Figure 3.2. Comparison of 1H NMR spectra (400 MHz, CDC13) of a) the TBDPS-protected Gly-L-
SerGlyGly tetrapeptide rotaxane 3.14, b) the deprotected Gly-L-SerGlyGly tetrapeptide rotaxane 3.19 at 
313K and c) the deprotected GlyGly-L-SerGlyGlY pentapeptide rotaxane 3.20 at 313K. 
It is noteworthy that in the aspartic series, rotaxane 3.23 did not display any 
consequent shuttling of the macrocycle on the NMR time scale, even though examination 
of CPK models indicated that the carboxylate lateral chain of the aspartic residue should 
not act as a stopper for the benzylic 1,3 -carbamide macrocycle. 
The N-Fmoc protected L-SerGlyGly tripeptide template, functionalized as a TBDPS 
ether on its lateral chain, was selected for further investigations. 
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Tripeptide rotaxane building blocks as new tools for convenient synthesis of 
oligopeptide [3]rolaxanes in solution 
Synthesis of oligopeptide [3]rotaxanes has never been reported so far in the literature. 
A convenient method for making such complex interlocked architectures is by "fusion" of 
the present and previously reported strategies-.' the 2,6 diphenyl para-nitrophenyl 
activated ester of the dipeptide rotaxane building block 3.28 is displaced by nucleophiic 
attack of an N-terminal free amine rotaxane building block. Both solvent polarity and 
steric hindrance of the nucleophile are parameters of importance. Therefore, the rotaxane 
building block 3.13 was extended by a Glyn  spacer (n=1 and 2) and further N-Fmoc 
deprotected to give the free amine rotaxanes 3.26 and 3.27, respectively. The reaction 
was performed by dissolution of the activated rotaxane building block 3.28 and the 
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oCI° 
 Ph Ph '  
3.29-3.31 
Scheme 3.6. Synthesis of oligopeptide [31rotaxanes from the building block 3.13. a) (i) N-Fmoc-Gly-
OH (n0-2), BOP, Et3N, CHC13, (ii) piperidine/CHC13: 1/3; 
b) activated ester rotaxane 3.28 in DMF, 65°C for n0 and CHC13, reflux for n0-2. 
The yields of [3]rotaxane formation are reported in table 3.3. With no Gly spacer, the 
lone pair of the rotaxane building block 3.13 is likely to be too sterically hindered by the 
close proximity of the macrocycle to induce any nucleophilic attack on 3.28 since only 
traces of [3]rotaxane 3.29 are detected by LC-MS after refluxmg in chloroform for one 
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week. This is consistent with the appearance of the 'H NIvIR spectra obtained in CDC13  
(Figure 3.1.). A second attempt was carried out in DMIF, the highly polar solvent was 
expected to disrupt the hydrogen bonding between the macrocycle and the free amine 
peptide rotaxane 3.13 
'29,30 but again only traces of 3.29 were detected by LC-MS. When 
one or two Gly spacers is present in 3.26 and 3.27, respectively, as the lone pair of the N-
terminal Gly residue is completely available for nucleophiic attack, oligopeptide 
[3]rotaxanes were synthesised in chloroform at reflux and isolated by preparative HPLC 
in about 50% yield. This strategy allows for the straightforward synthesis of oligopeptide 
[3]rotaxanes easily purified via preparative reverse phase }TPLC (gradient H20/MeOH) 
and obtained in average yields. 
n Peptide [3]rotaxane 
derivative 




Temperature 0C Yield % 
o GlyGly-L-SerGIYGIY 3.29 1 2 CHCI3  reflux 
traces 
o GlyGly-L-SerGIYGIY 3.29 1 2 DMF 65 
traces 
1 GIyGly-Gly-L-SerGIYGIY 3.30 1 1 CHCI3  reflux 
—50 
2 GlyGly-GIyGly-L-SeIGIYGIY 3.31 1 1 CHCI3 reflux —50 
Table 3.3. Synthesis of oligopeptide [3]rotaxanes 3.29-3.31. (n328 number of equivalents of Gly
-Gly 
activated ester rotaxane 3.28, n313 number of equivalents of L-SerGlyGly, Gly-L-SerGlyGly and 




We have described the synthesis of three tripeptide rotaxane building blocks, N-Fmoc 
and —iBoc protected L-SerGlyGly and L-AspGlyGly functionalized on their lateral chain 
by a labile bulky stopper. After N-deprotection using piperidine or TFA, further 
elongation of the building blocks via classical peptide coupling chemistry was carried out 
to easily give oligopeptide rotaxanes. The N-Fmoc protected L-SerGlyGly rotaxane 
building block was found to be the most efficient template, as the macrocycle displayed a 
fast shuttling along the peptide backbone after lateral chain deprotection. Reaction of the 
N-deprotected tripeptide building block with our previously described 2,6-diphenyl pam-
nitrophenyl activated ester dipeptide rotaxane successfully yielded oligopeptide 
[3rotaxanes, which were purified via reverse phase HPLC. Such peptide rotaxane 
building blocks are very versatile and convenient tools for making wide libraries of 
peptide interlocked architectures without problems of purification and solubility. 
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3.4. Experimental section 
Synthesis of oligopeptide rotaxanes by N-coupling with various stoppered amino 
acids 
Method/or the preparation of the tripeplide L-SerGlyGly thread 3.3 
amide 3.2 
N-a-Fmoc-L-serine (3.1, 1.815 g, 5.550 mmol), glycylglycine-2,2-diphenylethyl amide 
(1.721 g, 5.530 mmol) and DMAP (0677 g, 5.54 mmol) were dissolved in 100 rnL of 
CHC13. The reaction mixture was cooled at 0°C. Then EDCI.HC1 (1.609 g, 8.390 mmol) 
was added. The reaction mixture was stirred one hour at 0°C and brought to room 
temperature and stirred overnight. The crude material was washed with IM HC1 and 
saturated NaHCO3. The organic phase was dried over MgSO4. The solvent was removed 
under reduced pressure. The purification via silica gel chromatography (CHC13/MeOH: 
96/4) afforded a white powder. Yield (1.553 g, 45%); m.p. 90°C; 'H NIvIIR (400 MHz, 
CDC13): ö = 7.75 (d, 2H, J = 7.4 Hz, aromatic Ar-H Fmoc), 7.57 (d, 2H, J = 7.4 Hz, 
aromatic Ar-H Fmoc), 7.38 (t, 2H, J = 7.4 Hz, aromatic Ar-H Fmoc), 7.41-7.13 (m, 
14H, aromatic Ar-H & aromatic Ar-H Fmoc & CONH), 6.26 (br t, 1H, 
CONBCH2CHPh2), 5.99 (d, 1H, J = 7.6 Hz, Ser OCONHCH(CH20H)CO), 4.40 (d, 2H, 
J = 6.8 Hz, Fmoc CHCH2000NH), 4.27-4.21 (m, 1H, Ser NHCH(CH2OH)CO), 4.17 
(t, 1H, J = 6.8 Hz, Fmoc CHCH2000NH), 4.12 (t, 1H, J = 7.4 Hz, CONHCH2CHPh2), 
3.92 (dd, 1H, J = 5.2 Hz, J = 11.2 Hz, Ser N}ICH(CIfH'OH)CO), 3.89-3.84 (m, 2H, 
Gly NBCHCO), 3.81 (t, 2H, J = 7.4 Hz, CONBCFI2CHPh2), 3.70 (d, 2H, J = 4.8 Hz, 
Gly NHCH2CO), 3.62 (dd, TH, J = 5.2 Hz, J = 11.2 Hz, Ser NHCH(CHH'OH)CO); 13C 
NIVIR (100 IVIIHz, CDC13): 6 = 171.81, 169.54, 169.00, 157.86, 143.59, 141.52, 141.31, 
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128.75, 127.96, 127.83, 127.13, 126.92, 125.01, 120.06, 67.15, 62.98, 56.35, 50.28, 
47.05, 43.89, 43.14, 42.73; FAB-HRMS for C36H37N406 m/z [M+H4 ], calcd.: 621.27131, 
found: 621.27105. 
amide 3.3 
N-a-Fmoc-L-seryl glycylglycine-2,2-diphenylethYl amide (3.2, 0.819 g, 1.320 mmol) 
and imidazole (0.245 g, 3.600 mmol) were dissolved in dry DMF (8 mL) under nitrogen. 
TBDPSC1 (3.5 mL, 13.680 mmol) was added and the solution was stirred 24 hours at 
70°C. The solvent was removed under reduced pressure. The purification via silica gel 
chromatography (CHC13/MeOH: 98/2 to 90/10) afforded a yellowish powder. Yield 
(0.763 g, 67%); m.p. 18 8°C; 1H NMP. (400 MHz, CDC13): ö = 7.76 (d, 2H, aromatic Ar-
H Fmoc, J = 7.6 Hz), 7.63-7.12 (m, 26H, aromatic Ar-H & aromatic Ar-H Fmoc), 7.00 
(br t, 1H, CONIICH2), 6.88 (br t, 1H, CONIJCH2), 6.25 (br t, TH, CONIIC112), 5.54 (d, 
1H, J = 6.0 Hz, Ser OCON}ICH(CH20H)CO), 4.45-4.33 (m, 2H, Fmoc 
CHCHOCONH), 4.21-4.10 (m, 311, Fmoc CHCH2000NH & Ser 
NHCH(CHH'(OTBDPS))CO & CONHCH2CHPh2), 3.96 (dd, 1H, J = 4.8 Hz, J = 13.2 
Hz, Ser NHCH(CHH'(OTBDPS))CO), 3.91-3.75 (m, 6H, CONHCH2CHPh2 & Gly 
N1HCHCO & Gly NI{CH2CO), 3.70 (dd, 1H, J = 4.8 Hz, J = 13.2 Hz, Ser 
NHCH(CJ*1'(OTBDPS))CO), 1.04 (s, 9H, OSiC(CH3)3); 13C NIMIR (100 MHz, CDC13): 
o = 170.61, 168.71, 167.92, 157.85, 143.60, 143.58, 141.71, 141.37, 141.33, 135.44, 
134.80, 132.48, 132.27, 130.18, 128.65, 128.07, 128.05, 128.02, 128.00, 127.85, 
127.81, 127.71, 127.14, 127.09, 126.75, 125.01, 124.94, 120.07, 81.33, 67.26, 63.49, 
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56.90, 50.35, 47.13, 43.19, 43.05, 29.71; FAB-HRMS for C521155N406 m/z [M+Ft], 
calcd.: 859.3 8909, found: 859.3 8990. 
Method for the preparation of the N-Fmoc protected tripeptide L-AspGlyGly thread 
3.5 
N-a-Fmoc-L-(tert-butyl 	 amide 3.5 
Following the experimental procedure leading to derivative 3.2. 
Yield (0.822 g, 91%); amorphous solid; 1H NMR (400 M1-lz, CDC13): ö = 7.76 (d, 2H, 
J =7.6 Hz, aromatic Ar-H Fmoc), 7.58 (d, 211, J =7.2 Hz, aromatic Ar-H Fmoc), 7.41 
(td, 2H, J =2.4 Hz, J =7.6 Hz, aromatic Ar-H Fmoc), 7.34-7.16 (m, 1211, aromatic Ar-H 
& aromatic Ar-H Fmoc), 7.05 (br t, 1H, CONHCH2), 6.77 (br t, 1H, CONHCH2), 6.26 
(t, 1H, J =5,6 Hz, CONHCH2CHPh2), 5.66 (d, 1H, J 
=8.8 Hz, Asp 
OCONHCH(CH2CO2-tBU)CO), 4.52 (d, 2H, J = 6.0 Hz, Fmoc CHCH2000NH), 4.45-
4.38 (m, 1H, Asp NHCH(CH2CO2-tBu)CO), 4.22 (t, 1H, J = 6.0 Hz, Fmoc 
CHCH2000NH), 4.18 (t, 111, J 8.0 Hz, CONHCH2CHPh2), 3.94-3.71 (m, 611, 
CONHCH2CHPh2 & Gly NHCHCO), 2.90 (dd, 1H, J = 5.0 Hz, J = 17.2 Hz, Asp 
NHCH(CHH'CH2CO2-tBU)CO), 2.63 (dd, 1H, J = 5.0 Hz, J = 17.2 Hz, Asp 
CONHCH(CHH'CO2-tBU)CO), 1.41 (s, 911, CO2C(CH3)3); 13C NMR (100 MHz, 
CDC13): ö = 171.48, 171.45, 168.94, 168.73, 157.86, 143.50, 141.80, 141.37, 128.68, 
128.67, 128.09, 127.88, 127.15, 127.12, 126.77, 124.92, 124.87, 120.12, 120.10, 82.62, 
67.15, 51.37, 50.39, 47.18, 43.73, 43.30, 43.22, 37.23, 28.03; FAB-HRMS for 
C41H45N407 m/z [M+HI], calcd.: 705.32883, found: 705.32888. 
Methodfor the preparation of the N-tBoc tripeptide L-AspGlyGly thread 3.9 
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NterbutoxycarbonyL-L-(2,2-diPhenYl ethyl ester)-aspartic benzylic ester 3.7 
Following the experimental procedure leading to derivative 3.2. 
Yield (5.978 g, 95%); m.p. 122°C; 'H NMR (400 MITIZ, CDC13): 6 = 7.39-7.15 (m, 
15H, aromatic Ar-H), 5.27 (d, 111, J = 8.4 Hz, Asp 
OCONHCH(CH2CO2CH2CHPh2)C0), 5.10 (s, 2H, COOCPh2), 4.63-4.49 (m, 3H, 
COOCH2CHPh2 & Asp NHCi(CH2CO2CH2CHPh2)CO), 4.26 (t, 1H, J 
= 7.6 Hz, 
COOCH2CHPh2), 2.95 (dd, 1H, J = 4.4 Hz, J = 17.2 Hz, Asp 
NHCH(CHH'CO2CH2CHPh2)CO), 2.72 (dd, 1H, J = 4.4 Hz, J = 17.2 Hz, Asp 
NHCH(CHH'CO2CH2CHPh2)CO), 1.42 (s, 9H, Boc Cl3); 13C NMR (100 MHz, 
CDC13): 6 = 170.77, 170.59, 155.36, 140.82, 140.80, 135.34, 128.66, 128.40, 128.26, 
128.11, 126.92, 80.09, 67.16, 49.96, 49.67, 36.79, 28.31; FAB-HRMS for C301134N06 
m/z [M+H], calcd.: 504.2386 1, found: 504.23765. 
acid 3.8 
Nterbutoxycarbonyl-L-(2,2-diPhe11Yl ethyl ester) aspartic benzylic ester (3.7, 5.766 g, 
11.450 mmol) and catalytic palladium, 10% wt. on carbon powder were dissolved in 100 
ml, of EtOAc. The system was then placed under vacuum and hydrogen was introduced 
at atmospheric pressure for four hours. The reaction mixture was filtered over celite. The 
solvent was removed under reduced pressure to afford a white powder. Yield (4.626 g, 
98%); m.p. 155°C; 'H NIMIR (400 MHz, CDC13): 6 = 7.36-7.18 (m, 1OH, aromatic Ar- 
H), 5.31 (d, 1H, J = 8.4 Hz, Asp OCONBCH(CH2CO2CH2CHPh2)C0), 4.66 (d, 2H, J 
=7.8 Hz, COOCl3CHPh2), 4.54-4.52 (m, 111, Asp NHCH(CH2CO2CH2CHPh2)CO), 
4.35 (t, III, J = 7.8 Hz, CO2CH2CHPh2), 2.95 (br dd, 1H, Asp 
NHCH(CHH'CO2CH2CHPh2)CO), 2.61 (dd, 1H, J = 4.8 Hz, J = 17.2 Hz, Asp 
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NHCH(CHIH'CO2CI{2CHPh2)CO), 1.45 (s, 9H, Boc Crn); '3C NMR (100 MHz, 
CDC13): 6 = 170.77, 155.58, 140.73, 140.70, 128.67, 128.66, 128.32, 128.16, 128.13, 
126.95, 80.51, 67.33, 49.76, 49.69, 36.46, 28.30; FAB-HIRMS for C23H28N06 m/z 
[M+H4], calcd.: 414.19166, found: 414.19146. 
diphenyl ethyl amide 3.9 
Following the experimental procedure leading to derivatice 3.2. 
Yield (3.280 g, 49%); m. p. 64°C; 'H NMR (400 MHz, CDC13): 6 = 7.33-7.16 (in, 20H, 
aromatic Ar-H), 7.06 (t, 111, J =5.6 Hz, CONHCH2CO), 6.82 (br t, 1H, 
CONEICH20HPh2), 6.32 (t, 111, J=5.6 Hz, CONHCH2CO), 5.28 (d, 111, J=8.4 Hz, Asp 
OCONHCH(CH2CO2CH2CHPh2)CO), 4.67 (dd, 1H, J = 7.6 Hz, J = 11.2 Hz, 
CO2CHH'CIiP112), 4.58 (dd, IH, J = 7.6 Hz, J = 11.2 Hz, CO2CHIH'CHPh2), 4.36-4.29 
(in, 211, Asp NHCH(CH2CO2CH2CHPh2)CO & Asp NHCH(CH2CO2CHH'CfPh2)CO), 
4.19 (t, 111, J =6.8 Hz, CON}ICH2CHPh2), 3.92-3.80 (in, 3H, Gly NHCHH'CO & Gly 
NHCCO), 3.75 (t, 2H, J =6.8 Hz, CONHCH2CHPh2), 3.64 (dd, 1H, J = 5.6 Hz, J = 
16.8 Hz, Gly NHCIffl'CO), 2.89 (dd, 1H, J = 5.2 Hz, J = 17.2 Hz, Asp 
NHCH(CHH'CO2CH2C1HPh2)CO), 2.61 (dd, 111, J = 5.2 Hz, J = 17.2 Hz, Asp 
NHCH(C}iH'CO2CH2C1HPh2)CO), 1.45 (s, 9H, Boc CH);  13C NMR (100 MHz, 
CDC13): 6 = 171.57, 170.85, 168.77, 167.95, 158.11, 141.83, 140.74, 140.65, 139.82, 
131.10, 130.57, 129.20, 128.68, 128.65, 128.16, 128.12, 128.09, 127.29, 127.00, 
126.74, 125.92, 79.48, 67.45, 50.40, 49.74, 48.92, 45.70, 43.74, 42.92,42.42, 36.13, 
28.30; FAB-HRMS for C4,1447N407 m/z [M+H1, calcd.: 707.34448, found: 707.34508. 
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General procedure for the preparation of [2]rotaxane building blocks 3.10-3.12 
Thread 3.3, 3.5, 3.9 (1.910 mmol) was dissolved in 100 mL of CHC13 under nitrogen 
and stirred vigorously whilst solutions of the mixture of para-xylylene diamine (2.121 g, 
15.600 mmol) and NEt3 (3.965 g, 39.300 mmol) in 50 mL of CHC13 and the isophthaloyl 
dichloride (3.151 g, 15.500 mmol) in 50 mL of CHC13 were simultaneously added to the 
reaction mixture over a period of 3 hours using motor-driven syringe pumps. The 
reaction mixture was stirred 2 hours under nitrogen, then filtered over celite and the 
filtrate was evaporated under reduced pressure to afford a syrup which was purified via 
silica gel chromatography to yield, in order of elution, the unconsumed activated ester 
thread (AcOEt/cyclohexane: 1/1) and the rotaxane (CHC13/MeOH: 98/2). 
FmocL(O(tertbutyldipheny1siLy1))-sery1glycy1g1yCifle rotaxane 3.10 
Yield (0.078 g, 14%); overall yield after 4 cycles of rotaxane formation (0.278 g, 
73%); m.p. 137°C; 1H NIMR (400 MHz, CDCI3): ö = 8.23 (s, 2H, isophthaloyl 2-H), 8.02 
(d, 4H, J = 8.0 Hz, isophthaloyl 4-H & 6-H), 7.73 (d, 2H, aromatic Ar-H Fmoc, J = 7.6 
Hz), 7,63-7.51 (m, 8H, aromatic Ar-H & aromatic Ar-H Fmoc & macrocyclic CONH), 
7.47 (t, 2H, J = 7.6 Hz, isophthaloyl 5-H), 7.44-7.09 (m, 24 H, aromatic Ar-H),  7.01 (s, 
8H, macrocyclic para-xylylene Ar-H), 6.89 (br t, 1H, CONHCH2), 6.75 (br t, 1H, 
CONHCH2), 6.68 (br t, 1H, Gly CONHCH2CO), 5.42 (d, 111, J = 7.2 Hz, Ser 
OCONHCH(CH2(OTBDPS))CO), 4.66 (dd, 2H, J = 5.6 Hz, J = 14.0 Hz, macrocyclic 
NHCHH'), 4.53 (dd, 2H, J = 5.6 Hz, J = 14.0 Hz, macrocyclic NHCHH'), 4.30 (dd, 2H, 
J = 4.4 Hz, J = 14.0 Hz, macrocyclic NHCHH'), 4.25 (d, 2H, J = 3.2 Hz, Fmoc 
CHCH2000NH), 4.20 (dd, 2H, J = 4.4 Hz, J = 14.0 Hz, macrocyclic NHCHH'), 4.08-
3.96 (m, 3H, Fmoc CHCH2000NH & Ser NHCH(CH2(OTBDPS))CO & 
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CONHCH2CHPh2), 3.81 (dd, 111, J = 5.0 Hz, J = 10.2 Hz, Gly NHCHH'CO), 3.67 (dd, 
1H, J = 5.6 Hz, J = 10.2 Hz, Gly NHCHH'CO), 3.65-3.56 (m, 211, CONI{CCHPh2), 
3.25 (dd, 1H, J = 5.2 Hz, J = 16.0 Hz, Ser NHCI4(CHH'(OTBDPS))CO), 3.10 (br dd, 
1H, Ser NHCH(CHH'(OTBDPS))CO), 2.77 (br d, 21, Gly N}ICCO), 0.99 (s, 9H, 
OSiC(CH3)3); 13C NMR (100 MI{z, CDC13): 6 = 168.86, 167.91, 166.99, 166.93, 
157.89, 143.60, 143.40, 141.49, 141.28, 141.26, 137.35, 137.17, 135.42, 135.36, 
134.18, 133.98, 132.44, 132.29, 131.06, 130.18, 129.03, 128.97, 128.75, 127.99, 
127.82, 127.79, 127.09, 127.05, 126.95, 125.12, 124.95, 120.01, 81.33, 67.38, 63.03, 
56.97, 50.34, 46.87, 44.42, 44.28, 44.15, 42.69, 42.00, 26.77; FAB-HRIvIS for 
C84H83N8010Si mlz [M+H4], calcd.: 1391.60207, found: 1391.60250. 
Fmoc-L-(Iert-butyl ester)-asparticglycylgiycine rotaxane 3.11 
Yield (0.205 g, 19%); overall yield after 6 cycles of rotaxane formation (0.682 g, 
62%); m.p. 115°C; 'H NMR (400 MHz, CDC13): 6 = 8.31 (s, 2H, isophthaloyl 2-H), 8.06 
(d, 211, J= 8.0 Hz, isophthaloyl 4-H & 6-11), 8.05 (d, 211, J= 8.0 Hz, isophthaloyl 4-H & 
6-11), 7.73 (d, 2H, J = 7.6 Hz, aromatic Ar-H Fmoc), 7.67 (br t, 2H, macrocyclic 
CONIH), 7.55-7.48 (m, 211, isophthaloyl 5-11), 7.48-7.43 (m, 2H, macrocyclic CON}j), 
7.37 (t, 211, aromatic Ar-H Fmoc), 7.33-7.04 (m, 2311, aromatic Ar-H Fmoc & thread 
Ar-H & macrocyclic para-xylylene Ar-H & Gly CONHCH2CO), 6.70 (s, 1H, Gly 
CONHCH2CO), 6.52 (s, 111, CONIEICH2CHPh2), 6.12 (d, 1H, J = 8.4 Hz, Asp 
OCONHCH(CH2CO2-tBu)CO), 4.97-4.85 (m, 211, Fmoc CHCH7000NH), 4.48-4.39 
(m, 4H, macrocyclic NHCHH'), 4.15-4.07 (m, 311, Fmoc CIICH2000NH & Asp 
NHCH(CH2CO2-tBu)CO & CONHCH2CHPh2), 4.05-3.97 (m, 411, macrocyclic 
NHCHH'), 3.71 (t, 211, J= 6.8 Hz, CONHCCIWh2), 3.18 (br s, 211, Gly NHCHCO), 
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3.37 (dd, 111, J= 4.0 Hz, J = 17.2 Hz, Gly NHCHH'CO), 2.84 (dd, 1H, J = 4.0 Hz, J= 
17.2 Hz, Gly NHCHH'CO), 2.52 (dd, 1H, J = 4.0 Hz, J = 16.8 Hz, Asp 
NHCH(CHH'CO2-tBu)CO), 2.36 (dd, 1H, J = 4.0 Hz, J = 16.8 Hz, Asp 
NIICH(CHH'CO2-tBu)CO), 1.31 (s, 9H, CO2C(C113)3); 13C NIVIIR (100 MIHz, CDC13): 
= 171.40, 168.71, 167.63, 166.85, 166.76, 156.79, 143.26, 143.19, 141.40, 141.38, 
141.35, 137.76, 136.76, 134.06, 133.48, 131.65, 131.31, 130.67, 129.17, 129.01, 
128.75, 128.67, 128.61, 128.12, 128.06, 127.81, 127.05, 126.96, 125.01, 124.80, 
124.37, 120.04, 82.08, 67.43, 50.51, 50.42, 46.84, 44.55, 44.00, 43.84, 42.80, 42.38, 
35.33, 27.88; FAB-HRMS for C73H73N8011  m/z [M+}fl, calcd.: 1237.53988, found: 
1237. 5403 1. 
tBoc_L(2,2diphenyLethy1ester)-asparticgIycy1g1yCifle rotaxane 3.12 
Yield (0.059 g, 11%); overall yield after 5 cycles of rotaxane formation (0.199 g, 
49%); m.p. 147.5°C; 'H NMIR (400 MHz, CDC13): 8 = 8.25 (s, 2H, isophthaloyl 2-H), 
8.08 (d, 4H, J = 4.4 Hz, isophthaloyl 4-H & 6-H), 7.53-7.45 (m, 4H, macrocyclic CON}J 
& isophthaloyl 5-H), 7.38 (br t, 2H, macrocyclic CONH'), 7.32-7.10 (m, 20 H, thread 
Ar-H), 7.09 (s, 8H, macrocyclic para-xylylene Ar-H),  6.57 (br t, 1H, CONIHCH2), 6.47 
(br t, 1H, CONHCH2), 6.29 (br t, 1H, CONHCH2), 5.29 (d, iN, J =8.8 Hz, Asp 
OCONHCH(CH2CO2CH2CHPh2)CO), 4.75-4.42 (m, 6H, macrocyclic NTIICHIH' & Asp 
NHCH(CH2CO2CH2CHPh2)CO), 4.39-4.19 (m, 5H, macrocyclic NHCHH' & Asp 
NHCH(CH2CO2CH2CHPh2)CO), 	4.18-4.11 	(m, 	1H, 	Asp 
NHCH(CH2CO2CH2CHPh2)CO), 4.02 (t, 1H, J 8.0 Hz, CONHCH2CIIPh2), 3.65 (br d, 
2H, CONHCH2CHPh2), 3.24 (dd, 1H, J= 4.4 Hz, J = 17.2 Hz, Gly NHCHH'CO), 3.08 
(dd, 1H, J = 5.2 Hz, J = 17.2 Hz, Gly NHCHH'CO), 2.85 (s, 2H, Gly NHCHZCO), 2.58 
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(dd, 1H, J= 4.8 Hz, J= 17.2 Hz, Asp NHCH(CHH'CO2CH2CHPh2)CO), 2.39 (dd, IH, J 
6.0 Hz, J = 17.2 Hz, Asp NHCH(CHH'CO2CH2CHPh2)CO), 1.36 (s, 911, Boc Cii); 
13C NIVIIR (100 MHz, CDC13): 6 = 172.45, 172.37, 168.44, 166.84, 166.71, 158.00, 
141.38, 140.74, 140.55, 137.56, 137.03, 134.02, 133.93, 131.42, 131.25, 129.18, 
129.07, 128.80, 128.66, 128.61, 128.12, 128.05, 127.81, 127.02, 126.95, 124.69, 8023, 
67.29, 50.39, 49.74, 49.62, 44.46, 44.17, 44.10, 43.25, 42.70, 36.17, 28.22; FAB-HRMS 
for C73H75N8011 m/z [M+H], calcd.: 1239.55553, found: 1239.55403. 
General procedure for N-Fmoc deprotection 
N-Fmoc protected rotaxane (0.036 mmol) was dissolved in 2 mL piperidine/CHC13  
(1/3) and was stirred at rt for 2 hours. The solvent was removed under reduced pressure. 
The crude material was purified via silica-gel column chromatography (CHC13/MeOH: 
96/4) to afford the free amine rotaxane. 
L-(O-(tert-butyldiphenylsityL))-setyIglyCyIglyCifle rotaxane 313 
Yield (0.042 g, 99%); 1H NMR (400 MHz, CDC13): 5 = 8.26 (s, 2H, isophthaloyl 2-H), 
8.07 (d, 2H, J = 7.4 Hz, isophthaloyl 4-H & 6-H), 8.03 (d, 2H, J = 7.4 Hz, isophthaloyl 
4-H & 6-H), 7.78 (br t, 1H, macrocyclic CONE), 7.73 (br t, 2H, macrocyclic CONE), 
7.70 (br t, 1H, macrocyclic CONH), 7.51 (t, 211, J = 7.4 Hz, isophthaloyl 5-H), 7.44 (br 
t, 1H, CONHCH2CHPh2), 7.47-7.07 (m, 21H, aromatic Ar-H & Gly CONHCH2CO), 
7.05 (s, 811, macrocyclic para-xylylene Ar-H), 6.86 (br s, III, Gly CONIHCH2CO), 4.65 
(dd, 211, J = 6.4 Hz, J = 14.4 Hz, macro cyclic NHCHH'), 4.51 (dd, 211, J = 4.8 Hz, J = 
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14.4 Hz, macrocyclic NITCHH'), 4.37 (dd, 2H, J = 4.4 Hz, J = 14.0 Hz, macrocyclic 
NIHCHH'), 4.23 (dd, 2H, J= 1.8 Hz, J= 14.0 Hz, macrocyclic NHCHH'), 4.12 (t, 1H, J 
= 7.6 Hz, CONHCH2CIIPh2), 3.79 (t, 2H, J = 7.6 Hz, CONHCj0HPh2), 3.57-3.42 (m, 
3H, Gly NI{CCO & Ser NH2CH(CH2(OTBDPS)CO), 3.05 (dd, 1H, J = 4.8 Hz, J = 
17.0 Hz, Ser NH2CH(CHH'(OTBDPS))CO), 2.97 (br s, 2H, Gly NIHCHCO),  2.90 (dd, 
1H, J = 3.6 Hz, J = 17.0 Hz, Ser NH2CH(CHH'(OTBDPS))CO), 2.13-1.49 (m, 21-L Ser 
NICH(CH2(OTBDPS)CO), 0.99 (s, 9H, OSiC(CF13)3); 13C NMR (100 MHz, CDC13): 6 
= 169.89, 167.92, 166.79, 166.72, 141.44, 141.38, 137.53, 137.01, 135.41, 135.36, 
134.10, 133.56, 132.79, 132.66, 131.72, 131.29, 130.10, 130.06, 129.20, 129.10, 
128.82, 127.88, 127.83, 127.06, 124.27, 80.35, 65.42, 56.19, 50.53, 44.36, 44.13, 43.00, 
42.36, 36.37, 26.79; FAB-HRMS for C69H73N808Si m/z [M+H4], calcd.: 1169.53207, 
found: 1169.53017. 
General procedure for the synthesis of protected oligopeptide rotaxanes 3.14-3-18 
by N-terminal coupling with various stoppered amino acids 
L-(O-(tert-butyldiphenylsilyl))-serylglycylglyclne rotaxane (3.13, 0.042 g, 0.03 5 mmol), 
N-diphenylacetyl amino acid (0.019 g, 0.072 mmol) and NEt3 (till pH 11) and BOP 
(0.024 g, 0.055 mmol) were dissolved in 5 mL of dC13. The reaction mixture was 
stirred overnight at rt. The solvent was removed under reduced pressure. The crude 
material was purified via silica gel chromatography (CHC13/MeOH: 98/2 to 95/5). 
Glycyi-L-(O-(tert-butyidiphenylsiiyl))-serylglycyigiycine rotaxane 3.14 
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Yield (0.045 g, 90%); 'H NMR (400 MHz, CDC13): 6 = 8.18 (s, 2H, isophthaloyl 2-H), 
7.97 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 7.85 (br s, 4H, macrocyclic CONH), 
7.63-6.95 (m, 43 H, aromatic Ar-H & isophthaloyl 5-H & macrocyclicpara-xylylene Ar-
H & CONHCI{2), 6.89 (br t, iH, CONHCH2), 6.63 (d, TH, J = 7.2 Hz, 
CONIHCH(CH2(OTBDPS))CO), 5.05 (s, 1H, Ph2CHCO), 4.57-4.45 (m, 4H, macrocyclic 
NHCHH'), 4.34-4.18 (m, 5H, macrocyclic NHCHH' & Ser NHCH(CH2(OTBDPS))CO), 
4.00 (t, 1H, J = 8.0 Hz, CONIITCH2CHPh2), 3.86 (dd, 1H, J = 4.0 Hz, J = 10.0 Hz, Ser 
NHCH(CHH'(OTBDPS))CO), 3.72 (dd, 1H, J = 6.0 Hz, J = 16.8 Hz, Gly 
NHCHH'CO), 3.63-3.45 (m, 4H, CONHCH2CHPh2 & Ser NHCH(CHIJ'(OTBDPS))CO 
& Gly NHCHH'CO), 3.34 (dd, 1H, J = 4.0 Hz, J = 16.8 Hz, Gly NHCHH'CO), 3.25 
(dd, iH,J=4.O Hz, J= 16.0 Hz, Gly NHCHH'CO), 2.58 (dd, 1H,J = 5.2Hz,J = 15.8 
Hz, Gly NHCHH'CO), 2.05 (br dd, 1H, J = 15.8 Hz, Gly NHCHH'CO), 1.00 (s, 9H, 
OSiC(CH3)3); 13C NMR (100 MHz, CDC13): 6 = 173.81, 170.50, 169.30, 168.65, 
168.06, 167.52, 167.37, 141.80, 141.73, 139.02, 137.10, 136.93, 135.45, 135.34, 
134.60, 134.27, 132.69, 132.32, 130.85, 130.53, 130.13, 129.12, 128.92, 128.86, 
128.75, 128.67, 128.61, 127.98, 127.86, 127.27, 126.73, 126.15, 80.24, 65.86, 58.19, 
54.24, 50.38, 44.62, 44.56, 44.11, 43.73, 42.92, 41.19, 26.83; FAB-HRMS for 
C85H86N9O10Si m/z [M+W], calcd.: 1420.62669, found: 1420.62491. 
G1ycylg1ycyIL(O(tertbutyIdiphenyIsily1))-SeryIglyCYlgIYCifle rotaxane 3.15 
Yield (0.019 g, 77%); 'H NMR (400 MHz, CDC13): 6 = 8.19 (s, 2H, isophthaloyl 2-H), 
8.00 (d, 4H, J = 6.8 Hz, isophthaloyl 4-H & 6-1-1), 7.59-6.96 (m, 49 H, aromatic Ar-H & 
isophthaloyl 5-H & macrocyclic para-xylylene Ar-H & macrocyclic CONH & Gly 
CONHCH2CO), 6.68 (br s, 1H, CONH), 5.01 (s, 1H, Ph2CHCO), 4.67-4.46 (m, 5H, 
all 
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macrocyclic NHCHH' & Ser NHCH(CH2(OTBDPS))CO), 4.37-4.14 (m, 4H, 
macrocyclic NHCHI'), 4.05 (dd, 1H, J = 4.4 Hz, J = 16.8 Hz, Gly CONHCHH'CO), 
3.99-3.88 (m, 2H, Ser NHCH(CHH'(OTBDPS))CO & CONHCH2CHPh2), 3.78 (dd, 111, 
J = 4.8 Hz, J = 16.8 Hz, Gly NHCHH'CO), 3.70-3.57 (m, 2H, Ser 
NHCH(CHH'(OTBDPS))CO & Gly NHCHH'CO), 3.56-3.48 (m, 211, 
CONHCH2CHPh2), 3.42-3.30 (in, 2H, Gly NHCIIFJ'CO & Gly NHCHH'CO), 3.11 (dd, 
1H,J=5.O Hz, J=18.4 Hz, Gly NHCHH'CO),2.69(dd, 1H, J = 5.2 Hz, J = 15.2 Hz, 
Gly NHCHH'CO), 2.00 (dd, III, J = 6.0 Hz, J = 15.2 Hz, Gly NHCHH'CO), 0.98 (s, 
9H, OSiC(C)3); 13C NMR (100 MHz, CDC13): ö = 172.85, 170.45, 169.77, 169.18, 
168.09, 167.42, 167.28, 141.72, 141.65, 139.05, 138.99, 137.11, 137.05, 135.46, 
135.35, 134.59, 134.47, 132.69, 132.37, 130.65, 130.09, 129.09, 128.88, 128.79, 
128.70, 128.66, 128.61, 127.92, 127.84, 127.36, 127.32, 126.83, 126.24, 80.12, 64.69, 
54.53, 52.30, 50.41, 44.61, 43,97, 43.43, 43.01, 42.70, 41.28, 26.75; FAB-HIRMS for 
C871189N,oOi1Si m/z [M+H], calcd.: 1477.64816, found: 1477.64929. 
rotaxane 3.16 
Yield (0.011 g, 69%); 'H NMR (400 MHz, CDCI3): 6 = 8.24 (s, 211, isophthaloyl 2-H), 
8.02 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 7.84-7.74 (in, 4H, macrocyclic 
CONH), 7.60-7.00 (m, 35 H, aromatic Ar-H & isophthaloyl 5-H & thread CONH), 6.97 
(d, 8H, J = 1.2 Hz, macrocyclic para-xylylene Ar-H), 6.36 (br t, 1H, Gly 
CONHCH2CO), 6.06 (d, 1H, J = 3.6 Hz, Ala CONHCH(CH3)CO), 4.84 (s, 1H, 
P1712CHCO), 4.79-4.62 (in, 4H, macrocyclic NIHCI{H'), 4.21-4.05 (in, 4H, macrocyclic 
NHC}Uj'), 4.00 (t, 2H, J = 7.4 Hz, CONHCII2CHPh2), 3.94-3.90 (m, 111, Ser 
NHCH(CHH'(OTBDPS))CO), 3.83-3.79 (in, 111, Ala N}ICH(CH3)CO), 3.68 (dd, 111, J 
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= 5.6 Hz, J= 13.4 Hz, Gly NHCHH'CO), 3.56 (t, 2H, J = 7.4 Hz, CONHCCHPh2), 
3.36 (dd, 111, J = 5.0 Hz, J = 14.6 Hz, Ser NHCH(CHH'(OTBDPS))CO), 3.16 (dd, 1H, 
J = 5.0 Hz, J = 14.6 Hz, Ser NHCH(CIffl'(OTBDPS))CO), 3.03 (dd, 1H, J = 5.6 Hz, J 
= 13.4 Hz, Gly NHCHH'CO), 2.56 (dd, IH, J = 4.6 Hz, J = 16.6 Hz, Gly NHCHH'CO), 
2.36 (dd, 111, J = 4.6 Hz, J= 16.6 Hz, Gly NHCHH'CO), 1.19 (d, 311, J = 7.2 Hz, Ala 
NHCH(CHI,)CO), 1.06 (s, 914, OSiC(CH3)3); 13C NMR (1100 MHz, CDC13): ö = 174.75, 
172.08, 1171.88, 170.37, 169.79, 168.07, 141.62, 141.49, 141.42, 138.94, 138.30, 
138.06, 137.12, 136.89, 135.39, 134.47, 132.35, 130.92, 130.86, 130.71, 130.27, 
130.09, 129.26, 129.07, 128.97, 128.88, 128.80, 128.72, 128.67, 128.04, 127.95, 
127.90, 127.69, 127.62, 127.44, 127.32, 126.93, 126.85, 125.95, 125.45, 79.92, 63.09, 
58.42, 55.04, 51.85,50.62,44.50,44.311,44.11,43.12,42.05,26.91, 116.92; FAB-I{RMS 
for C86H88N9O10Si m/z [M-I-Hi, calcd.: 1434.64235, found: 1434.64217. 
LIeucy1L(O(1ert_buty1diphefly1Si1y1))-Sery1glYCYLgIYCifle rotaxane 3.17 
Yield (0.006 mg, 47%); 'H NMR (400 MHz, CDCI3): 5 = 8.21 (s, 2H, isophthaloyl 2-
H), 8.03 (d, 2H, J = 7.8 Hz, isophthaloyl 4-H & 6-H), 7.99 (d, 2H, J = 7.8 Hz, 
isophthaloyl 4-H' & 6-H'), 7.81 (br t, 411, macrocycic CONH'), 7.66-6.87 (m, 43 H, 
aromatic Ar-ll & isophthaloyl 5-H & macrocyclic para-xylylene Ar-H & thread CONH), 
6.82 (d, 1H, J = 8.4 Hz, Ser CON}ICH(CH2(OTBDPS))CO), 6.09 (d, 1H, J = 5.2 Hz, 
Gly CON}JCH2CO), 5.06 (s, 1H, Ph2CHCO), 4.68-4.63 (m, 2H, macrocycic NHCHH'), 
4.46-4.41 (m, 211, macrocycic NHCHH'), 4.27-4.21 (in, 4H, macrocycic NHCHH'), 
4.13-4.11 (m, 111, Leu NHCH(CH2CH(CH3)2)CO), 3.91 (t, 211, J = 8.4 Hz, 
CONHCH2CHPh2), 3.87-3.83 (m, 111, Ser NHCH(CH2(OTBDPS))CO), 3.69 (dd, 111, J 
= 6.0 Hz, J = 17.2 Hz, Gly NHCHH'CO), 3.42 (dd, 1H, J = 4.8 Hz, J = 16.0 Hz, Ser 
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NHCH(CHH'(OTBDPS))CO), 3.37-3.29 (m, 2H, CONHCjCHPh2), 3.10 (dd, 1H, J = 
4.8 Hz, J = 16.0 Hz, Ser NHCH(CII}J'(OTBDPS))CO), 2.97 (dd, 1H, J = 6.0 Hz, J = 
17.2 Hz, Gly N}TCHH'CO), 2.41 (dd, 1H, J = 4.4 Hz, J = 15.4 Hz, Gly NHCHH'CO), 
1.94 (dd, 1H, J = 3.6 Hz, J = 15.4 Hz, Gly N}ICHH'CO), 1.36-1.18 (m, 3H, Leu 
NHCH(CH2CII(CH3)2)CO & Leu NHCH(CH2CH(CH3)2)CO), 0.98 (s, 9H, 
OSiC(CFI3)3), 0.86 (d, 611, J = 6.4 Hz, Leu NHCH(CH2CH(Ciii)2)CO); 13C NMR (100 
M4z, CDC13): ö = 174.90, 171.91, 169.74, 168.01, 167.50, 166.88, 141.66, 141.49, 
139.21, 138.27, 137.11, 135.37, 134.46, 134.24, 133.98, 132.96, 132.40, 131.32, 
130.90, 130.57, 130.25, 129.97, 129.29, 129.00, 128.91, 128.80, 128.71, 128.62, 
128.03, 127.90, 127.84, 127.78, 127.65, 127.50, 127.30, 126.90, 126.82, 126.72, 
126.24, 125.45, 80.02, 63.21, 58.56, 54.92, 54.70, 50.43, 44.58, 44.30, 44.01, 43.29, 
41.37, 26.70, 24.62, 22.84, 22.54, 19.46; FAB-HRMS for C89H94N9O10Si m/z [M+Hi, 
calcd.: 1476.68930, found: 1476.69098. 
GIycyIL(2,2diphenyIethyIeSter)aSPartiCgIYCYtgIYC1fle rotaxane 3.18 
In this particular example, the tBoc protected rotaxane building block 3.12 was 
deprotected using TFA and the free amine  was released in situ for the N-coupling 
reaction. 
Yield (0.031 g, 70%); m.p. 145.6°C; 1H NMR (400 MHz, CDC13): 8 = 8.24 (s, 2H, 
isophthaloyl 2-H), 8.01 (d, 4H, J = 4.4 Hz, isophthaloyl 4-H & 6-H), 7.77 (br t, 211, 
macrocyclic CON}j), 7.72 (br t, 2H, macrocyclic COW), 7.47 (t, 2H, J = 7,6 Hz, 
isophthaloyl 5-H), 7.35 (br t, 1H, Gly CONHCH2CO), 7.31-7.11 (m, 31 H, thread Ar-H 
& CONTCH2CHPh2), 7.07 (d, 1H, J = 8.4 Hz, Asp CONHCH(CH2CO2CH2CHPh2)CO), 
7.00 (s, 8H, macrocyclic para-xylylene Ar-H), 6.85 (br t, 1H, Gly*  
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Ph2CHCONETCH2CO), 6.56 (br t, 111, G1yCONCH2CO), 5.02 (s, lET, Ph2CCO), 
4.64-4.45 (m, 711, macrocyclic N}TCHH' & Asp NHCH(CH2CO2CH2CHPh2)CO & Asp 
NHCH(CH2CO2CH2CHPh2)CO), 4.33-4.17 (m, 5H, macrocyclic NHCHH' & Asp 
NHCH(CH2CO2CH2CHPh2)CO), 3.99 (t, 2H, J = 7.6 Hz, CONHCIJ2CHPh2), 3.57 (t, 
1H, J = 7.6 Hz, CONHCH2CHPh2), 3.47 (br s, 2H, Gly Ph2CHCONHCHCO), 3.23 (dd, 
111, J = 4.8 Hz, J = 16.6 Hz, Gly NHCI{H'CO), 3.07 (dd, 1H, J = 6.0 Hz, J = 16.6 Hz, 
Gly NHCHI'CO), 2.50 (t, 111, J = 4.0 Hz, Gly NHCHCO), 2.60 (dd, 111, J = 5.2 Hz, J 
= 17.2 Hz, Asp NHCH(CHH'CO2CH2CHPh2)CO), 2.41 (dd, 111, J = 5.6 Hz, J = 17.2 
Hz, Asp NHCH(CHJI'CO2CH2CHPh2)CO); '3C NMR (100 MHz, CDCI3): ö = 173.37, 
170.69, 170.15, 168.36, 168.13, 167.29, 166.50, 166.22, 140.73, 139.96, 139.83, 
138.03, 137.90, 136.28, 136.11, 133.46, 133.25, 130.33, 130.09, 128.27, 128.18, 
128.08, 128.00, 127.87, 127.83, 127.80, 127.31, 127.27, 126.99, 126.97, 126.68, 
126.61, 126.12, 126.07, 124.60, 57.45, 49.52, 48.78, 48.18, 43.58, 43.56, 43.34, 42.15, 
40.82; FAB-FIRMS for C841130N9011 m/z [M+Ifl, calcd.: 1390.59773, found: 
1390.60005. 
General procedure for the TBDPS deprotection 
Protected oligopeptide rotaxanes 3.14-3.17 (0.019 mmol) were dissolved in 1 mL of 
THF and then treated with 0.1 mL of 1 mol. dm 3  solution of TBAF in THE. The reaction 
mixture was stirred at rt for one hour and then concentrated under reduced pressure. The 
crude material was purified via silica gel chromatography (CHC13/MeOH: 98/2 to 90/10). 
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GIycyl-L-serylglycylglycine rotaxane 3.19 
Yield (0.023 g, 100%); 'H NMR (400 MHz, 313K, CDC13): 6 = 8.19 (s, 2H, 
isophthaloyl 2-H), 7.99 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 7.65 (br s, 2H, 
macrocyclic CON}1), 7.64 (br s, 2H, macrocyclic CONH'), 7.44 (t, 211, J = 7.6 I-Iz, 
isophthaloyl 5-H), 7.28-7.02 (m, 22 H, aromatic Ar-H & CONH), 6.98 (s, 8H, 
macro cyclic para-xylylene Ar-H), 6.76 (br t, 1H, Gly CONHCH2CO), 6.69 (br t, 1H, Gly 
CONHCH2CO), 6.60 (br s, 1H, CONH), 4.80 (s, 1H, Ph2CHCO), 4.47-4.43 (m, 4H, 
macrocyclic NHCHH'), 4.30-4.26 (m, 4H, macrocyclic NHCHE-j'), 4.16-4.07 (m, 1H, 
Ser NHCH(CH20H)CO), 4.01 (t, 111, J= 7.6 Hz, CONHCH2CHPh2), 3.69-3.56 (m, 4H, 
Ser NHCH(CHH'OH)CO & CONHCCHPh2  & Gly NHCHH'CO), 3.39 (dd, 1H, J = 
5.2 Hz, J = 10.8 Hz, Ser NHCH(CHH'OH)CO), 3.35-3.25 (m, 3H, Gly NHCHH'CO & 
Gly NHCH2CO), 2.83 (br d, 1H, Gly NHCHH'CO), 2.75 (br d, 1H, Gly NHCHH'CO); 
13C NMR (100 MHz, CDC13): 6 = 169.47, 169.34, 168.92, 168.37, 167.35, 167.28, 
141.66, 138.84, 136.99, 134.20, 130.96, 129.02, 128.92, 128.79, 128.75, 128.68, 
127.87, 127.48, 126.85, 125.47, 62.10, 58.13, 54.99, 50.28, 44.34, 44.04, 43.08, 42.72, 
42.65, 41.76; FAB-HRMS for C691468N9010  m/z [M+H], calcd.: 1182.50892, found: 
1182.50460. 
Glycylglycyl-L-serylglycylglycine rotaxane 3.20 
Yield (0.019 g, 100%); 'H NMR (400 MHz, 313K, CDC13): 6 = 8.21 (s, 2H, 
isophthaloyl 2-H), 8.01 (d, 4H, J = 7.8 Hz, isophthaloyl 4-H & 6-H), 7.74-7.67 (m, 4H, 
macrocyclic CONH), 7.46 (t, 211, J = 7.8 Hz, isophthaloyl 5-11), 7.35-7.04 (m, 31 H, 
aromatic Ar-H & macrocyclic para-xylylene Ar-H & CONH), 6.75 (br t, 111, Gly 
CONHCH2CO), 6.61-6.52 (m, 2H, CONH), 4.80 (s, 111, Ph2CHCO), 4.56-4.44 (m, 4H, 
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macrocyclic NHCHH'), 4.34-4.23 (m, 4H, macrocyclic NHCHH'), 4.16-4.08 (m, 1H, 
Ser NHCH(CH20H)CO), 4.01 (t, 1H, J= 7.6 Hz, CONIHCH2CIEfPh2), 3.68-3.54 (m, 31-L 
Ser NHCH(CW4'OH)CO & CONHCH2CHPh2), 3.53-3.24 (m, 61-I, Ser 
NHCH(CHH'OH)CO & Gly NHCHH'CO & Gly NHCHZCO & Gly NHCIICO), 2.98- 
2.81 (m, 3H, Gly NHCHH'CO & Gly NHCH2CO); '3C NMR (100 MHz, CDC13): ö 
169.51, 169.44, 168.31, 168.12, 167.85, 167.39, 167.25, 141.69, 138.21, 137.12, 
134.37, 130.93, 129.1.9, 128.82, 128.76, 128.68, 128.41, 127.90, 127.56, 126.84, 
125.17, 61.07, 58.14, 54.25, 49.78, 44.32, 44.01, 43.71, 43.11, 42.27, 41.12; FAB-
HRMS for C71H71N10011 m/z [M+ifl,  calcd.: 1239.53038, found: 1239.53367. 
L-alanyl-L-serylglycylglyCifle rotaxane 3.21 
Yield (0.017 g, 100%); 1H NMR (400 MHz, 323K, CDC13): 6 = 8.28 (s, 2H, 
isophthaloyl 2-11), 8.11 (d, 411, J = 7.8 Hz, isophthaloyl 4-H & 6-11), 7.62-7.45 (m, 611, 
macrocyclic CONIH & isophthaloyl 5-H), 7.34-6.97 (m, 28 H, aromatic Ar-H & 
macrocyclic para-xylylene Ar-H),  6.83 (t, 111, Gly CONHCH2CO), 6.32-6.23 (m, 2H, 
CONHCH2CHPh2 & Gly CONHCH2CO), 6.16-6.10 (m, 2H, Ala CON}JCH(CH3)CO & 
Ser CONHCH(CH20H)CO), 4.92 (s, 111, Ph2CHCO), 4.61 (dd, 2H, J= 5.2 Hz, J= 14.6 
Hz, macrocyclic NHCHH'), 4.56 (dd, 2H, J = 5.2 Hz, J = 14.4 Hz, macrocyclic 
NHCHH'), 4.34 (dd, 211, J = 5.2 Hz, J = 14.6 Hz, macrocyclic NHCHH'), 4.27 (dd, 2H, 
J = 5.2 Hz, J = 14.4 Hz, macrocyclic NHCHH'), 4.19-4.12 (ni, 111, Ala 
NHCH(CH3)CO), 4.06-4.00 (m, 1H, Ser NHCH(CH20H)CO), 3.96 (t, 1H, J = 7.2 Hz, 
CONHCH2CHPh2), 3.55-3.36 (m, 411, CONHCH2CHPh2 & Ser NIHCH(CHH'OH)CO & 
Gly NHCHH'CO), 3.08 (dd, 111, J = 6.0 Hz, J = 17.2 Hz, Gly NHCHFI'CO), 2.92 (dd, 
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1H, J= 5.2 Hz, J= 16.4 Hz, Ser NHCH(CHH'OH)CO), 2.63 (dd, 1H, J = 5.2 Hz, J 
18.414z, Gly NHCH}{'CO), 2.53 (dd, 1H, J = 5.6 Hz, J = 18.4 Hz, Gly NHCHH'CO), 
1.49-1.43 (m, 1}i, Ser NHCH(C}{H'OH)CO), 1.14 (d, 311, J = 7.6 Hz, Ala 
NHCH(CH)CO); 13C NIMIR (100 MHz, CDC13): ö = 169.44, 169.12, 168.57, 168.49, 
168.12, 167.42, 167.24, 141.62, 141.52, 138.48, 137.10, 134.53, 134.16, 131.06, 
130.76, 128.95, 128.91, 128.79, 128.73, 128.69, 127.83, 127.77, 127.62, 127.58, 
126.87, 125.77, 61.50, 58.20, 55.21, 50.91, 50.16, 44.61, 44.68, 44.30, 44.13, 42.81, 
16.89; FAB-HRMS for C70R70N9010 m/z [M+H], calcd.: 1196.52457, found: 
1196.52447. 
L-Ieucyl-L-serylglyCylglyCifle rotaxane 3.22 
Yield (0.012 g, 100%); 'H NIVIR (400 MIHz, 313K, CDC13): ö = 8.21 (s, 2H, 
isophthaloyl 2-H), 8.04 (d, 2H, J= 8.0 Hz, isophthaloyl 4-H & 6-H), 7.99 (d, 2H, J= 8.0 
Hz, isophthaloyl 4-H & 6-H), 7.70 (br t, 2H, macrocyclic CONH), 7.60 (hr t, 2H, 
macrocyclic CONEJ'), 7.51 (t, 2H, J = 7.6 Hz, isophthaloyl 5-HI'), 7.33-6.95 (m, 2811, 
aromatic Ar-H & macrocyclic para-xylylene Ar-H), 6.90 (d, 1H, J = 6.4 Hz, Ser 
CONHCH(CH20H)CO), 6.79 (br t, 1H, CONHCH2CHPh2), 6.50 (br t, 1H, Gly 
CONHCH2CO), 6,42 (hr t, 1H1  Gly CONHCH2CO), 6.11 (d, 1H, J = 5.6Hz, Leu 
CONHCH(CH2CH(CH3)2)CO), 4.98 (s, 1H, Ph2CHCO), 4.61 (dd, 2H, J 6.0 Hz, J = 
14.6 Hz, macrocyclic NHCHH'), 4.53 (dd, 211, J = 5.6 Hz, J = 14.2 Hz, macrocyclic 
NHCHH'), 4.35 (dd, 2H, J = 5.6 Hz, J" 14.2 Hz, macrocyclic NHCHH'), 4.26 (dd, 2H, 
J = 6.0 Hz, J = 14.6 Hz, macrocyclic NHCHH'), 4.19-4.11 (m, 1H, Leu 
NHCH(CH2CH(CH3)2)CO), 4.03-3.96 (m, 2H, Ser NHCH(CH201FI)CO & 
CONHCH2CHPh2), 3.60-3.37 (m, 4H, Ser NI'HCH(CHH'OH)CO & CONI{CHCHPh2 & 
102 
Chapter Three 
Gly NHCHH'CO), 3.04 (dd, 1H, J = 6.0 Hz, J = 11.6 Hz, Gly NHCHH'CO), 2.83 (dd, 
111, J = 5.2 Hz, J = 17.2 Hz, Ser NHCH(CHT4'OH)CO), 2.39 (dd, 1H, J = 4.8 Hz, J = 
16.4 Hz, Gly NHCHH'CO), 2.00 (dd, 111, J = 4.8 Hz, J = 16.4 Hz, Gly NHCHH'CO), 
1.58 (m, 4H, Ser N}1CH(CH20H)CO & Leu NHCH(CH2CH(CH3)2)CO & Leu 
NHCH(CH2CH(CH3)2)CO), 0.77-0.68 (m, 611, Leu NHCH(CH2CH(CH)2)CO); 13C 
NIvIR (100 MHz, CDC13): 6 = 174.05, 172.59, 171.08, 169.41, 168.09, 167.45, 167.28, 
141.76, 139.25, 138.54, 137.19, 134.38, 131.09, 130.57, 129.08, 128.97, 128.82, 
128.71, 128.59, 127.82, 127.62, 127.35, 126.84, 126.69, 125.49, 62.42, 54.57, 53.98, 
53.80, 50.38, 44.35, 44.17, 42.96, 41.79, 40.98, 24.79, 22.82, 21.99; FAB-HRMS for 
C73H76N9010 m/z [M+H1], calcd.: 1238.57152, found: 1238.57192. 
GIycyI-L-asparticglycylglycine rotaxane 3.23 
Rotaxane (3.18, 0.021 g, 0.015 mmol) and KOH (0.001 g, 0.015 mmol) was dissolved 
in 3 mL of MeOH. The reaction mixture was stirred at RT during 3 hours. The solvent 
was removed under reduced pressure to afford a white powder. 
Yield (0.027 g, 100%); 1H NMR (400 MHz, 323K, CDC13): 6 = 8.13 (s, 2H, 
isophthaloyl 2-H), 8.01 (ci, 4H, J = 7.4 Hz, isophthaloyl 4-H & 6-H), 7.60 (br t, 4H, 
macrocyclic CONU), 7.47 (t, 2H J = 7.4 Hz, isophthaloyl 5-11), 7.36-7.09 (m, 20 H, 
thread Ar-H), 7.01 (s, 811, macrocyclic para-xylylene Ar-H), 6.96 & 6.92 & 6.53 & 6.40 
& 5.98 (br s, 511, CONH), 4.97 (s, IH, Ph2CHCO), 4.57-4.12 (m, 9H, macrocyclic 
NHCH2  & Asp NTETCH(CH2CO2K)CO), 4.02-3.92 (m, 1H, CONHCH2CHPh2), 3.84-3.75 
(m, 211, CONHCfl2CHPh2), 3.62-3.48 (m, 2H, Gly Ph2CHCONHCFI2CO), 3.21 (br dd, 
1H, Gly NHCHH'CO), 2.98 (br dd, 111, Gly NHCHH'CO), 2.78 (br dd, 1H, Asp 
NHCH(CHH'CO2K)CO), 2.68-2.59 (m, 2H, Gly NBCHCO), 2.45 (br dd, 1H, Asp 
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NHCH(CH'CO2K)CO); FAB-HRMS for C70H 7N9O11  mlz [M+H+Ki, calcd.: 
1248.45971, found: 1248.45931. 
General procedure for the synthesis of oligopeptide 131rotaxanes in solution 
Following the experimental procedure leading to oligopeptide rotaxanes 3.14-3.18 
rotaxane 3.24 
Yield (0.034 g, 86%); 111 NMR (400 MHz, CDCI3): 8 = 8.24 (s, 2H, isophthaloyl 2-H), 
8.08 (br t, 2H, macrocyclic CONkJ), 8.03 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 
7.93 (br t, 2H, macrocyclic COW), 7.74 (d, 2H, J = 4.8 Hz, aromatic Ar-H Fmoc), 
7.61 (d, 2H, J = 6.8 Hz, aromatic Ar-H Fmoc), 7.55-6.94 (m, 37H, aromatic Ar-H & 
aromatic Ar-H Fmoc & isophthaloyl 5-H & macrocyclic para-xylylene Ar-H & CO NH 
6.55 (br t, 1H, CONBCH2CO), 4.63-4.52 (m, SH, macrocyclic NHCHH' & 
OCONHCH2CO), 4.39-4.27 (m, 6H, macrocyclic NHCHIJ' & Fmoc CHCH2000NH), 
4.21-4.19 (m, 1H, Ser NIFICH(CH2(OTBDPS))CO), 4.17 (t, 1H, J = 7.6 Hz, Fmoc 
CHCH2000NH), 3.99 (t, 1H, J= 8.8 Hz, CONBCH2CHPh2), 3.93 (dd, J= 2.8 Hz, J= 
10.2 Hz, Ser NHCH(CHIIT'(OTBDPS))CO), 3.74 (dd, J = 7.2 Hz, J = 17.2 Hz, Gly 
NHC}{H'CO), 3.57 (dd, J = 5.2 Hz, J = 10.2 Hz, Ser NHCH(CHH'(OTBDPS))CO), 
3.54-3.33 (m, 5H, Gly MTCH}J'CO & Gly NBCHH'CO & Gly NHCHII'CO & 
CONIHCH2CHPh2), 2.73 (dd, 1H,J = 7.2 Hz, J' 18.0 Hz, G1yNIETCHH'CO), 2.11 (dd, 
1H, J = 7.2 Hz, J = 18.0 Hz, Gly NIHCI{H'CO), 0.96 (s, 9H, OSiC(CH3)3); 13C N]\4R 
(100 MHz, CDC13): 8 = 170.51, 169.19, 167.96, 167.55, 167.38, 157.45, 143.68, 
143.58, 141.82, 141.70, 141.26, 141.22, 137.20, 136.99, 135.41, 135.30, 134.65, 
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134.27, 132.42, 132.02, 130.85, 130.55, 130.13, 129.08, 128.81, 128.66, 128.60, 
127.97, 127.88, 127.85, 127.80, 127.16, 127.13, 126.82, 126.70, 126.19, 125.13, 
120.00, 67.54, 63.18, 54.22, 50.34, 46.96, 44.88, 44.67, 44.48, 44.03, 42.82, 41.30, 
26.71; FAB-HRMS for C86H86N9011Si rn/z [M+H1], calcd.: 1448.62161, found: 
1448.62124. 
rotaxane 3.25 
Yield (0.032 g, 78%); 'H NMR (400 M1-Iz, CDC13): ö = 8.20 (s, 2H, isophthaloyl 2-H), 
7.98 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-1-1), 7.92-7.86 (m, 4H, macrocyclic 
CONLI), 7.72 (d, 2H, J = 7.2 Hz, aromatic Ar-H Fmoc), 7.58-6.94 (m, 39H, aromatic 
Ar-H & aromatic Ar-H Fmoc & isophthaloyl 5-H & macrocyclic para-xylylene Ar-H & 
CONll, 6.86 (d, 1H, J = 6.8 Hz, Ser CONHCH(CH2(OTBDPS))CO), 6.13 (br t, 1H, 
CONIHCH2CO), 4.59-4.50 (in, 511, macrocyclic NHCHH' & OCONHCH2CO), 4.43-
4.37 (m, 1H, Ser NHCH(CH2(OTBDPS))CO), 4.35-4.22 (m, 4H, macrocyclic 
NHCHH'), 4.15 (t, 111, J = 6.8 Hz, Fmoc CHCH2000NH), 3.98 (t, 111, J = 7.6Hz, 
CONHCH2CHPh2), 3.94-3.87 (m, 2H, Gly NHCHH'CO & Gly NHCHH'CO), 3.75 (dd, 
111, J = 4.8 Hz, J = 17.2 Hz, Gly NHCHH'CO), 3.69-3.62 (m, 111, Ser 
NHCH(CHH'(OTBDPS))CO), 3.56-3.47 (m, 211, CONHCH2CHPh2), 3.47-3.36 (m, 2H, 
Ser NHCH(CHH'(OTBDPS))CO & Gly NHCHH'CO), 3.35-3.27 (in, 211, Gly 
N}TCH2CO), 2.67 (dd, 111, J 5.2 Hz, J 16.8 Hz, G1yNHCHH'CO), 2.12 (dd, 111, J= 
5.2 Hz, J = 16.8 Hz, Gly NHCHH'CO), 0.98 (s, 911, OSiC(C)3); 13C NMIR (100 MHz, 
CDC13): 6 = 170.55, 170.46, 169.27, 168.64, 168.03, 167.60, 167.45, 156.79, 143.67, 
141.74, 141.65, 141.24, 137.02, 136.97, 135.44, 135.32, 134.58, 134.34, 132.60, 
132.25, 130.73, 130.54, 130.11, 129.00, 128.84, 128.65, 128.60, 127.92, 127.86, 
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127.83, 127.76, 127.12, 127.07, 126.82, 126.73, 126.27, 125.07, 120.00, 80.03, 
67.23,63.46, 54.64, 50.34, 47.01, 44.63, 44.57, 44.44, 44.04, 43.12, 42.81, 41.32, 26.74; 
FAB-II1RMS for C88H89N10012Si m/z [M+T{], calcd.: 1505.64307, found: 1505.64504. 
Following the general procedure for the N-Fmoc deprotection 
G1ycy1 L (O(tertbutyIdipheflYISilY1))serYIgIYcYlgIYCme rotaxane 3.26 
Yield (0.012 g, 36%); 1H NMR (400 MHz, CDC13): ö = 8.26 (s, 2H, isophthaloyl 2-H), 
8.05 (d, 4H, J = 9.2 Hz, isophthaloyl 4-H & 6-H), 7.86-7.75 (m, 4H, macrocyclic 
CONkJ), 7.63-7.09 (m, 24H, aromatic Ar-H & isophthaloyl 5-H & CONH), 7.04 (s, 8H, 
macrocyclic para-xylylene Ar-H), 6.90-6.78 (m, 2H, CONB), 4.64 (dd, 2H, J = 6.4 Hz, J 
= 14.4 Hz, macrocyclic NHCHH'), 4.55 (dd, 2H, J= 5.2 Hz, .J = 13.6 Hz, macrocyclic 
NHCFIH'), 4.31 (dd, 2H, Jz  4.0 Hz, J = 14.4 Hz, macrocyclic NIHCITH'), 4.22-4.15 (m, 
3H, macrocyclic NHC}UJ' & Ser NIHCH(CH2(OTBDPS))CO), 4.02 (t, 111, J = 8.0 Hz, 
CONHCH2CIjP112), 3.94 (dd, J = 4.4 Hz, J = 10.0 Hz, Ser 
NHCH(CHH'(OTBDPS))CO), 3.66 (dd, J = 4.8 Hz, J = 10.0 Hz, Ser 
NHCH(CHH'(OTBDPS))CO), 3.62-3.57 (m, 2H, CONHCH2CHPh2), 3.10 (dd, 1H, J= 
6.0 Hz, J = 17.0 Hz, Gly NHCHH'CO), 3.08 (d, 2H, J = 8.8 Hz, Gly NHCHCO), 2.99 
(dd, 1H, J = 6.0 Hz, J = 17.0 Hz, Gly NHCHH'CO), 2.85 (dd, 1H, J= 4.4 Hz, J= 16.4 
Hz, Gly NHCHH'CO), 2.71 (dd, 1H, J = 4.0 Hz, J= 16.4 Hz, Gly NHCHH'CO), 1.86-
1.62 (m, 211, N}jCH2CO), 1.01 (s, 914, OSiC(CFJ3)3); 13C NIVIR (100 MHz, CDC13): ö = 
170.86, 169.02, 167.87, 167.13, 167.07, 141.45, 141.54, 137.27, 137.07, 135.43, 
135.42, 134.29, 133.92, 132.46, 132.38, 131.17, 131.05, 130.14, 130.11, 129.08, 
128.93, 128.72, 128.25, 127.92, 127.85, 126.90, 125.25, 80.14, 62.75, 53.98, 50.31, 
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45.82, 44.36, 44.27, 44.06, 42.71, 41.91, 26.75; FAB-FIRMS for C711176N909Si m/z 
[M+T{4 ], calcd.: 1226.55353, found: 1226.55231. 
rotaxane 3.27 
Yield (0.023 g, 87%); 'H NMR (400 MHz, 323K, C2D2C14): ö = 8.22 (s, 2H, 
isophthaloyl 2-11), 7.97 (d, 411, J = 6.8 Hz, isophthaloyl 4-11 & 6-H), 7.63 (br t, 411, 
macrocyclic CON}J), 7.51-7.04 (m, 24H, aromatic Ar-H & isophthaloyl 5-H & CONET), 
6.96 (s, 811, macrocyclic para-xylylene Ar-H), 6.75 & 6.56 & 6.37 (br s, 311, CONH, 
4.5-4.37 (m, 411, macrocyclic NIHCHH'), 4.32-4.05 (m, 711, macrocyclic NH. CHH' & 
CONHCH2CHPh2 & Gly NHCHH'CO), 3.94-3.81 (m, 211, Ser 
NHCH(CH2(OTBDPS))CO & Gly NHCHH'CO), 3.66-3.53 (m, 2H, CONHCH2CHPh2 
& 	Ser 	N}ICH(CLIH'(OTBDPS))CO), 	3.48-3.39 	(in, 	111, 	Ser 
NHCH(CHTEI'(OTBDPS))CO), 3.37-3.29 (in, 211, Gly NHCHH'CO & Gly 
NHCHH'CO), 3.24-3.10 (m, 211, Gly NHCHH'CO & Gly NHCHH'CO), 2.55-2.35 (m, 
111, Gly NHCHH'CO), 2.22-2.01 (in, 111, Gly NHCHH'CO), 1.28-1.11 (br t, 211, Gly 
NB2CH2CO), 0.92 (s, 911, OSiC(CH3)3); 13C NMR (100 MHz, C2D2C4): 8 = 173.25, 
171.14, 169.98, 167.85, 167.63, 168.27, 167.08, 144.94, 144.83, 144.15. 142.22, 
140.91, 139.50, 137.49, 136.40, 135.89, 135.78, 133.99, 133.13, 132.82, 131.56, 
130.74, 129.84, 129.66, 129.58, 129.57, 129.38, 129.28, 128.53, 128.48, 128.36, 68.75, 
54.82, 50.62, 45.06, 44.99, 44.97, 44.94, 44.91, 44.88, 44.83, 27.22; FAB-HRMS for 
C73H79N10O10S1 m/z [M+H'], calcd.: 1283.57499, found: 1283.57406. 
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General procedure for the coupling of [2]rotaxanes 3.13, 3.26, 3.27 with the activated 
ester rotaxane 3.28' 
The [2]rotaxane 3.13, 3.26 or 3.27 (0.010 mmol) and the activated rotaxane 3.28 
(0.010 mmol) were dissolved in 10 mL of CHC13. The reaction mixture was then heated 
at reflux for seven days and monitored by TLC (CHC13/MeOH: 90/10). The solvent was 
removed under reduced pressure. The crude material was directly purified via reverse 
phase preparative HPLC (gradient H20/MeOH: 95/5) using a Luna 5u C18(2) 100A 
column (250 mm x 2.00 mm, 5 gm) purchased from Phenomenex. 
[3] rotaxane 
3.30 
Yield (0.010 g, 50%); 'H MM (400 MIHz, 363K, C2D2C14): 8 = 8.16 (s, 4H, 
isophthaloyl 2-H & isophthaloyl 2-H'), 8.06 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 
7.89 (d, 4H, J= 7.2 Hz, isophthaloyl 4-H' & 6-H'), 7.50-7.03 (m, 42H, aromatic Ar-H & 
isophthaloyl 5-H & 5-H', macrocyclic CONH & CONH'), 6.94 & 6.93 (2s, 1611, 
macrocycicpara-xylylene Ar-H & Ar-H'), 6.81 & 6.49 & 6.43 & 6.27 & 6.21 & 6.08 & 
5 69 (7 br s, 7H, CONH), 4.52-4.16 (m, 1911, macrocyclic NHCHH' & macrocyclic 
NHCHH' & Ph2CHCO & Ser NHCH(CH2(OTBDPS))CO & CONHCH2CHPh2), 3.90-
3.82 (m, 1H, Gly NHCFIH'CO), 3.79-3.73 (m, 111, CONHCHH'CHPh2), 3.58-3.51 (m, 
1H, CONHCHH'CHPh2), 3.49-3.40 (m, IH, Gly NHCHH'CO), 3.34-2.95 (m, 8H, Gly 
NHCH2CO & Gly NHCHCO & Gly NI1CH2CO & Gly NTIICH2CO), 2.57 (br dd, 1H, 
Ser NHCH(CFIH'(OTBDPS))CO), 2.34 (br dd, 1H, Ser NIHCH(CHH'(OTBDPS))CO), 
0.91 (s, 911, OSiC(C113)3); 13C NMR (100 MHz, C2D2C14): 5 = 172.95, 170.87, 170.79, 
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170.71, 170.55, 170.32, 69.70, 169.61, 168.60, 142.14, 140.59, 139.01, 137.84, 137.39, 
135.90, 135.87, 135.70, 135.07, 134.64, 133.15, 132.99, 132.73, 132.42, 131.97, 
131.15, 130.77, 130.71, 130.66, 130.30, 129.77, 129.66, 129.28, 129.17, 129.04, 
128.53, 128.46, 128.41, 128.30, 128.25, 128.16, 128.14, 127.79, 127.41, 127.30, 81.03, 
63,77, 55.12, 54.55, 49.77, 45.20, 45.19, 45.14, 44.64, 44.62, 44.60, 44.53, 44.39, 
44.35, 44.32, 27.24; FAB-HRMS for C121H120N15016Si m/z [M+1{], calcd.: 2066.88068, 
found: 2066. 87980. 
G1ycyI gI ycyLg1ycylg1ycyIL_(O(tertbutyIdipheflY1SiIYl))Se1YlglYCYIglYC111e 
131 rotaxane 3.31 
Yield (0.017 g, 50%); 111  NMIR (400 MHz, 373K, C2D204): ö = 8.14-8.07 (m, 411, 
isophthaloyl 2-H & 2-11'), 8.00-7.87 (m, 8H, isophthaloyl 4-H & 6-H & 4-H' & 6-H'), 
7.38-7.03 (m, 42H, isophthaloyl 5-H & 5-H' & macrocyclic CONH &CONH', aromatic 
Ar-H), 6.90 & 6.85 (2s, 1611, macrocyclic para-xylylene Ar-H & Ar-H'), 6.71 & 6.52 & 
6.39 & 6.31 & 6.29 & 6.09 & 5 99 (8 br s, 711, CONH), 4.70-4.54 (m, 1H, Ser 
NHCH(CH2(OTBDPS))CO), 4.41-4.18 (m, 1811, macrocyclic NHCHH' & macrocyclic 
NHCHH' & Ph2CHCO & CONHCH2CHPh2), 3.73 (s, 2H, Gly NHCHZCO), 3.41-3.18 
(m, 12H, CONHCHCHPh2 & Gly NHCH2CO), 2.90-2.88 (in,, 2H, Ser 
NHCH(CH(OTBDPS))CO), 1.15 (s, 9H, OSiC(CH3)3); 13C NMR (100 MHz, C2D2C4): 
173.41, 171.73, 171.17, 170.23, 169.08, 166.34, 166.07, 165.91, 163.84, 163.61, 
143.50, 142.15, 136.53, 136.48, 136.18, 135.75, 135.28. 135.08, 135.00, 134.94, 
134.24, 132.96, 131.53, 131.42, 130.30, 129.94, 129.88, 129.86, 129.75, 129.41, 
129.30, 129.22, 129.19, 129.17, 129.14, 128.89, 128.88, 128.86, 128.58, 128.43, 
128.34, 128.07, 127.77, 127.71, 127.49, 127.44, 81.07, 52.07, 51.95, 51.37, 45.63, 
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45.22, 44.94, 44.88, 44.05, 43.26, 42.52, 43.76, 43.42, 42.43, 42.00, 28.48; FAB-HRMS 
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Synthesis of a two-side-extension rotaxane building 
block for extensive oligopeptide rotaxane synthesis! 
Prepared, together with Chapter Three, as a paper to Angewandte Chemie 
International Edition in English. 
Abstract: 
The synthesis of an N-Fmoc protected tripeptide L-SerGlyGly rotaxane building 
block, functionalized on the lateral chain by an ether bulky stopper, is described. Its 
sequential extension on the C- and N-terminal sides was carried out to easily give 
oligopeptide rotaxanes in very good yields. The method was then applied to the synthesis 
of the first unprotected peptide rotaxane with free amine and carboxylic acid terminal 
functions. Such peptide rotaxane building blocks could be utilised to make large libraries 
of interlocked peptides without problems of punfication and solubility. 
Keywords: 
activated ester - amino acid lateral chain - protection - peptide coupling - 




The synthesis of dipeptide rotaxanes incorporating benzylic 1,3-carbamide 
macrocycles, using a five-component hydrogen bond-directed assembly has been recently 
reported. 13 However, such an approach is restricted to short peptide sequences due to 
the folding of the backbone by intramolecular hydrogen-bonding in the longer peptides.4 
Methods to overcome this problem and synthesise oligopeptide rotaxanes in very good 
yields have been developed recently: (i) the synthesis of versatile activated ester rotaxane 
building blocks which can be elongated via their C-terminal side' and (ii) the synthesis of 
N-protected tripeptide rotaxane building blocks, functionalized on the lateral chain by 
labile bulky stoppers and extendable on their N-terminal side via classical peptide 
coupling reactions after N-deprotection.6  A combined strategy we describe herein is the 
synthesis of a new N-Fmoc protected L-SerGlyGly tripeptide rotaxane building block 
which can be both C- and N-extended via classical peptide coupling reactions. The choice 
of the N-Fmoc protected L-SerGlyGly activated ester sequence as a tripeptide was five-
fold: (i) it contains the most efficient GlyGly dipeptide template ,4  (ii) L-SerGlyGly was 
found to be a more efficient template than L-AspGlyGly as the macrocycle experienced a 
fast shuttling along the peptide backbone after coupling and lateral chain deprotection of 
the prior ,6  (iii) a labile ether on the lateral chain of the L-Ser residue acts as a labile bulky 
stopper for the macrocycle,6  (iv) 2,6diphenylpara-nitrOphenyl acts both as a bulky 
stopper and an activated ester, 
1,7  (v) N-terminal Fmoc deprotection of an L-Ser residue 
promotes peptide coupling reactions to give oligopeptide rotaxanes, followed by further 
deprotection of the labile bulky stopper.6 
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4.2. Results and discussion 
Synthesis of the tripepride activated ester rotaxane building block 
The N-Fmoc-L-SerGlyGly tripeptide activated ester thread 4.6 was prepared in a five step 
sequence by classical peptide coupling  reaction (Scheme 4.1.). Rotaxane 4.7 was 
synthesised as described above, purified via silica gel chromatography and could be 
stored for many weeks at room temperature with no degradation. 
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Scheme 4.1. Synthesis of the two-side-extension tripeptide rotaxane building block 4.7. a) HOCH2Ph, 
DMAP, EDCI.HC1, CHC13, 100%; b) (i) TFA, CHC13, (ii) DIIPEA, CHC13, (iii) N-Fmoc-L-Ser-011, 
DIvIAP, EDCI1-IC1, CHC13, 57%; c) (i) TBDPSC1, imidazole, DMF, 73%, (ii) 112, Pd/C, P atm, EtOAc, 
100%, (iii) 2,6-diphenyl para-nitrophenol, BOP, Et3N, CHC13, 53%; c) isophthaloyl dichloride, para- 
xylylene diamine, Et3N, CHC13, 14% (26% overall yield after 8 cycles of rotaxane formation). 
The 'H NMR spectra of the N-Fmoc-L-SerGlyGly activated ester thread 4.6 and its 
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asymmetry of the thread stoppers leads to two different dd signals for the enantiotopiC 
benzylic hydrogens H1  of the macrocycle. A shielding effect on the hydrogens of the 
thread located in the cavity of the macrocycle is observed. Thus in spectrum b, the signals 
for 	and He of the rotaxane building block 4.7 are shifted upfield by 6 = 0.54 and 
1.31 
ppm, respectively, compared with the c
orresponding signals in the spectrum of the thread 
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Figure 4.1. Comparison of the 1H NUR spectra (400 IvlIHz, CDC1
3) of a) the N-Fmoc protected 
activated tripeptide L-SerGlyGlY activated thread 4.6 
and b) the N-Fmoc protected activated tripeptide 







Extensive oligopeptide synthesis via the two-side extension promoter 
In a typical procedure,5  a mixture of the rotaxane building block 
4.7 and five 
equivalents of a mono- or tri-peptide as a free amine moiety was heated at reflux in 
chloroform (Scheme 4.2.). The isolated resulting derivatives 4.8, 4.9 and 4.16 
were then 
reacted following our present method: 6 
 N-Fmoc deprotection using piperidine in 
chloroform, followed by further coupling with two equivalents of stoppered mono-, di- or 
tri-peptide using BOP and final lateral deprotectiOn. it is noteworthy that the TBDPS 
deprotectiofl using a IM TBAF solution in TI{F was unsuccessful for the octa- and nona-
peptide rotaxanes 4.15 and 4.19 respectively and required the use of pure TFA. 
yOr0 
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Scheme 4.2. Synthesis of oligopeptide rotaxanes 
4.14-4.15 by elongation and coupling of the two-side-
extension rotaxane promoter 4.7. a) Stoppered amino acid (n1, 3), CHC13 
 reflux; b) (i) 
piperidine/CHC13 1/3, (ii) stoppered amino acid (n' 1-3), BOP, Et3N, CHCI3; 
c) TBAF 1M in TI-IF for 4.12 and TFA for 4.13. 
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The yields of oligopeptide rotaxanes were excellent as reported in table 4.1. 
Peptide rotaxane sequence 	
Yield % 	Yield % 
C-elongation N-elongation 
GlyL-SerGlYGlY-GlY 4.12! 4.14 	
93/4.8 	96/4.12 
GIyGlyLSerGlYGlYL-AIaGIYGIY 4.13/4.15 	 94/ 4.9 	
91/ 4.14 
TFA. H-L-Leu-L-P heGIyLSerGIYGIYGlYLhe4t_euOH 4.18/4.19 	78/ 4.16 	
84/4.18 
Table 4.1. Synthesis of oligopeptide rotaxanes from the two-side-extension rotaxane promoter 4.7. 
It is noteworthy that rotaxane 4.19 is the first example ever reported of an unprotected 
peptide rotaxane with free amine and carboxylic acid functions on the N- and C-terminal 
sides of the peptide backbone, respectively (Scheme 4.3.). The successive lateral chains 
4 of the Leu and Phe residues are bulky enough to act as stoppers for the macrocycle. 
0 0 
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Scheme 4.3. Nonapeptide rotaxane 4.19, stoppered by the lateral chains of the last two amino acid 
residues. 
Influence of the macrocycle on the nonapeptide conformation in solution in CD30H is 




The double extension of the rotaxane building block 4.7 is a key tool for the easy 
synthesis of libraries of unprotected oligopeptide rotaxanes (i) in very good yields, (ii) 
able to be purified via 
silica gel chromatography and (iii) without solubility problems in 
organic solvents. Studies into its incorporation in glucuronylated prodrugs for ADEPT 
strategy in cancer chemotherapy are ongoing, in collaboration with the Gesson group at 




We have described the synthesis of an N-Fmoc protected tripeptide L-SerGlyGlY 
activated ester rotaxane building block functionalized on its lateral chain by a labile bulky 
stopper. It can be stored many weeks at room temperature with no degradation. It has 
been efficiently used for the synthesis of oligopeptide rotaxanes, in very good yields, by 
successive extension on its C- 
and N-terminal sides. Such a peptide rotaxane building 
block is potentially a very convenient tool for building wide libraries of peptide 
interlocked architectures as it reacts both with nucleophiles and electrophiles. 
Investigations towards its loading on solid support as a method for synthesising large 
libraries of polyrotaxafleS are currently ongoing in our group. 
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4.4. Experimental section 
Method for the preparation of the thread 4.6 
beuzylic ester 4.2 
tBocglycylglYC1fle (4.1, 5.228 g, 
22.500 mmol), benzylalcohol (2.5 mL, 24.200 mmol) 
and DMAP (8.258 g, 
67.590 mmol) were dissolved in 100 mL of CHC13. The reaction 
mixture was cooled at 0°C. Then EDCI.HC1 (6.477 g, 
33.790 mmol) was added. The 
reaction mixture was stirred one hour at 0°C and brought to room temperature and 
stirred overnight. The crude material was washed with IM HC1 and saturated NaHCO3. 
The organic phase was dried over MgSO4. The solvent was removed under reduced 
pressure to afford a white powder. Yield (7.257 g, 100%); m.p. 74°C; 
111 NMIR (400 
MHz, CDC13): 6 = 7.40-7.33 (m, 5H, aromatic Ar-H), 6.57 (br t, 1H, CONHCFI2CO), 
5.19 (s, 2H, CO2
CH2Ph), 5.10 (br s, 1H, BocOCONHCH2CO), 4.11 (d, 211, J 5.2 Hz, 
Gly NHCII2CO), 3.85 (d, 2H, J = 5.2 
Hz, Gly NHCH2CO), 1.46 (s, 9H, Boc CH3); 13C 
NUR (100 MHz, CDC13
): 6 = 169.84, 169.63, 156.09, 135.07, 128.66, 128.58, 128.38, 
80.39, 67.28, 44.17, 41.23, 28.29; FAB-HRMS for C16H23N2
0 m/z [M+Hi, calcd.: 
323.16070, found: 323.16069. 
benzyl ester 4.3 
TFA was added to a solution of 	
benzylic ester (4.2, 
4.571 g, 14.180 mmol) in CHC13
. The reaction was stirred for 4 hours and then 
concentrated under reduced pressure. To a solution of the residue in CHC13 
 was added 
DIPEA (2.427 mL, 14.180 mmol), followed by addition of NciFmoc-L-Ser111e (4.641 g, 
14.180 mmol) and DMAP (0677 g, 5.540 mmol) in 100 mL of CHC13
. The reaction 
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mixture was cooled at 0°C. Then EDCI.FIC1 (4.083 g, 14.180 mmol) was added. The 
reaction mixture was stirred one hour at 0°C and brought to room temperature and 
stirred overnight. The crude material was washed with IM HCI and saturated NaHCO3. 
The organic phase was dried over MgSO4. The solvent was removed under reduced 
pressure. The purification via silica gel 
chromatography (CHC13/1\4eOH: 98/2 to 92/8) 
afforded a white powder. Yield (4.309 g, 57%); m.p. 132°C; 
1  NMIR (400 MHz, 
CDCI3): = 7.73 (d, 211, J = 7.6 Hz, aromatic Ar-H Fmoc), 757-7.24 (m, 1311, aromatic 
Ar-H & aromatic Ar-H Fmoc & CONH), 6.12 (d, 1H, J 
= 6.4 Hz, Ser 
OCONBCH(C112011)), 5.12 (s, 2H, CO2CH2Ph), 4.38 (d, 2H, J 
= 7.0 Hz, Fmoc 
CHCH2OCONH), 4.33-4.26 (in, 1H, Ser NHCH(CH
2OH)CO), 4.16 (t, 1H, J = 7.0 Hz, 
Fmoc CHCH2000NH), 4.05-3.91 (m, 5H, Ser NHCH(CHH'OH)CO & Gly N}ICH2C0 
& Gly NHCH2CO), 3.70-3.63 (m, IH, Ser NT-ICH(CT1H'OH)CO), 2.04-1.93 (m, IH, Ser 
NUCH(CHH'OH)CO); '3C NMR (100 MIHz, CDCI
3): ö = 170.95, 170.12, 169.53, 
158.00, 143.62, 141.29, 134.85, 128.66, 128.63, 128.35, 127.81, 127.13, 125.04, 
120.05, 67.45, 67.24, 62.92, 56.33, 47.04, 43.05, 41.25; FAB-HRMS for C
29H29N307Na 
m/z [M+Na], calcd.: 554.1903 5, found: 554.19050. 
benzyl ester 4.4 
NcL-Fmoc-L-seIYl glycyiglycine benzyl ester (4.3, 1.890 g, 3.550 mmol) and imidazole 
(0.609 g, 8.950 mmol) were dissolved in dry DMF (5 mL) under nitrogen. TBDPSC1 (4.5 
mL, 17.580 mmol) was added and the solution was stirred 24 hours at rt. The solvent 
was removed under reduced pressure. The purification via silica gel chromatography 
(CHCI3/MeOR 98/2) afforded a white powder. Yield (2.060 g, 73%); M.P. 155°C; 
1H 
NMR (400 MHz, CDCI3): ö = 7.76 (d, 2H, aromatic Ar-H Fmoc, J 
= 7.2 Hz), 7.64-7.23 
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(m 21H, aromatic Ar-H & aromatic Ar-H Fmoc), 7.05 (br t, IH, CONHCH2CO), 6.97 
(br t, TH, CONHCH2CO), 5.63 (d, 1H, J = 6.0 Hz, Ser 
OCONHCH(CH2(OTBDPS))CO), 5.11 (s, 2H, CO2CH2Ph), 4.46-4.35 (m, 2H, Fmoc 
CHCH2OCONH), 4.31-4.25 (in, 1H, Ser NHCH(CH2(OTBDPS))CO), 4.19 (t, 1H, 
J = 
6.8 Hz, Fmoc CHCH2000NH), 4.09-3.93 (111. 5H, Ser NHCH(CHH'(OTBDPS))CO & 
Gly N}TCIIIZCO & Gly NHCH2CO),  3.84 (dd, 1H, J = 5.2 Hz, J 
= 10.4 Hz, Ser 
NHCH(CHH'(OTBDPS))CO), 1.05 (s, 911, OSiC(C113)3); '3C NTMR (100 MHz, CDC13): 
= 169.15, 169.03, 168.24, 157.95, 141.33, 135.48, 135.45, 134.80, 130.14, 128.64, 
128.55, 128.37, 127.98, 127.79, 127.12, 125.08, 124.96, 120.05, 80.03, 68.01, 67.41, 
67.20, 57.12, 56.15, 43.11, 41.18, 26.80; FAB-HRMS for C45H48N307Si m/z [M+Hi, 
calcd.: 770.32616, found: 770.32591. 
4.5 
benzyl ester (4.4, 2.338 g, 
3.037 mmol) and catalytic palladium, 10% wt. on carbon powder were dissolved in 80 
mL of AcOEt. The system was then placed under vacuum and hydrogen was introduced 
at atmospheric pressure for four hours. The reaction mixture was filtered over celite. The 
solvent was removed under reduced pressure to afford a white powder. Yield (2.065 g, 
100%); m.p. 81°C; 11-1 NMR (400 MHz, CDCI3): ö = 7.73 (d, 2H, aromatic Ar-H Fmoc, 
J = 6.8 Hz), 7.58 (d, 2H, aromatic Ar-H Fmoc, J = 6.8 Hz), 7.42-7.24 (m, 15H, 
aromatic Ar-H & aromatic Ar-H Fmoc & CONE), 7.15 (br t, 1H, CONHCH2CO), 5.71 
(d, 111, J = 6.4 Hz, Ser OCONHCH(CH2(OTBDPS))CO), 4.39-4.31 (m, 3H, Fmoc 
CHCiiiOCONH & Ser NHCH(CH2(OTBDPS))CO), 4.19-4.11 (m, 2H, Fmoc 
CHCH2000NH & Ser NHCH(CHH'(OTBDPS))CO), 3.99 (brd, 2H, Gly NHCH2CO), 
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3.93 (brd, 2H, Gly NHCHCO), 3.82 (dd, 1H, J 
= 4.8 Hz, J = 9.6 Hz, Ser 
NBCH(CHH'(OTBDPS))CO), 1.02 (s, 9H, OSiC(CH3)3); 13C NIVIIR (100 MHz, CDC1
3): 
= 172.05, 170.82, 169.51, 156.57, 143.67, 143.48, 141.24, 135.43, 134.79, 132.38, 
130.06, 129.64, 127.93, 127.91, 127.79, 127.70, 127.12, 126.90, 125.07, 125.01, 
120.01, 119.83, 80.12, 67.43, 63.81, 56.58, 46.95, 42.90, 41.22, 26.73; FAB-HRMS for 
C38H42N3O7Si m/z [M+W], calcd.: 680.2792 1, found: 680.27965. 
diphenyipheflYleSter 4.6 
(4.5, 2.065 g, 3.040 
mmol), 4-nitro-2,6-dipheflYl phenol (1.770 g, 6.080 mmol), DIPEA (0.530 mL, 3.040 
mmol) and BOP (2.017 g, 4.560 mmol) were dissolved in 60 mL of CHC13. The reaction 
mixture was stirred overnight at room temperature. The crude material was purified via 
silica gel chromatography (AcOEt/cyclohexane: 1/2 to 1/1) to afford a yellow powder. 
Yield (1.534 g, 53%); m.p. 104°C; 1H NMR (400 M14z, CDC13
): 8 = 8.24 (s, 2H, NO2-
Ph-H), 7.76 (d, 2H, aromatic Ar-H Fmoc, J = 7.6 Hz), 7.61-7.22 (m, 2611, aromatic Ar-
H & aromatic Ar-H Fmoc & CONB, 6.57 (br t, 1H, CONHCH2
CO), 6.44 (br t, 111, 
CONIHCH2CO), 5.37 (d, 111, J = 5.2 Hz, Ser OCONHC11(CH2(0TBD))), 4.38 
(dd, 1H, J = 6.4 Hz, J = 10.4 Hz, Fmoc CHCHH'OCONH), 4.30 (dd, 111, 
J = 6.4 Hz, J 
= 10.4 Hz, Fmoc C11CHh'OCONH), 4.18-4.10 (m, 2H, Fmoc CT4CH2
000NH & Ser 
NHCWCH2(OTBDPS))CO), 4.00 (dd, 1H, 
J = 4.8 Hz, J = 10.8 Hz, Ser 
NHCH(CHH'(OTBDPS))), 3.88 (dd, 1H, J 
= 5.2 Hz, J = 18.8 Hz, Gly 
NHCHH'CO), 3.82-3.73 (m, 3H, Gly NHCH2CO & Ser NHCH(CHH'(OTBDPS))CO),  
3.69 (dd, 1H, J = 4.8 Hz, J 
= 18.8 Hz, Gly NHCHH'CO), 1.03 (s, 911, OSiC(CH3)3); 13C 
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NMR (100 NI1FIz, CDC13): 6 = 171.12, 167.78, 166.94, 157.71, 149.25, 145.95, 143.62, 
141.30, 137.37, 135.46, 135.42, 135.26, 130.17, 128.84, 128.78, 128.68, 128.00, 
127.98, 127.85, 127.81, 127.09, 127.05, 124.99, 124.93, 124.88, 120.07, 80.73, 67.25, 
63.35, 56.89, 47.05, 42.84, 40.85, 26.77; FAB-FIRMS for C56H53N409Si m/z [M+H], 
calcd.: 953.35818, found: 953.35770. 
activated 	ester 
rotaxane 4.7 
diphenyiphenylester (4.6, 0.495, 0.520 mmol) was dissolved in 20 mL of CHC13 under 
nitrogen and stirred vigorously whilst solutions of the mixture of para-xylylene diamine 
(1.135 g, 8.350 mmol) and NEt3  (1.685 g, 16.680 mmol) in 35 mL of CHC13 and the 
isophthaloyl dichloride (1.694 g, 8.340 mmol) in 35 mL of CHC13 were simultaneously 
added to the reaction mixture over a period of 3 hours using motor-driven syringe 
pumps. The reaction mixture was stirred 2 hours under nitrogen, then filtered over celite 
and the filtrate was evaporated under reduced pressure to afford a syrup which was 
purified via silica gel chromatography to yield, in order of elution, the unconsumed 
activated ester thread (AcOEt/cyclohexane: 1/1) and the rotaxane (CHCI3/1\4eOH: 98/2). 
Yield (0.108 g, 14%); Overall yield after 8 cycles of rotaxane formation (0.546 g, 26%); 
m.p. 144°C; 'H NMR (400 MHz, CDC13): 8 = 8.23 (s, 2H, NO2-Ph-H), 8.07 (s, 2H, 
isophthaloyl 2-H), 8.03 (d, 2H, J = 7.8 Hz, isophthaloyl 4-H & 6-H), 7.96 (d, 2H, J = 7.8 
Hz, isophthaloyl 4-H & 6-H), 7.77-7.17 (m, 27H, aromatic Ar-H & aromatic Ar-H Fmoc 
& macrocyclic CONH, isophthaloyl 5-H, thread CONIH), 6.94 (d, 4H, J = 8.2 Hz, 
macrocyclic para-xylylene Ar-H), 6.91 (d, 4H, J = 8.2 Hz, macrocyclic para-xylylene, 
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Ar-H'), 6.48 (br s, 1H, CONIHCH2CO), 5.22 (d, 1H, J =6.0 Hz, Ser 
OCONHCH(CH2(OTBDPS)CO), 4.65 (dd, 2H, J = 6.0 Hz, J = 13.6 Hz, macrocyclic 
NHCHH'), 4.33 (dd, 211, .J = 4.4 Hz, J = 14.2Hz, macrocyclic NHCHH'), 4.24 (dd, 2H, 
J = 4.8 Hz, J = 14.2 Hz, macrocyclic NHCHH'), 4.12-4.02 (m, 411, macrocyclic 
NHCHH' & Fmoc CHCHZOCONH), 3.93 (t, 1H, J = 6.8 Hz, Fmoc CHCH2000N}{), 
3.75 (dd, 1H, J = 5.6 Hz, J = 18.4 Hz, Gly NHCHH'CO), 3.67-3.53 (m, 4H, Ser 
NHCH(CH2(OTBDPS)CO & Gly NHCHT]'CO & Gly NI{C1CO),  2.90 (dd, 111, J = 
3.2 Hz, J = 17.0 Hz, Ser NHCH(CHH'(OTBDPS))CO), 2.36 (dd, 111, J = 4.0 Hz, J = 
17.0 Hz, Ser NHCH(CHH'(OTBDPS))CO), 0.99 (s, 9H, OSiC(CH3)3); 13C NMR (100 
MHz, CDC13): 6 = 169.20, 168.12, 167.02, 166.86, 166.20, 158.12, 149.09, 146.10, 
141.26, 137.39, 137.34, 137.10, 133.92, 132.41, 132.24, 131.27, 131.17, 130.87, 
130.18, 129.22, 128.96, 128.87, 128.79, 128.69, 128.56, 127.98, 127.89, 127.83, 
127.11, 127.04, 125.15, 125.04, 124.94, 120.01, 81.02, 67.58, 62.39, 52.44, 46.97, 
44.32, 44.12, 42.72, 40.68, 26.74; FAB-HRMS for C88H81N8013Si m/z [M+F[], calcd.: 
1485.56924, found: 1485.56038. 
General procedure for the elongation of 12]rotaxane building block 4.7 
The [2]rotaxane building block 4.7 (0.079 mmol) and a stoppered nucleophile (0.395 
mmol) were dissolved in 6 mL of CHC13. The reaction mixture was then heated at reflux 
and monitored by TLC (CHC13/1\4eOH: 90/10). The solvent was removed under reduced 
pressure. The crude material was directly purified via silica gel chromatography 
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(CHC13/MeOH: from 98/2 to 90/10) to afford m order of elution the 2,6-diphenyl-para-
nitrophenol, and the elongated rotaxane as a white powder. 
N-a-Fmoc-L-(O-(tert-butyldiphenylsilyl))-serylglycylglycylglycine ro taxane 4.8 
Yield (0.062 g, 93%); 'H NrvIR (400 MHz, CDC13): ö = 8.21 (s, 2H, isophthaloyl 2-H), 
8.01 (d, 4H, J = 7.6 Hz, isophthaloyl 4-H & 6-H), 7.73 (d, 2H, J = 7.6 Hz, aromatic Ar-
H Fmoc), 7.67-7.59 (br t, 411, macrocyclic CONH), 7.58-7.06 (m, 36 H, aromatic Ar-ti 
& aromatic Ar-H Fmoc & isophthaloyl 5-H & macrocyclic para-xylylene Ar-H), 7.04-
6.98 (m, 2H, Gly CON}ICH2CO), 6.93 (br t, 1H, Gly CONHCH2CO), 5.50 (d, 1H, J 
7.2 Hz, Ser OCON}TCH(CH2(OTBDPS))CO), 4.59 (dd, 2H, J = 6.0 Hz, J = 14.0 Hi, 
macrocyclic NHCHH'), 4.52-4.43 (m. 4H. macrocyclic NHCHH' & CO2CH2CHPh2), 
4.35 (dd, 211, J = 4.8 Hz, J = 14.0 Hz, macrocyclic NHCHH'), 4.29-4.22 (m, 3H, 
macrocyclic NHCHH' & Fmoc CHCHH'OCONH), 4.21-4.14 (m, 2H, Fmoc 
CHCHH'OCONH & CO2CH2CHPh2), 4.08-3.99 (m, 2H, Ser 
NHCH(CH2(OTBDPS))CO & Fmoc CHCH2000NEI), 3.78 (dd, 1H, J = 5.2 Hz, J = 
10.2 Hz, Ser NHCH(CHH'(OTBDPS))CO), 3.69 (dd, IH, J = 4.8 Hz, J 10.2 Hz, Ser 
NHCH(CHH'(OTBDPS))CO), 3.29 (br d, 211, Gly NIF{CFICO), 3.24 (dd, 1H, J = 5.2 
Hz, J = 16.8 Hz, Gly NHCHH'CO), 3.18-3.11 (m, 2H, Gly NHCHH'CO & Gly 
NHCHH'CO), 3.04 (dd, 111, J = 4.8 Hz, J = 16.0 Hz, Gly*  NHCHH'CO), 0.99 (s, 9H, 
OSiC(C)3); 13C NTvIIR (100 MHz, CDC13): 6 = 170.70, 169.32, 169.27, 168.85, 
167.05, 156.63, 143.56, 143.39, 141.26, 141.22, 140.81, 140.47, 137.38, 137.22, 
135.41, 135.37, 134.28, 134.10, 132.44, 132.28, 131.12, 131.02, 130.15, 129.05, 
128.98, 128.69, 128.62, 128.29, 128.13, 128.00, 127.97, 127.92, 127.80, 127.09, 
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126.91, 124.98, 124.94, 120.02, 80.72, 67.64, 67.09, 63.04, 56.20, 49.55, 46.87, 44.35, 
44.21, 42.52, 42.38, 40.90, 26.75; FAB-FIRMS for C86H85N8012Si m/z [M+H], calcd.: 
1449.60563, found: 1449.60571. 
N-a-Fmoc-L-(O-(tert-butyldiphenylsilyl))-serylglycylglycyl-L-alanylglycylglycine 
rotaxane 4.9 
Yield (0.068 g, 94%); 1H NMR (400 MHz, CDCI3): ö = 8.27 (s, 2H, isophthaloyl 2-H), 
8.02 (d, 2H, J = 6.6 Hz, isophthaloyl 4-H & 6-11), 8.00 (d, 2H, J = 6.6 Hz, isophthaloyl 
4-H & 6-H), 7.86 (br t, 2H, macrocyclic CONH), 7.75 (br t, 2H, macrocyclic COW), 
7.72 (d, 2H, J = 7.6 Hz, aromatic Ar-H Fmoc), 7.61-7.13 (m, 32 H, aromatic Ar-H & 
isophthaloyl 5-11 & aromatic Ar-H Fmoc & CONH), 7.08 (s, 811, macrocyclic pam-
xylylene Ar-H), 6.96 (br s, 1H, CONHCH2CO), 5.69 (d, 1H, J = 5.6 Hz, Ser 
OCON}{CH(CH2(OTBDPS))CO), 4.62 (dd, 2H, J = 4.4 Hz, J = 18.0 Hz, macrocyclic 
NHCHH'), 4.49-4.40 (m, 4H, macrocyclic NHCHH' & CO2CflCHPh2), 4.39-4.31 (m, 
4H, macrocyclic NHCHH' & Fmoc CHCH2000NH), 4.24 (dd, 211, J= 6.8 Hz, J= 18.0 
Hz, macrocyclic NHCHH'), 4.17-4.13 (m, 211, Ser NIHCH(CH2(OTBDPS))CO & 
CO2CH2CHPh2), 4.06 (t, 111, J = 6.8 Hz, Fmoc CHCH2000NH), 4.03-3.97 (m, 1H, Ala 
NHCH(CH3)CO), 3.92 (dd, 111, J = 6.0 Hz, J = 11.0 Hz, Ser 
NHCH(CHH'(OTBDPS))CO), 3.83 (dd, 1H, J = 4.8 Hz, J = 11.0 Hz, Ser 
NHCH(CI{H'(OTBDPS))CO), 3.53 (dd, Hi, J = 5.6 Hz, J = 17.2 Hz, Gly 
NHCHH'CO), 3.46-3.42 (m, 311, G1yNHCH2CO & Gly NETCHH'CO), 3.38 (dd, 1H, J= 
4.4 Hz, J = 14.0 Hz, Gly NIHCI{E{'CO), 3.29 (dd, 111, J = 4.8 Hz, J = 17.2 Hz, Gly 
N}JCHH'CO), 3.17 (br dd, 111, J = 15.6 Hz, Gly NHCHH'CO), 3.02 (br dd, 111, .J 
15.6 Hz, G1yNIHCHH'CO), 1.11 (d, 3H,J = 6.8 Hz, MaNIHCH(Cj)CO), 1.02(s, 911, 
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OSiC(CFI3)3); 13C NIvIIR (100 MHz, CDC13): 8 = 172.58, 171.16, 	169.55, 169.37, 
169.14, 	167.31, 	167.16, 156.80, 143.53, 	143.40, 	141.26, 	141.22, 	140.65, 140.48, 
137.39, 	137.07, 	135.44, 135.41, 134.33, 	134.16, 	132.47, 	132.32, 	131.13, 130.99, 
130.15, 	129.86, 	129.06, 128.94, 128.67, 	128.10, 	127.98, 	127.84, 	127.81, 127.66, 
127.09, 	127.00, 	126.94, 125.22, 124.94, 	120.05, 79.85, 67.58, 67.49, 63.29, 56.89, 
49.50, 48.94, 46.91, 44.35, 44.17, 43.06, 42.54, 40.91, 26.77, 16.92; FAB-RRMS for 
C91H93N10014Si m/z [M+iEfl, calcd.: 1577.66420, found: 1577.65004. 
L-Ieucine-tert-butyl ester rotaxane 4.16 
Yield (0.074 g, 98%);'H NMR (400 MHz, CDC13): = 8.27 (s, 1H, isophthaloyl 2-H), 
8.22 (s, 111, isophthaloyl 2-H), 8.02 (d, 2H, J = 7.8 Hz, isophthaloyl 4-H & 6-H), 7.98 
(d, 2H, J = 7.8 Hz, isophthaloyl 4-H & 6-H), 7.86 (br t, 211, macrocyclic CONH), 7.79 
(br t, 2H, macrocyclic CONH'), 7.74-7.15 (m, 29 H, aromatic Ar-H & isophthaloyl 5-H 
& aromatic Ar-H Fmoc & CONH), 7.10 (s, 4H, macrocyclicpara-xylylene Ar-H), 7.09 
(s, 4H, macrocyclic para-xylylene Ar-H),  6.56 (br s, 1H, CONH), 5.58 (d, 1H, J = 6.8 
Hz, Ser OCONHCH(CH2(OTBDPS))CO), 4.62-4.43 (m, 5H, , macrocyclic NHCHH' & 
NHCHH' & Phe NHCH(CH2Ph)CO), 4.38-4.21 (m, 711, macrocyclic NHCHH' & 
NHCHH' & Fmoc CHCHH'OCONH & Fmoc CHCHH'OCONIH & Leu 
NHCH(CH2CH(CH3)2)CO), 4.19-3.97 (m, 2H, Fmoc CHCH2000NH & Ser 
NHCH(CH2(OTBDPS))CO), 3.80 (dd, 111, J = 5.6 Hz, J = 10.2 Hz, Ser 
NHCH(CHH'(OTBDPS))CO), 3.75 (dd, 111, J = 5.2 Hz, J = 10.2 Hz, Ser 
NIHCH(C}{H'(OTBDPS))CO), 3.25 (dd, 1H, J = 4.8 Hz, J = 16.8 Hz, Gly 
NTTCHH'CO), 3.17-3.05 (m, 2H, Gly NIICHH'CO & G1yNHCHH'CO), 2.99 (dd, 111, J 
130 
Chapter Four 
= 4.0 Hz, J = 16.8 Hz, Gly NHC}{H'CO), 2.95-2.89 (m, 2H, Gly NHCH} ['CO & Phe 
NHCH(CHH'Ph)CO), 2.84 (dd, 1H, J = 7.6 Hz, J = 13.6 Hz, Phe NHCH(CHH'Ph)CO), 
2.60 (dd, 111, J = 4.4 Hz, J = 17.2 Hz, Gly NIHCHH'CO), 1.50-1.33 (m, 12H, Leu 
NHCH(CCH(CH3)2)CO & Leu NHCH(CH2CH(CH3)2)CO & CO2(C)3), 1.00 (s, 
9H, OSiC(CH3)3), 0.81 (d, 3H, J= 5.8 Hz, Leu NHCH(CH2CH(CH3)(CH'3)CO), 0.78(d, 
3H, J= 5.8 Hz, Leu NHCH(CH2CH(CH3)(Cfl'3)CO); 13C NMR (100 MHz, CDC13): 6 = 
171.56, 170.56, 170.32, 170.16, 169.17, 168.18, 167.28, 167.16, 143.57, 141.26, 
137.29, 136.29, 136.14, 135.43, 134.42, 134.17, 132.51, 132.40, 131.08, 130.99, 
130.12, 129.36, 129.19, 129.03, 128.92, 128.83, 128.70, 128.65, 128.21, 127.96, 
127.81, 127.13, 127.08, 125.71, 125.41, 124.99, 120.02, 82.11, 82.01, 67.34, 63.17, 
56.46, 54.77, 51.74, 46.91, 44.41, 44.26, 42.75, 42.24, 41.77, 41.35, 38.43, 27.97, 
26.76, 24.80, 22.51; FAB-HRMS for C91H101N10O14Si mlz [M+H4], calcd.: 1585.72680, 
found: 1585.73695 
General procedure for N-Fmoc deprotection of rotaxane derivates 4.8, 4.9, 4.16 
N-Fmoc protected rotaxane (0.036 mmol) was dissolved in 2 mL piperidine/CHC13  
(1/3) and was stirred at it for 2 hours. The solvent was removed under reduced pressure. 
The crude material was purified via silica-gel column chromatography (CHCI3/MeOH: 
96/4) to afford the free amine rotaxane. 
L_(O(tert.buty1dipheny1si1y1))-SeryIg1yCy1g1yCy1g1yCifle rotaxane 4.10 
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Yield (0.035 g, 100%); 'H NTv1iR (400 MHz, CDC13): 6 = 8.26 (s, 2H, isophthaloyl 2-
H), 8.09 (d, 2H, J = 8.4 Hz, isophthaloyl 4-H & 6-H), 8.06 (d, 2H, J = 8.4 Hz, 
isophthaloyl 4-H & 6-H), 7.65 (br t, 2H, macrocyclic CON}I), 7.65 (br t, 2H, 
macrocyclic COW), 7.50 (t, 2H, J = 8.4 Hz, isophthaloyl 5-H), 7.45-7.09 (m, 30 H, 
aromatic Ar-H & macrocyclic para-xylylene Ar-H), 7.05 (br t, 111, CONIT), 4.62-4.49 
(m, 6H, macrocycic NHCHH' & NHCHH' & CO2CH2CHPh2), 4.38 (dd, 2H, J = 4.8 
Hz, J = 14.0 Hz, macrocyclic NHCHH'), 4.30 (dd, 2H, J = 4.0 Hz, J = 14.0 Hz, 
macrocyclic NHCHH'), 4.24 (t, 1H, J = 7.6 Hz, CO2CH2CHPh2), 3.68 (d, 2H, J = 5.2 
Hz, Gly NHCH2CO), 3.52 (dd, 111, J = 4.8 Hz, .1 = 9.6 Hz, Ser 
NH2CH(CHH'(OTBDPS))CO), 3.47 (dd, 1H, J = 5.0 Hz, J = 17.2 Hz, Gly 
NHCHH'CO), 3.38 (dd, 1H, J = 4.8 Hz, J = 9.6 Hz, Ser NH2CH(C1{H'(OTBDPS))CO), 
3.25 (dd, 1H, J = 4.2 Hz, J = 17.0 Hz, Gly NHCHH'CO), 3.15 (dd, 1H, J= 4.2 Hz, J= 
17.0 Hz, Gly NHCHH'CO), 3.04 (dd, 1H, J = 5.0 Hz, J = 17.2 Hz, Gly NHCIIH'CO), 
2.96-2.90 (m, 1H, Ser N}T2CH(CHH'(OTBDPS))CO), 1.95-1.55 (m, 2H, Ser 
N}CH(CHH'(OTBDPS))CO), 0.98 (s, 9H, OSiC(CH3)3); 13C NMR (100 MHz, 
CDC13): 6 = 173.84, 169.97, 169.09, 168.60, 166.79, 141.12, 140.48, 137.46, 137.20, 
135.39, 135.34, 134.12, 133.64, 132.75, 132.65, 131.58, 131.26, 130.03, 129.50, 
129.20, 129.09, 128.66, 128.30, 128.13, 128.02, 127.86, 127.00, 124.23, 80.01, 67.59, 
65.40, 56.21, 49.63, 44.19, 44.10, 42.79, 42.38, 41.06, 26.77; FAB-HRMS for 





Yield (0.042 g, 71%); i  NN'IR (400 MHz, 313K, CDC13): 6 = 8.28 (s, 211, 
isophthaloyl 2-H), 8.09 (d, 4H, J = 6.8 Hz, isophthaloyl 4-H & 6-11), 7.68 (br t, 411, 
macrocyclic CONIH), 7.58-7.01 (m, 34 H, isophthaloyl 5-H & aromatic Ar-H & CON} 
& macrocyclic para-xylylene Ar-H), 6.90 (br t, 1H, CONIH), 4.62-4.46 (m, 6H, 
macrocyclic NHCHH' & macrocyclic NHCHH' & CO2CCHPh2), 4.45-4.38 (m, 3H, 
macrocyclic NHCHH' & Ser NEI2CH(CH2(OTBDPS))CO), 4.31 (dd, 2H, J = 4.0 Hz, J 
= 13.6 Hz, macrocyclic NHCHH'), 4.20 (t, 1H, .1 = 7.6 Hz, CO2CH2C1JPh2), 4.15-4.08 
(m, 1H, Ala NHCH(CH3)CO), 3.74 (dd, 111, J = 3.6 Hz, J = 10.8 Hz, Ser 
NH2CH(C}IIH'(OTBDPS))CO), 3.58-3.15 (m, 9H, Ser NH2CH(CHH'(OTBDPS))CO & 
Gly NHCfl2CO & Gly N}{CIIICO & Gly NHCH2CO & G1yNHCH2CO), 2.46-2.12 (m, 
211, Ser NIH2CH(CH2(OTBDPS))CO), 1.15 (d, 3H, J = 6.4 Hz, Ala NHC(Cfl)CO),  0.99 
(s, 9H, OSiC(C113)3); '3C NMIR (100 MHz, CDC13): 6 = 174.31, 172.75, 169.79, 169.49, 
169.25, 168.92, 167.11, 140.54, 137.37, 137.28, 135.41, 134.23, 134.09, 132.71, 
131.21, 130.05, 129.06, 128.93, 128.69, 128.03, 127.87, 127.02, 124.82, 79.85, 67.58, 
65.49, 56.49, 49.56, 49.11, 44.27, 44.16, 42.79, 42.58, 42.32, 40.98, 26.79, 17.35; FAB-
HRMS for C76H83N10O12S1 m/z [M+H], calcd.: 13 55.59612, found: 13 55.59738. 
L-(O-(tert-butyldiphenylsilyl))-serylglycylglycylglycyi-L-phenylalanyl-L-Ieucine-
tert-butyl ester rotaxane 4.17 
Yield (0.050 g, 78%); 1H NMR (400 MHz, CDC13): 8 = 8.30 (s, 211, isophthaloyl 2-11), 
8.10(d, 211, J= 8.6 Hz, isophthaloyl 4-H & 6-11), 8.07 (d, 211, J= 8.6 Hz, isophthaloyl 4-
H & 6-11), 7.69-7.57 (m, 411, macrocyclic CONIH), 7.56-7.13 (m, 19 H, isophthaloyl 5-H 
& aromatic Ar-H & CON) 7.09 (s, 811, macrocyclic para-xylylene Ar-H), 6.92 (d, 1H, 
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J = 7.2 Hz, CON11), 6.85 (br t, 1H, CONH), 6.46 (d, IH, J = 7.6 Hz, CONIH), 4.60-4.42 
(m, 5H, macrocyclic NHCHH' & macrocyclic NHCHH' & Phe NHCH(CH2Ph)CO), 
4.41-4.25 (m, 5H, macrocyclic NHCHH' & macrocyclic NHCH' & Leu 
NHCH(CH2CH(CH3)2)CO), 3.72-3.63 (m, 1 H, Ser NH2CH(C112(OTBDPS))CO), 3.47-
3.37 (m, 2H, Gly NHCHH'CO & Gly NHCHH'CO), 3.36-3.24 (m, 3H, Ser 
NH2CH(CHH'(OTBDPS))CO & Phe NHCH(CHH'Ph)CO & Gly NHCHH'CO), 3.11 
(dd, 1H, J = 3.2 Hz, J = 16.4 Hz, Phe NHCH(CHH'Ph)CO), 3.06-2.98 (m, 2H, Ser 
NH2CH(CHH'(OTBDPS))CO & Gly NHCHH'CO), 2.97-2.84 (m, 2H, Gly 
NHCHH'CO & Gly-NHCHH'CO), 1.86-1.65 (m, 2H, Ser N}CH(CH2(OTBDPS))CO), 
1.58-1.46 (m, 1H, Leu NHCH(CH2CH(CH3)(CH'3)CO), 1.45-1.33 (m, 11H, Leu 
NHCH(CHzCH(CH3)(CH'3)CO & CO2(CH3)3), 1.00 (s, 9H, OSiC(CH3)3), 0.85 (m, 6H, 
Leu NHCH(CH2CH(CH3)(CH'3)CO & Leu NHCH(CH2CH(CH3)(CH'3)CO); 13C NMR 
(100 MHz, CDC13): 8 = 171.99, 171.58, 170.27, 170.23, 169.89, 168.78, 167.98, 
166.84, 137.45, 137.37, 136.22, 136.12, 135.41, 135.38, 133.88, 132.77, 131.41, 
131.33, 130.05, 130.02, 129.27, 129.12, 129.00, 128.60, 128.53, 127.86, 127.07, 
127.03, 124.66, 124.52, 82.03, 82.00, 65.59, 56.43, 54.52, 51.74, 44.16, 42.53, 42.41, 
41.43, 41.19, 38.81, 38.58, 27.97, 26.80, 24.81, 22.52, 22.10; FAB-HRMS for 
C76H91N10012Si m/z [M+F], calcd.: 136365872, found: 1363.65512. 
N-terminal coupling of rotaxane derivatives 4.10, 4.11 and 4.17 
L(O(tertbutylthphenylsi1y1))-SerylglyCylglyC1fle rotaxane (4.10, 4.11 or 4.17, 0.025 
mmol), N-diphenylacetyl amino  acid (0.050 mmol) and NEt3 (till pH 11) and BOP (0.017 
g, 0.038 mmol) were dissolved in 10 mL of CHC13. The reaction mixture was stirred 
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overnight at a The solvent was removed under reduced pressure. The crude material 
was purified via silica gel chromatography (CHC13/MeOH: 98/2 to 86/14). 
rotaxane 4.12 
Yield (0.040 g, 96%); 111  NMR (400 MHz, CDC13): ö = 8.20 (s, 211, isophthaloyl 2-11), 
8.04-7.99 (m, 8H, isophthaloyl 4-H & 6-H & macrocyclic CONH), 7.55-7.04 (m, 44H, 
aromatic Ar-H & isophthaloyl 5-H & macrocyclic para-xylylene Ar-H & CONE!), 6.76 
(d, 1H, J = 6.8 Hz, Ser CON}{CH(CHH'(OTBDPS))CO), 5.05 (s, 1H, Ph2CHCO), 4.52 
(dd, 2H, J = 6.4 Hz, J = 14.4 Hz, macro cyclic NHCHH'), 4.47 (dd, 211, J = 5.2 Hz, J = 
14.0 Hz, macrocycic NHCHH'), 4.40 (d, 2H, J = 7.6 Hz, CO2CCHPh2), 4.33 (dd, 2H, 
J = 4.4 Hz, J = 14.4 Hz, macrocyclic NHCHH'), 4.29 (dd, 211, J = 4.0 Hz, J = 14.0 Hz, 
macrocyclic NHCHH'), 4.24-4.22 (m, 1H, Ser N1-TCH(CH2(OTBDPS))CO), 4.15 (t, [H, 
J = 7.6 Hz, CO2CH2CHPh2), 3.81-3.71 (ni, 2H, Ser NHCH(CI{H'(OTBDPS))CO & Gly 
NHCHH'CO), 3.56 (dd, 1H, J = 6.4 Hz, J = 10.4 Hz, Ser 
NHCH(CHH'(OTBDPS))CO), 3.51 (dd, TH, J = 6.4 Hz, J = 17.2 Hz, Gly 
NHCHH'CO), 3.41 (dd, 1H, J = 4.4 Hz, J= 16.0 Hz, Gly NHCHH'CO), 3.30 (dd, 111, J 
= 5.2 Hz, J = 17.2 Hz, Gly NHCHH'CO), 3.25-3.20 (m, 2H, Gly NHCH2CO), 2.86 (dd, 
111, J' 5.6 Hz, J = 16.4 Hz, Gly NHCHH'CO), 2.63 (dd, 1H, J = 5.6 Hz, J= 16.4 Hz, 
Gly NHCHH'CO), 0.99 (s, 911, OSiC(CH3)3); 13C NMR (100 MHz, CDC13): ö = 173.64, 
170.47, 169.38, 169.29, 169.11, 169.06, 167.47, 167.33, 140.57, 140.55, 139.09, 
139.06, 137.36, 137.06, 135.44, 135.35, 134.63, 134.32, 132.62, 132.29, 130.98, 
130.66, 130.07, 129.15, 128.94, 128.84, 128.76, 128.74, 128.66, 128.63, 128.11, 
128.01, 127.93, 127.86, 127.30, 127.22, 126.99, 125.80, 80.12, 67.48, 63.09, 58.05, 
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54.71, 49.52, 44.55, 44.42, 43.79, 42.75, 41.61, 40.75, 26.77; FAB-HRMS for 
C87H88N9012Si mlz [M+}fl, calcd.: 1478.63217, found: 1478.63873. 
Glycylglycyl-L-(O-(tert-buty tdiphenylsilyl))-serylglycylglycyl-L- 
alanylglycylglycine rotaxane 4.13 
Yield (0.037 g, 91%); 1H NMR (400 MHz, 323K, CDC13): ö = 8.25 (s, 2H, 
isophthaloyl 2-H), 8.05 (d, 211, J= 5.2 Hz, isophthaloyl 4-H & 6-H), 8.04 (d, 2H, J= 5.2 
Hz, isophthaloyl 4-H & 6-H), 7.81 (br t, 2H, macrocyclic CONH), 7.66 (br t, 2H, 
macrocyclic COW), 7.61-6.98 (m, 46H, aromatic Ar-H & isophthaloyl 5-H & 
macrocyclic para-xylylene Ar-H & CONII), 6.87 (br t, 111, CONE!), 6.80 (br t, 1H, 
CONk), 4.96 (s, 1H, Ph2CHCO), 4.59 (dd, 211, J = 6.4 Hz, J = 13.6 Hz, macrocyclic 
NHCHH'), 4.47 (dd, 2H, J = 4.8 Hz, 1 = 14.8 Hz, macrocyclic NHCHH'), 4.41-4.33 (m, 
4H, macrocyclic NHCHH' & CO2CCHPh2), 4.28 (dd, 2H, J = 4.0 Hz, J = 13.6 Hz, 
macrocyclic NHCHH'), 4.13 (t, 111, J = 7.2 Hz, CO2CH2CHPh2), 4.05-3.93 (m, 2H, Ala 
NHCH(CH3)CO & Gly NHCHH'CO), 3.87 (dd, 111, J = 5.2 Hz, J = 10.4 Hz, Gly 
NHCHH'CO), 3.83-3.78 (m, 1H, Gly NHCHH'CO), 3.73-3.61 (m, 21-L Ser 
NHCH(CH2(OTBDPS))CO & Gly NHCHH'CO), 3.57 (dd, 1H, J = 4.4 Hz, J = 18.4 Hz, 
Ser NHCH(CIffl'(OTBDPS))CO), 3.51-3.38 (m, 3H, Ser NHCH(CHH'(OTBDPS))CO 
& Gly NHCCO), 3.30-3.19 (m, 311, Gly NHCHH'CO & Gly NHCCO), 3.18-3.06 
(m, 2H, Gly NHCHH'CO & Gly NHCHH'CO), 2.95 (dd, 111, J = 4.4 Hz, J = 16.4 Hz, 
Gly NHCHH'CO), 1.14 (d, 3H, J = 7.2 Hz, Ala NHC(C)CO), 1.02 (s, 911, 
OSiC(C)3); 13C NMR (100 MHz, CDC13): 8 = 173.52, 173.02, 172.97, 172.88, 
171.23, 170.30, 169.79, 169.44, 169.33, 167.44, 167.34, 140.41, 138.98, 138.89, 
137.38, 137.05, 135.40, 135.37, 134.18, 134.07, 132.42, 131.08, 130.99, 129.97, 
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128.98, 128.86, 128.74, 128.70, 128.59, 127.86, 127.81, 127.78, 127.26, 126.92, 
125.27, 80.05, 67.53, 62.79, 58.13, 56.17, 51.47, 50.21, 49.46, 44.05, 43.98, 42.81, 
42.75, 42.33, 41.83, 40.91, 40.59, 26.56, 16.65; FAB-HRMS for C94H99N12015Si mlz 
[M+H], calcd.: 1663.71222, found: 1663.72154. 
tBoc-L-teucyl-L-phenylalanylglycyl-L-(O-(tert-butyldiphenylsilyl))- 
serylglycylglycylglycyl-L-phenylalanyl-L-leucine-tert-butyl ester rotaxane 4.18 
Yield (0.054 g, 84%); 111  NMR (400 MIHz, CDCI3): 6 = 8.30 (s, 2H, isophthaloyl 2-H), 
8.06 (d, 4H, J = 7.2 Hz, isophthaloyl 4-H & 6-H), 7.90 (br t, 2H, macrocyclic CONIH), 
7.85 (br t, 2H, macrocyclic CONE'), 7.60-7.00 (m, 31H, aromatic Ar-H & isophthaloyl 
5-H & CON}1 & macrocyclic para-xylylene Ar-H & CONE), 6.90 (br t, IH, CONE), 
6.79 (d, 1H, J = 7.2 Hz, CONH), 6.63 (br d, 1H, CON}J), 6.54 (br s, 1H, CONII), 6.47 
(br s, 1H, CONIH),  6.13 (d, 1H, J = 6.8 Hz, Leu CON}ICH(CH2CH(CH3)2)CO), 5.92 (d, 
1H, J = 8.0 Hz, N-terminal Gly CONHCH2CO), 4.92 (br d, 1H, Leu 
CON}ICH(CH2CH(CH3)2)CO), 4.76-4.54 (m, 4H, macrocycic NHCHH' & NHCHH'), 
4.50-4.43 (m, 1H, N-terminal Phe NHCH(CH2Ph)CO), 4.39-4.14 (rn, 8H, macrocyclic 
NHCHH' & NHCHH' & C-terminal Leu NEICH(CH2CH(CH3)2)CO & C-terminal Phe 
NHCH(CH2Ph)CO & Ser NHCH(CH2(OTBDPS))CO & N-terminal Gly NHCHH'CO), 
3.93-3.86 (in, 1H, N-terminal Leu NHCH(CH2CH(CH3)2)CO), 3.83-3.78 (in, 1H, N-
terminal Gly NHCHH'CO), 3.74-3.62 (in, 111, C-terminal Gly NHCHH'CO), 3.51-3.35 
(In, 2H, C-terminal Gly NHCHH'CO & C-terminal Gly NHCHH'CO), 3.25 (dd, 1H, J = 
6.8 Hz, J = 17.2 Hz, C-terminal Gly NHCHH'CO), 3.20-3.14 (in, 1H, C-terminal Gly 
NHCHH'CO), 3.10-2.96 (in, 3H, C-terminal Gly NHCH'CO & N-terminal Phe 
NECH(CHH'Ph)CO & Ser NHCH(CHH'(OTBDPS))CO), 2.89-2.76 (m, 3H, Ser 
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NIHCH(C1{H'(OTBDPS))CO & C-terminal Phe CONHCH(CHH'Ph)CO & C-terminal 
Phe NHCH(CHH'Ph)CO), 2.65-2.62 (ni, 1H, N-terminal Phe NHCH(CIHH'Ph)CO), 
1.57-1.47 (ni, 1H, Leu NHCH(CH2CH(CH3)(CH'3)CO), 1.43-1.32 (m, 22H, Leu 
NHCH(CH2CH(CH3)(CH'3)CO & CO2(C)3 & Boc Crn),  1.00 (s, 9H, OSiC(C)3), 
0.86-0.75 (m, 6H, Leu NHCH(CH2CH(C)(CH'3)CO) & Leu 
N}ICH(CH2CH(CH3)(CH'3)CO); 13C NMR (100 M1-Iz, CDCI3): 8 = 173.19, 172.54, 
171.73, 171.40, 170.76, 170.46, 170.12, 169.62, 167.84, 167.31, 167.08, 157.38, 
137.36, 137.25, 136.15, 136.00, 135.52, 134.42, 134.13, 132.81, 132.60, 131.24, 
131.01, 129.93, 129.30, 129.20, 128.97, 128.92, 128.82, 128.65, 127.78, 127.32, 
127.27, 127.15, 127.00, 125.59, 81.91, 81.20, 81.03, 55.16, 54.78, 54.57, 54.40, 51.79, 
51.59, 44.58, 44.38, 43.87, 42.76, 42.20, 41.27, 41.00, 40.34, 38.73, 36.72, 28.22, 
27.98, 26.79, 24.80, 22.84, 22.49, 22.07, 21.91, 21.65; FAB-HR.MS for C98H122N13017Si 
m/z [M+}", calcd.: 1781.88845, found: 1781.88738. 
TBDPS deprotection of rotaxane derivatives 4.12, 4.13 and 4.18 
GIycyl-L-serylglycylglycylglycine rotaxane 4.14 
Glycyl-L-(O-(tert-butyldiphenylsilyl))-serylglycylglycylglycine rotaxane 4.12 (0.028 g, 
0.019 mmol) were dissolved in 1 mL of THF and then treated with 0.1 mL of 1 mol.dm 3  
solution of TBAF in THF. The reaction mixture was stirred at P for one hour and then 
concentrated under reduced pressure. The crude material was purified via silica gel 
chromatography (CHCI3/MeOH: 98/2 to 86/14). Yield (0.016 g, 71%); 111 NMR (400 
MHz, 3231, , CDCI3): 6 = 8.20 (s, 2H, isophthaloyl 2-H), 8.00 (d, 4H, J = 7.6 Hz, 
isophthaloyl 4-H & 6-H), 7.61(br t, 4H, macrocyclic CONH), 7.43 (d, 211, J 7.6 Hz, 
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isophthaloyl 5-H), 7.28-6.98 (m, 3011, aromatic Ar-H & macrocyclicpara-xylylene Ar-H 
& CONU), 6.94 (br t, 1H, CONH), 6.85 (br t, 1H, CONIR), 6.59 (br t, 1H, CON}1), 4.78 
(s, 1H, Ph2CHCO), 4.51-4.28 (m, IOH, macrocyclic NHCHH' & NHCH' & 
CO2CH2CHPh2), 4.20 (t, 1H, J = 7.2 Hz, CO2CH2CIWh2), 4.13-4.06 (m, 1H, Ser 
NHCH(CH2OH)CO), 3.66 (dd, 111, J= 3.2 Hz, J= 10.8 Hz, Ser NHCH(CHH'OH)CO), 
3.45-3.29 (m, 7H, Ser NHCH(CHH'OH)CO & GLyNHCH2CO & G1yNHCH2CO & Gly 
NHCH2CO), 3.11 (br d, 2H, Gly NHCFIZCO), 2.14 (m, 111, Ser NHCH(CHH'OH)CO); 
13C NIVIIR (100 MHz, CDC13): ö = 173.36, 170.85, 169.52, 169.35, 169.19, 167.42, 
167.35, 167.21, 140.52, 138.80, 137.24, 134.18, 131.11, 130.99, 129.05, 128.94, 
128.71, 128.65, 128.00, 127.42, 126.99, 125.14, 67.58, 61.76, 58.14, 54.98, 49.57, 
44.26, 44.21, 44.13, 44.08, 42.86, 42.55; FAB-HRMS for C71H70N9012Si m!z [M+H], 
calcd.: 1240.51439, found: 1240.51300. 
G1ycyIg1ycyJLsery1gtycy1g1ycy1-L-a1aflylgIYCYlgiYCifle rotaxane 4.15 
rotaxane (4.13, 0.017 g, 0.010 mmol) and diphenylethanol (0.001 g, 0.050 mmol) were 
dissolved in 3 mL of TFA. The reaction mixture was stirred at room temperature for one 
hour and then concentrated under reduced pressure. The crude material was precipitated 
out of diethylether. Yield (0.014 g, 100%); 'HNIVIR (400 MHz, MeOD-d4): 8 = 8.27 (s, 
2H, isophthaloyl 2-H), 7.99 (d, 4H, J = 7.8 Hz, isophthaloyl 4-H & 6-H), 7.54 (t, 2H, J = 
7.8 Hz, isophthaloyl 5-H), 7.22-6.87 (m, 28H, aromatic Ar-H & macrocyclic para-
xylylene Ar-H),  4.53 (s, 1H, Ph2CHCO), 4.44-4.34 (in, 4H, macrocyclic NHCHH' & 
NHCHH'), 4.28-4,21 (m, 6H, macrocyclic NHCHH' & NHCHH' & CO2CHC1Wh2), 
4.19-4.13 (m, 3H, Ser NHCH(CH20H)CO & Ala NHCH(CH3)CO & CO2CH2CHPh2), 
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4.12-3.99 (m, 1H, Ser NHCH(CH20H)CO), 3.88-3.68 (m, 4H, Gly NHCH2CO & Gly 
NHCHZCO), 3.62 (br d, 1H, Gly NHCHH'CO), 3.60-3.59 (m, 1H, Ser 
NHCH(CHH'OH)CO), 3.58-3.56 (m, 2H, Gly NI1CCO), 3.54-3.51 (m, 211, Ser 
N}iICH(CHH'OH)CO & Gly NHCHH'CO), 3.49 (br d, 1H, Gly NHCHH'CO), 3.47-3.44 
(m, 311, Gly NHCIIICO & Gly NHCHH'CO), 1.19 (d, 3H, J = 7.2 Hz, Ala 
NHCH(Cj)CO); 13C NMR (100 MHz, MeOD): = 175.51, 174.06, 173.09, 172.15, 
172.08, 171.02, 170.83, 270.50, 168.88, 165.28, 164.90, 142.35, 141.64, 138.67, 
135.75, 135.72, 131.81, 130.09, 130.05, 130.00, 129.97, 129.63, 129.52, 129.26, 
129.03, 128.87, 128.16, 127.85, 127.74, 67.32, 62.67, 45.70, 45.23, 45.14, 45.10, 45.08, 
43.71, 43.41, 42.15, 41.54, 16.27; FAB-HRMS for C78H81N12015 mlz [M+Hi, calcd: 




serylglycylglycylglycyl-L-phenylalanyl-L-leucine-tert-butyl ester rotaxane (4.18, 0.019 g, 
0.010 mmol) was dissolved in 6 mL of TFA. The reaction mixture was stirred overnight 
at room temperature and then concentrated under reduced pressure. The crude material 
was precipitated out of diethylether. Yield (0.0 14 g, 100%); 1H NMR (400 MIITIz, MeOD-
d4): 6 = 8.40 (s, 2H, isophthaloyl 2-H), 8.05 (d, 2H, J = 7.5 Hz, isophthaloyl 4-H & 6-
H), 8.03 (d, 2H, J = 7.5 Hz, isophthaloyl 4-H & 6-H), 7.61 (t, 2H, J = 7.5 Hz, 
isophthaloyl 5-H), 7.41-7.18 (m, I OH, aromatic Ar-H), 7.16 (s, 8H, macrocycic para-
xylylene Ar-H), 4.59-4.49 (m, 3H, Ser NHCH(CH20H)CO & C- and N-terminal Phe 
NHCH(CH2Ph)CO), 4.47-4.39 (m, 8H, macrocyclic NHCHH' & NIHCHEI'), 4.37-4.35 
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(m, 1H, Leu NHCH(CH2CH(CH3)2)CO), 4,22 (dd, 1H, J = 2.8 Hz, J = 5.6 Hz, Gly 
NHCHH'CO), 3.91 (dd, 1H, J = 4.8 Hz, J = 10.4 Hz, Gly NHCHH'CO), 3.84-3.79 (m, 
1H, Leu' N}ICH(CH2CH(CH3)2)CO), 3.72 (dd, 1H, J = 4.8 Hz, J = 10.4 Hz, Gly 
NHCHH'CO), 3.69-3.62 (m, 2H, Gly NECHI-'CO & Gly NHCHH'CO), 3.56-3.51 (m, 
2H, Gly NIHCCO), 3.48 (dd, 1H, J— 4.8 Hz, J = 7.2 Hz, Gly NHCHH'CO), 3.15-3.06 
& 2.99-2.90 & 2.81-2.71 (m, 6H, C- and N-terminal Phe NIHCH(CH2Ph)CO & Ser 
NHCH(CH20H)CO), 1.67-1,41 (m, 6H, C- and N-terminal Leu 
NHCH(CCH(CH3)2)CO & Leu NHCH(CH2CH(CH3)2)CO), 0.86-0.77 (m, 12H, C-
and N-terminal Leu NHCH(CH2CH(CF13)2)CO); '3C NMR (100 MHz, MeOD): ö = 
175.66, 173.82, 173.52, 172.58, 172.20, 171.66, 171.14, 170.42, 170.23, 169.28, 
169.09, 138.64, 138.60, 138.44, 138.17, 135.66, 135.61, 131.82, 131.75, 130.38, 
130.27, 130.24, 130.09, 129.95, 129.59, 129.55, 128.87, 128.64, 128.06, 127.97, 
127.88, 62.79, 56.79, 56.13, 56.00, 52.73, 52.21, 45.43, 45.32, 45.28, 43.37, 43.18, 
42.44, 41.58, 41.38, 39.22, 38,10, 26.73, 25.95, 25.23, 23.34, 21.90, 21.53; FAB-HRMS 
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Conclusion and Outlook 
Recently, dipeptides have been successfully derivatised into rotaxanes incorporating 
benzylic 1,3-carbamide macrocycles, using a five-component hydrogen bond-directed 
assembly. 1,2  When encapsulated within a tetraamide macrocycle, oligopeptides present 
interesting changing properties: their solubility in organic solvents, their lipophilicity and 
their vulnerability against enzymes  can be incredibly modulated by the macrocycle acting 
as a protective sheath around the peptide backbone. However, encapsulation via the 
clipping strategy has been limited so far to short peptide sequences since intramolecular 
hydrogen bonding and insufficient solubility of longer peptide threads in apolar solvents 
can induce the folding of the backbone, thus preventing a good preorganization between 
the peptide thread and the precursor of the macrocycle .4,1 
This thesis dealt with the design of new chemical tools able to overcome such 
problems. Short peptide rotaxane building blocks were synthesized and extended on their 
terminal sides to promote the synthesis of oligopeptide rotaxanes in very good yields 
(Scheme 5.1.). 
In Chapter Two '6  activated ester rotaxane building blocks, in dipeptide and fumaric 
series, were synthesized. Their elongation on the C-terminal side was applied to the 




In Chapter Three,' we described the synthesis of three N-protected L-SerGlyGly and L-
AspGlyGly tripeptide rotaxane building blocks, functionalized on the lateral chain by a 
labile bulky stopper. After N-deprotection, further elongation via classical peptide 
coupling chemistry was carried out to give oligopeptide [2] and [3]rotaxanes. 
Chapter Four' dealt with the fusion of the two previous strategies. An N-Fmoc 
protected tripeptide L-SerGlyGly activated ester rotaxane building block, functionalized 
on its lateral chain by a labile ether, was synthesized. Successive extension on its C- and 
N-terminal sides led to the synthesis of oligopeptide rotaxanes, in very good yields. This 
strategy was especially applied to the synthesis of the first oligopeptide rotaxane with free 
amine and carboxylic acid terminal sides. 
We have demonstrated the feasibility of synthesizing model oligopeptide rotaxanes, in 




Direct clipping of the macrocycle 
around the oligopeptide thread 1-5 
dipeptides: 6 to 62% 
tripeptides: 1-2.5% 
	
tn- to pentapeptides 	 penta- to nonapeptides 	tetra- and pentapeptides 
55 to 91% yield 	 66 to 89% yield 	 47 to 90% yield 
I 	 I 	 I 
C-elongation 6 	 C- & N-elongation 7 N-elongation 
/ 
hNO2 hrr 
1 	 11 	 N NNPh Ph 	 1  Oic Ph 
Phh 	 PG 	
N,1. 
Scheme 5.1. Extension of short peptide rotaxane building blocks for 
the synthesis of oligopeptide rotaxanes. 
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However even though such compounds have reached academic success, major 
problems still have to be overcome before industrialisation  of any kind. The purification 
step - one reaction, one column - is indeed a critical point. 
Key-steps towards successful peptide based prodrug systems are three-fold: 
the delivery of the prodrug. Water solubility and lipophilicity properties of 
rotaxanes need to be modulated in order to cross natural barriers (brain, 
cells...). Functionalisation of the macrocycle has led to promising results.3  
the drug release. It can occur by cleavage of the macrocycle or stoppers which 
both need to be non toxic and excretable. For example the use of a cyclic 
peptide as macrocycle could be an interesting option and such studies are 
actually ongoing in the Leigh group. Cleavage would occur via a specific-
stimulus 
pecific 
l s such as irradiation of a photosensitive group, enzymatic degradation 
with slipping out of the macrocycle... Previous studies in the group showed 
that carbohydrate-branched carbohydrates can be effectively cleaved allowing 
the slow release of the macrocycle. 
the design of specific drugs. The strategies developed so far did not allow much 
freedom in terms of the peptide drug primary structure and the nature of the 
macrocycle. The use of a cleavable building block rotaxane able to promote the 
slipping of the macrocycle onto an added peptide backbone would be a really 
impressive tool towards the powerful synthesis of impossible peptide rotaxanes. 
The tailoring  of these three main topics is the key towards the use of peptide rotaxanes 
as powerful and universal drug delivery systems. 
Conclusion 
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